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PARTl 
REVIEW OF COMMUNITY-ACQUIRED PNEUMONIA 
CHAPTER! 
INTRODUCTION 
Pneumonia, one of the earliest recognised diseases, still remains a medical enigma. 
The causative organism may remain unknown in up to 60% of cases of community-
acquired pneumonia, with new organisms still being discovered, factors which aid in 
determining disease severity or influencing its prognosis are still poorly defined, the 
efficacy of many aspects of care remain anecdotal and unproved, and even the newer 
antibiotics have not been shown to be better than the old and tried regimens. 
Its aetiological diagnosis is imprecise and the efficacy of aspects of treatment is still 
debatable, despite powerful antibiotics and modem intensive care.1-3 Although 
agents like Klebsiella pneumoniae (Friedlander's Bacillus) and Streptococcus 
pneumoniae have been known to cause pneumonia since the last century, more 
recently discovered agents such as Legionella pneumophila (discovered in 1976), and 
Chlamydia pneumoniae (1986) are now recognised to be major causes of community-
acquired pneumonia.4-8 While the clinical diagnosis of pneumonia may be made 
with confidence in the majority of patients, and is likely to be incorrect in as few as 
5% of cases, where another pulmonary disease such as pulmonary embolism, or less 
common diseases such as eosinophilic pneumonia, cryptogenic organising pneumonia 
(COP), may masquerade as pneumonia,9,10 it is the diagnosis of the aetiological 
agent which is far more problematic, and the causative agent may remain unknown in 
up to 50% of all cases. With the increasing availability of newer invasive techniques 
for obtaining pulmonary specimens, improved culture and serological techniques, and 
techniques using the polymerase chain reactions and DNA probes, fewer cases will 
remain undiagnosed. 7, 11-16 
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Measures of the severity of illness in pneumonia, other than broad criteria for hospital 
admission, remain controversial and inaccurate, although it is now generally 
recognised that the elderly, patients with underlying disease, leukopenia, confusion, 
renal dysfunction and those with gram negative and staphylococcal infections require 
hospital admission.17, 18 
Criteria for determining the need for ICU admission, or intubation and ventilatory 
support, or prognostic indicators have not yet been clearly defined.19-22 The role of 
modem intensive care with optimum antibiotic therapy, close monitoring and organ 
support, new ventilatory techniques utilising PEEP, inverse ratio ventilation, or 
CPAP. has also not yet been adequately determined. Unilateral lung ventilation and 
more radical forms of therapy such as surgery have also not been adequately evaluated 
and their use remains based on anecdotal reports.1,23-28 
Many new antibiotics with improved pharmacokinetics, broader spectrum of activity, 
and fewer adverse effects have been developed, yet none has been shown to be more 
effective than the traditional historically proven agents.29,30 No antibiotic studies 
however, have been designed to show improvement over the existing agents, but only 
equivalence in clinical and microbiological safety and efficacy. 
Pneumonia is a disease with numerous aetiologies, and many diverse patterns of 
presentation, which may be influenced by numerous factors including seasonal 
influences, regional effects, the site of acquisition (e.g. hospital or community 
acquired), and host differences, including age, underlying disease, and most 
importantly immuno-compromised host defences. All these factors exert an influence 
on the spectrum of causative agents. As the initial treatment invariably requires 
empirical antibiotic therapy, before the results of microbiological investigations 
become available, the above variables which influence the aetiology of the 
pneumonia, need to be considered in order to make a logical selection of antibiotics. 
This makes a distinctive classification of pneumonia that defines the likely spectrum 
of pathogens, essential for describing the disease, planning treatment, and evaluating 
treatment and outcome. 
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In this thesis I will review the current knowledge of community-acquired pneumonia, 
including its classification, pathogenesis, pathology, aetiology, diagnosis, and 
antibiotic therapy and report my experience with severe community-acquired 
pneumonia in patients requiring admission to our respiratory intensive care unit. The 
original research in this thesis comprises a prospective, descriptive analysis of 196 
cases of severe community-acquired pneumonia requiring admission to the 
Respiratory Intensive Unit at Groote Schuur Hospital from January, 1987 until 
December, 1992, with emphasis on the influence of aetiology on the severity of 
pneumonia, the· aetiological diagnosis of pneumonia in severely ill patients, measures 
of severity of pneumonia, and an audit of ICU therapy and outcome. In addition, 
different aspects of novel therapies and specific aetiological varieties of pneumonia 
which have been investigated over the past ten years will be presented. 
Classification of Pneumonia 
A number of different classifications of pneumonia have been used in the past, 
including a widely accepted pathological classification. This divides pneumonia into 
lobar, bronchopneumonia or interstitial pneumonia, with further subdivisions 
according to the aetiological agent. This classification is however of little value in the 
clinical setting, where the determination of the aetiology of pneumonia using clinical 
features is of paramount importance in determining therapy. Furthermore, these 
classic, pathological features are altered following modem supportive therapy; and the 
histological appearance invariably demonstrates non-specific changes of diffuse 
alveolar damage, reflecting the effects of oxygen and ventilatory therapy, rather than 
the effects of the organism. 
A radiological classification into lobar, bronchopneumonia and interstitial pneumonia, 
noting the presence or absence of an effusion, is another widely accepted means of 
classification, but its ability to assist in determining the aetiological diagnosis has 
recently been questioned. 9 ,31 
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The most commonly used clinical classification divides pneumonia into broad, easily 
defined categories of community-acquired, nosocomial, aspiration and pneumonia in 
the immuno-compromised host. This classification may also incorporate both the 
pathological and radiological features described above, as the pathological and 
radiological descriptions are usually comparable. 
In some recent studies of community-acquired pneumonia (CAP), the selection of the 
study patients by the addition of qualifying criteria such as lobar radiological 
abnormalities, may have introduced bias by pre selecting particular organisms 32. In 
other studies, the inclusion of patients with pulmonary tuberculosis may have 
influenced the incidence of causative organisms and clinical features, as well as 
information on patient outcome. 33 Perhaps of even more concern with some studies 
is the inclusion of significantly immunocompromised patients, such as Human 
Immuno-deficiency Virus (HIV) infected patients, who are both at increased risk of 
developing pneumonia and have an increased mortality.34,35 These potential 
problems with classification serve to emphasise the importance of standardising 
definitions of pneumonia, in order to achieve uniformity and avoid selection bias 
influencing subsequent results. 
Whilst nosocomial pneumonia has recently been the subject of an international 
consensus meeting, and widely accepted definitions and a system of classification 
have been recommended 36,37, no definitions or classification of CAP are generally 
accepted at present, and a consensus on classification should be a priority in order to 
allow our understanding of CAP to advance. Following the initial submission of this 
thesis, a North American and Canadian consensus meeting on diagnosis, assessment 
of severity, and initial antimicrobial therapy has been held and guidelines published. 
The disease was still not clearly defined, and all cases of community-acquired 
pneumonia were considered in the broad definition of the disease. Subdivisions in 
terms of the severity of disease (into those patients requiring outpatient treatment, 
hospital treatment or those with severe pneumonia usually requiring ICU treatment), 
the presence of co-morbid illness, and or age (>59 years) have been recommended to 
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determine initial therapy.38 Unfortunately, these guidelines were drawn up using 
only 9 recent prospective studies from North America and Western Europe and may 
thus lack general application. 
Table 1: Classification of pneumonia. 
1. Primary community-acquired pneumonia.(CAP) 
1.1 CAP in the Elderly 
1.2 CAP with underlying Chronic Obstructive Lung Disease 
1.3 CAP with Diabetes 
1.4 CAP with Neuromuscular disease 
2.Nosocomial pneumonia. 
1.1 Non-ventilator associated 
1.2 Ventilator associated. (V AP) 
1.2.1 Early onset 
1.2.2 Late onset pneumonia 
3. Aspiration. 
3.1 Nosocomial. 
3.2 Community acquired. 
4. Immuno-compromised hosts. 
4.1 Renal transplant. 
4.2 Cardiac transplant. 
4.3 Bone marrow transplants 
4.4 Leukopenic patients( white cell count <1,000 cells/ml) 
4.5 Systemic disease e.g. Systemic lupus erythematosis 
4.6 AIDS. 
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Definitions 
1. Community-acquired pneumonia. These are patients who develop a pneumonia 
in the community or within 48 hours of being admitted to hospital, and may thus be 
presumed to have been "incubating" their infection on admission. 
2.Nosocomial pneumonia. Nosocomial pneumonia is a pneumonia developing in a 
patient at least 48 hours after hospital admission, or developing in a patient who has 
been hospitalised in the previous month. Nosocomial pneumonia can be further 
classified as non-ventilator or ventilator-associated pneumonia (V AP), and the latter 
may be divided into those occurring early within 5 days of admission (early onset 
pneumonia [BOP]) ,and those occurring after 5 days of admission. 36,39. 
3. Aspiration pneumonia. Aspiration pneumonia is defined as a pneumonia 
occurring in a patient following a clear history of aspiration, or in a patient who has a 
depressed level of consciousness where the likelihood of aspiration is high. The 
aspiration may either have occurred in the community i.e. community-acquired or in 
the hospital i.e. nosocomial. 
4. Pneumonia in immuno-compromised hosts. This includes patients whose 
immunity is significantly depressed as a result of either disease or drugs and in 
particular includes patients who have had transplants and patients with HIV infection. 
5. Non-responding pneumonia. This is a term reserved for patients who have failed 
to improve after 5 to 7 days of antibiotic therapy. Whilst there is usually no 
worsening of the disease there is minimal or no response. 
Patients with slowly responding pneumonia may also fall into this category as they 
would require a similar clinical approach but these patients would have a definite but 
slower than expected response.. The condition of non-responding pneumonia may 
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also be referred to as non resolving or slowly resolving pneumonia and, since the 
initial presentation of this thesis, three new reviews on the subject have been 
published.40-42 
These patients form a specific group which reqmres specific diagnostic and 
therapeutic approaches. 
'f 
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CHAPTER2 
PATHOGENESIS 
Introduction 
Pneumonia occurs when the normal pulmonary defence mechanisms are unable to 
prevent the proliferation of micro-organisms which have gained access to the lung. 
These organisms multiply and cause pulmonary parenchymal inflammation, with an 
influx of inflammatory cells, interstitial fluid and alveolar exudate; this results in a 
systemic inflammatory response, and deterioration in pulmonary gas exchange. The 
development of pneumonia therefore depends on the balance between the numbers, 
virulence and pathogenicity of the micro-organisms, and the host immune-defence 
mechanisms.43-45 
The organisms causing pneumonia may either originate from within the patient 
(endogenous) or from the environment or other carriers (exogenous). There are six 
main routes for entry, which are largely determined by the type of micro-organism, 
and include: inhalation, usually in droplet form, aspiration, micro-aspiration with 
subsequent colonisation of the respiratory tract, and haematogenous seeding, with 
inoculation and direct spread from contiguous sites being less common. More recently 
with recognition of bowel failure in critically ill patients, bacterial translocation from 
the gut as a source for pulmonary infection has been suggested, but this mechanism 
I~ 
remains speculative, with recent literature refuting this entity.46,47 In~lation is 
only important in nosocomial infections or near drowning where non-respirable fluid 
from ventilatory apparatus may enter the lungs,48 however it can be largely 
disregarded as a cause of community-acquired pneumonia, unless the patient is on 
some form of home inhalation therapy. 
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1. Routes of lung infection 
1.1 Aspiration. 
Aspiration, usually micro-aspiration of endogenous micro-flora from the 
oropharynx into the lungs is becoming recognised as one of the most 
important causes of both community-acquired and nosocomial 
pneumonia.43,49,50 This is the most likely route of pneumonia caused by S. 
pneumoniae and H. influenzae, which are by far the most common causes of 
community-acquired pneumonia. 9 ,51,52 
It is evident that, even in normal people, small amounts of oropharyngeal 
secretions are aspirated during sleep. 53 Any decrease in the level of 
consciousness makes aspiration more likely. This mechanism is of particular 
importance in alcoholics where oropharyngeal reflexes are frequently more 
depressed, and in the elderly and those who are receiving hypnotics or 
nocturnal sedation. Aspiration is probably the major predisposing cause for 
the increased incidence of pneumonia in these patients. It may also account 
for the high incidence of K. pneumoniae pneumonia in alcoholics. Other 
patients at high risk of aspiration are those with bulbar dysfunction, especially 
those patients who are endotracheally intubated or have tracheostomies. Both 
these forms of intubation render the protective laryngeal reflexes incompetent, 
and in spite of appropriate cuff inflation, allow ongoing aspiration of supra 
cuff secretions. This is undoubtedly one of the most important mechanisms 
responsible for the high incidence of nosocomial pneumonia in patients who 
are intubated.54-56 
The organisms which are aspirated in the normal individual comprise the 
normal flora of the oropharynx, including S. pneumoniae, H. influenzae, S. 
aureus and Moraxella catarrhalis. In the elderly and in patients who are ill, 
particularly those who are hospitalised, the flora of the oropharynx and upper 
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respiratory tract is recognised to change, with colonisation by Gram negative 
Enterobacteriaceae becoming common. 57,58 
While anaerobic microbial flora form the major component of normal flora 
they are seldom implicated as important pathogens in pneumonia except in 
cases of aspiration pneumonia or lung abscess. 59 The reason for this could be 
that anaerobic cultures are seldom performed in pneumonia unless special 
microbiological specimens are obtained. The host defences may also be 
capable of preventing proliferation of the usually less invasive anaerobic 
micro-organisms, unless there are additional anaerobic conditions such as 
would occur with a major aspiration. 
1.2 Aerogenous inhalation. 
The inhalation of micro-organisms is a far less common portal of entry, 
however, certain agents and in particular viruses (Influenza A, Respiratory 
Syncytial Virus, and Para-influenza Viruses), Mycoplasma pneumoniae, 
Legionella pneumophila and Mycobacterium tuberculosis, are almost 
invariably transmitted via this route. These infections are usually transmitted 
in droplet form from other infected people, or from unaffected carriers.43,60 
Legionella pneumophila, an organism which is frequently found in water, is 
often transmitted from a water supply reservoir, and may gain entry to the 
patient from humidifiers, air-conditioners or showers.5 This route of infection 
is the cause of epidemics of viral and Mycoplasma pneumoniae infections. 
Outbreaks of influenza in winter, and clusters of Mycoplasma pneumoniae 
infections occurring in young people who are confined together, such as in 
army barracks, occur by this mechanism. 61,62 A similar situation is seen in 
outbreaks of histoplasmosis in people who have been in infected caves, and 
who have inhaled the spores of Histoplasma capsulatum. 
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1.3 Colonisation. 
Initial colonisation of the oropharynx or upper airways, followed by infection 
is an unusual mechanism for community-acquired pneumonia, except in those 
who have pre-existing disease, particularly broncho-pulmonary disease .This is 
an important consideration in patients who have an underlying bronchial 
abnormality, such as bronchiectasis or chronic bronchitis, which allows 
adherence and colonisation by such organisms as either S. pneumoniae or H. 
influenzae most commonly.43,63 Such colonisation of the lower respiratory 
tract usually causes relatively minor inflammatory effects with increased 
mucus production. At times, when there is additional derangement of the 
natural barriers such as following influenzae, the colonisation by these 
organisms may proceed to active bronchial infection and even parenchymal 
invasion. 64 Thus in patients with chronic obstructive pulmonary disease 
infections with H. influenzae are far more common than in normal patients. 
Patients with cystic fibrosis form a unique group as they are frequently 
colonised with either a mucoid form of Pseudomonas aeruginosa or 
Staphylococcus aureus. Pneumonia in these patients is often caused by these 
organisms. 65 
Any systemic disease which alters the immune defence to allow colonisation 
of the gastro-intestinal tract, and upper or lower respiratory tract with 
potentially pathogenic organisms, may predispose to pulmonary infection. 
This is particularly relevant in hospitalised patients who are commonly 
colonised with Gram negative bacteria. In the intubated patient, colonisation 
of the oropharynx is but a step away from tracheal colonisation, and invariably 
precedes infection in the majority of patients who develop nosocomial 
pneumonia. 49 ,66,67 
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1.4. Haematogenous route. 
This route of infection is relatively uncommon in community-acquired 
pneumonia, and when it occurs, is frequently caused by infections with S 
aureus, arising from either soft tissue, bone, or joint infections, which may 
not necessarily have been obvious on initial presentation. 68 Other 
haematogenous infections may be associated with septic venous thrombosis 
involving the internal jugular vein secondary to ear infections, intravenous 
lines, or septic pelvic thrombophlebitis associated with gynaecological sepsis. 
These infections are frequently poly-microbial, often involving anaerobic 
organisms. 68-70 
The haematogenous route of infection is also seen in immunocomprornised 
patients with invasive aspergillosis.71 This route of infection frequently has 
characteristic multi-lobular opacification on the chest radiograph, which may 
coalesce to diffuse opacification if the disease progresses. 69 
1.5. Spread from contiguous infection. 
This route of infection is exceedingly uncommon, but may occasionally be 
seen secondary to a mediastinitis, pericarditis or rupture of a liver abscess 
through the diaphragm. 
1.6 Inoculation. 
Inoculation, as opposed to inhalation, is the direct introduction of droplets, too 
large to be normally respirable, which are not conventionally inhaled but 
rather mechanically sprayed directly into the lungs. This form of pneumonia 
is invariably associated with ventilatory or nebuliser apparatus, and as such is 
frequently nosocornial in origin. It may however occasionally be the route of 
infection with agents such as Legionella pneumophila, where inoculation may 
occur as droplets from hurnidifiers.48 
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2. Pathogenicity of micro-organisms. 
The majority of pneumonias result from an underlying abnormality of the host 
defence mechanisms, leading to an inability to suppress the load of pathogenic 
organisms presented to them. Others are however related to the intrinsic 
pathogenicity of the particular agents, which allows them to cause a 
pneumonic process in spite of normal defence mechanisms.72 Although these 
agents may be highly infectious, they are not necessarily particularly virulent 
and may cause only mild disease. They include the respiratory viruses, 
Mycoplasma pneumoniae, Chlamydia spp. and Histoplasma capsulatum. 
These organisms are easily transmitted between individuals and tend to spread 
by the aerogenous route. They frequently cause epidemics or clustering of 
infections where people are living in close proximity to one another.44 
3. Host defence abnormalities. 
Numerous respiratory tract defence mechanisms are active, and prevent 
damage and infection occurring to the delicate pulmonary tissues. These may 
be conveniently classified into physical, humoral and cellular mechanisms. 
(see table 2). 
3 .1. Physical barriers 
3 .1.1 Air conditioning effects 
The upper airway including the nose and oropharynx presents a large surface 
area of moist, warm, mucosa to the inhaled air which provides an efficient air-
conditioning effect. By the time air reaches the lobar bronchi it has already 
been warmed to body temperature and has been fully humidified. Low 
concentrations of soluble gases such as chlorine, ammonia and sulphur 
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dioxide may be completely removed. If the soluble gases are in high 
concentrations, or if insoluble gases such as ozone and oxides of nitrogen are 
present, they will reach the respiratory bronchioles, where damage leading to 
bronchiolitis may occur. 
Although the air conditioning effect itself has little influence on destroying 
bacteria, it prevents damage to the respiratory bronchial mucosa and 
mucociliary escalator, which help to prevent any infection occurring 
secondary to physical damage.45,60 
3.1.2 Aerodynamic effects 
Particle deposition in the airway occurs by a number of mechanisms including 
inertial impaction, sedimentation and diffusion. The mechanism which results 
in the most deposition depends on the size, shape and density of particles, 
airflow velocities, respiratory frequency, and airway calibre. 
a) Inertial impaction 
Large particles are removed by the vibrissae filter at the nares, but those of 30 
microns or less pass to the nasal cavity with its large surface area created by 
the septum and turbinates. Here 90% of particles of 10 microns and 75% of 5 
micron particles are removed. The posterior nasopharynx and pharynx remove 
the remaining large particles. The tonsils and adenoids form a ring of 
immunologically active tissue in this area and this filters out impurities. The 
air entering the trachea has few particles larger than 5 - 10 microns because of 
the efficiency of inertial impaction. However only 20% of particles smaller 
than 5 microns are removed by impaction.45,60 
Table 2: Pulmonary host defences 
1. Physical barriers 
1.1 Air-conditioning effect 
1.2 Aerodynamic filter 
a) Inertial impaction 
b) Sedimentation 
c) Diffusion 
1.3 Airway reflexes 
a) Cough 
b) Sneeze 
c) Bronchoconstriction 
d) Laryngospasm 
1.4 Mucocilliary escalator 
2. Humoral barriers 
2.1 Non specific soluble factors 
a) Lysosome 
b) Lactoferrin 
c) Interferron 
2.2 Immunologic barriers 
a) lgA 
b) IgM 
3. Cellular barriers 
3.1 Alveolar macrophages 
3.2 Neutrophils 
3.3 Lymphocytes 
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b) Sedimentation 
This is the chief mechanism for removal of particles between 5 and 0.6 
microns in size. Gravitational forces allow the particles to settle in the 
peripheral airways from the fifth bronchial division to the terminal lung units 
where the airflow velocity is less than 10 cm per second, which is necessary 
for sedimentation. This condition of low flow also exists adjacent to the 
airways higher up in the bronchial tree, however the main region for 
sedimentation is where the total airflow is low. 
c) Diffusion 
Particles of less than 0.01 microns in size are deposited by diffusion or 
Brownian movement in the peripheral portions of the lung. It is interesting to 
note that particles between .1 and .5 microns are virtually unaffected by the 
mechanisms of diffusion and sedimentation, and only 20% are retained. The 
aerodynamic diameter of viruses vary between .02 and .25 microns, whereas 
bacteria vary between .25 and 10 microns and, although many of these fall 
within the particle size that are hardly retained within the lungs, they usually 
form part of droplets of a greater size and are therefore deposited. 60 
3.1.3 Airway reflexes45,60 
Cough, sneeze, gag, and bronchoconstrictor reflexes are all vital in preventing 
the inhalation of foreign agents, upper airway secretions, food particles, and 
gastric acid which has been refluxed. The lower oesophageal sphincter, which 
prevents reflux, may also be considered as an airway reflex. The lower 
oesophageal sphincter mechanism is particularly important in the critically ill 
or hospitalised patient, where the stomach may become colonised with 
potentially pathogenic micro-organisms.43 
a) Cough 
An effective cough can produce an explosive expiration with an airflow of 
25,000 cm per second, and this blast of air removes secretions from the trachea 
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and major bronchi. It has little effect on the more peripheral airways other 
than acting as a gas liquid pump, which moves mucus to a proximal bronchus 
where it can be coughed up. The mechanism of cough is a deep inspiration 
often to total lung capacity followed by glottic closure for about .2 seconds 
with maximum chest wall, diaphragm and abdominal muscle contraction. 
Prior to glottic opening, the intra-thoracic pressure rises to as much as 50 to 
100 mm Hg pressure; the glottis then opens and allows an explosive rush of 
air out through the mouth. Dynamic compression of the airways will increase 
the net velocity of airflow. The cough is the most important protective 
mechanism of the entire airway, and failure of this mechanism is a common 
cause of community-acquired or nosocomial pneumonia. Failure of the 
cough defence is a frequent cause of pneumonia associated with 
neuromuscular weakness and inco-ordination, severe chronic obstructive 
pulmonary disease, asthma and postoperative and post-traumatic pneumonia. 
b) Sneeze 
A sneeze is similar to a cough, but inspiration is usually limited, and forced 
exhalation occurs through the nose. This protective mechanism results from 
nasal stimuli. 
c) Bronchoconstriction 
This reflex of bronchoconstriction may result from any gaseous, physical, 
liquid or particulate stimulus. Bronchoconstriction acts a defence mechanism 
by limiting air entry into the peripheral distal air spaces and thereby reducing 
damage. It usually has little part to play in the prevention of pneumonia.45 
d) Laryngospasm 
This laryngeal reflex results in intense closure of the true and false vocal cords 
and prevents aspiration of secretions and other noxious substances. It is an 
important reflex which prevents macro-aspiration in all but deeply comatosed 
patients. 
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3 .1.4 Mucociliary escalator 
The mucus and mucociliary transport system of the upper and lower airway 
provide a physical, physiological and immunological barrier against the 
environment.73 Particles of foreign material, including bacterial and other 
pathogenic agents, are trapped in the mucous blanket lying over the ciliated 
epithelium, and are moved up the mucociliary escalator to a point in the 
respiratory tree where the bronchial secretions can be expelled by coughing. 60 
Failure of this defence mechanism may occur either due to an abnormality of 
mucous production, or ciliary function. In diseases such as chronic bronchitis, 
the number of mucus goblet cells increases, and excessive quantities of mucus 
are produced. This excessive mucous production, combined with pus cells 
from the chronic inflammation, lead to a loss of elasticity with the increased 
viscosity, resulting in a decreased efficiency of the mucociliary escalator with 
increased propensity to infection. 
Ciliary action may be reduced by tobacco smoke, dry gases and other air 
pollutants, and a similar effect may be evident in diseases including asthma, 
bronchiectasis and recent viral and Mycoplasma pneumoniae infections. This 
ciliary dysfunction may require a month or more to return to normal. Other 
primary ultra structural defects of the cilia are seen in genetic disturbances 
such as the immotile cilia syndrome and Kartagener's syndrome. 
Abnormalities of these two components of the mucociliary escalator 
contribute significantly to inflammatory bronchial disease as well as 
predispose to pneumonia. 7 4-7 6 
Cystic fibrosis, an autosomal recessive genetic disorder which has recently 
been localised to an abnormality at the Cen-q22 region of chromosome 7, has 
a major influence on this barrier which leads to the clinical disease.77,78 The 
pathogenesis is characterised by 2 general features: 1.) The affected cells are 
epithelia. 2.) The abnormality in the epithelial cells involve the regulation of 
ion transport: there is an abnormal regulation of the activation state of the 
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plasma membrane chloride channels, as well as an increased absorption of 
sodium ions in the airway epithelia. This results in decreased water content of 
secretions which changes the visco-elastic properties and linkage between the 
mucous component of secretions and cilia. This reduces both mucocilliary and 
cough clearance of secretions. 
These initial defects resulting in reduced clearance of thickened secretions 
promote infections by S. aureus and Ps. aeruginosa The susceptibility to 
these infections may be increased by a change in the sulphate content of 
airway cell surface glycocalyx which facilitates bacterial adherence.79 This 
persistent bacterial colonisation and infection, with the release of exotoxins, 
lead to airway destruction and bronchiectasis. Lipopolysaccharides, exotoxin 
A, and a cell wall associated rhamnolipid from Ps. aeruginosa have all been 
implicated. 80 The main cause of damage is an excessive inflammatory host 
response with inflammatory cell enzymes being the main players rather than 
any lack of immunological response. 
3.2 Humoral barriers 
3.2.1 Non specific soluble factors. 
A number of non-specific circulating soluble factors provide a defence against 
infection and protect the integrity of the mucosa! epithelial surface. These 
include lysosomes, lactoferrin, interferon, complement and numerous 
cytokines. When these cytokines, particularly tumour necrosis factor (TNF) 
are excessively activated, they appear to be the mechanism by which multiple 
system organ dysfunction occurs. 
Lactoferrin is a molecule synthesised in glandular mucosa! cells which has 
potent bacteriostatic activity, probably due to the binding of metallic ions. 
Lactoferrin together with IgA plays a leading role in preventing bacterial 
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invasion. The other circulating factors have less well defined effects m 
preventing infection, but all appear to have a role. 
3.2.2 Immunologic defences 
Antibodies are complex glycoproteins known as immunoglobulins. Both IgA 
and IgM are developed following exposure to an antigen, and they play a 
leading role in preventing infection.81,82 The effectiveness of these 
antibodies in preventing infection usually correlates with their quantity in the 
bronchial secretions, rather than in the circulation. Dimeric IgA occurs 
predominantly on mucosa! surfaces, whereas monomeric IgA occurs in the 
serum. The polymeric IgA and IgM are linked, via disulphide bonds, with a 
protein called J-chain. It is produced by B lymphocytes and is required to 
initiate secretion of lgM and dimeric IgA. Secretory component is another 
protein which is uniquely associated with mucosa! lgA and lgM where it acts 
as a membrane receptor facilitating endocytosis, transport and secretion of the 
immunoglobulin onto the mucosa! surface. Most important of these local 
secretory antibody defence mechanisms in the lung are secretory IgA 
antibodies, which form a primary defence mechanism. This mechanism is 
particularly active in viral infections, including Rhinovirus, Adenovirus, 
influenza viruses, para-influenza viruses and Echo viruses. 
The role of antibodies in protection against infection requires enlisting host 
effector cells and activating the complement system to eradicate infecting 
organisms in a co-ordinated way. Antibodies and complement need to act 
against organisms in an extra-cellular site to minimise damage to host cells. 
Specific antibodies achieve this extra-cellular activity by: 
i.) Opsonisation of organisms for ingestion and destruction by phagocyte cells 
ii.) Cell-free lysis of susceptible organisms by the complement system 
iii.) Neutralisation of toxins 
iv.) Inhibition of attachment of organisms to host cells. 
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v.) Inhibition of the infectivity of extracellular viruses. 
Organisms that are harboured in an intracellular situation are in a sanctuary 
where they are protected against antibodies or complement. 
3.3 Cellular barriers 
3.3.1 Alveolar Macrophages 
The lung macrophage originates from blood monocytes and migrates out of 
the bloodstream across the pulmonary capillary endothelium. 83. These cells 
may also proliferate after entering the alveoli. There are a number of different 
kinds of lung macrophages including bronchial, alveolar, and interstitial 
macrophages. The alveolar macrophage represents a population that is 
morphologically and functionally heterogeneous. It is characterised by a 
lobulated nucleus and vacuolated cytoplasm containing many mitochondria 
and lysosomes, and their size may vary from 12 to 40 m. They can be further 
divided into sub populations with different membrane-receptor expressions 
and cell function such as phagocytosis and mediator release. 84 
Macrophages interact with their environment by binding molecules to specific 
surface receptors. The alveolar macrophage is the resident phagocyte of the 
alveolar space and is one of the most important defence mechanisms against 
pulmonary infection. This function is facilitated by surface receptors for the 
Fe fragment of several immunoglobulins and for the complement fragment 
C3b which are essential for the phagocytosis of opsonised micro-organisms. 85 
These cells phagocytose both organic and inorganic material deposited distal 
to the ciliated airways. The majority of these are subsequently carried 
upwards by the mucociliary escalator and expectorated or swallowed, but 
some enter the lymphatics, and drain to regional lymph nodes, or directly into 
the venous system. Occasionally macrophages may enter the bloodstream 
directly. These cells may also be stimulated to produce a number of soluble 
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substances necessary for lung defence. The macrophages may also be 
activated by interaction with lymphocytes to produce increased bacterial 
killing.83 
3.3.2 Neutrophils 
Neutrophils are not normally present in the lung but congregate in response to 
infection or other pulmonary insults, and they form the basis of the 
inflammatory response in pneumonia.45 They produce soluble factors 
including tumour necrosis factor, interleukins, and platelet activating factor, all 
of which are bactericidal. They also phagocytose organisms directly. Over-
production of the soluble factors due to marked aggregation of neutrophils in 
the lung, will lead to progressive capillary leak and the adult respiratory 
distress . syndrome (ARDS) associated with sepsis. This mechanism rather 
than pneumonic inflammation may sometimes account for the rapid 
radiographic spread of pneumonia. 
3.3.3 Lymphocytes 
A local cell mediated immune response exists in the lung, which is similar to 
the humoral IgA type response. Both B and T cells are present in the lung, and 
these appear to produce antibodies when stimulated by direct intra-nasal or 
intra-tracheal antigen presentation. These cells may come from the blood, but 
are more likely to arise from bronchus-associated lymphoid tissue.45 T cells 
obviously form a major barrier against infection, and when this defence is 
defective, such as in transplant, other immunosuppressed, or particularly in 
AIDS patients, pulmonary infections with opportunistic organisms, 
particularly Pneumocystis carinii and Mycobacteria spp., occur frequently. 
23 
4. Specific host and micro-organism interactions. 
4.1 S. aureus. 
Invasive infection by S. aureus requires a series of interactions with the host 
including adhesion, invasion, chemotaxis of neutrophils, phagocytosis, and 
intracellular killing. 
4.1.1 Adhesion 
Colonisation by S aureus requires initial adhesion to host cells and this occurs 
in three situations. 
i.) Adherence to nasal mucosa is mediated by the teichnoic acid component of 
S. aureus which is increased in carriers or following infection with Influenzae 
A. 
ii.) Adherence to disrupted skin , endothelial surfaces and foreign surf aces 
requires interaction with fibrinogen, fibronectin, laminin and possibly collagen 
IV. 
iii.) During septicaemia attachment of S. aureus involves both adherence and 
post adherence events, such as phagocytosis by endothelial cells. These 
provide a solid anchoring system to allow bacterial settling. 
4.1.2 Invasion 
After colonisation, the organism needs to penetrate through the defences 
provided by the epithelial or mucosa! surfaces. Little is known about how 
mvas1on occurs. 
4.1.3 Chemotaxis 
Following invasion, ingestion and killing by both the neutrophil and 
macrophage systems become the major line of defence. Migration of these 
cells to the site of infection requires elaboration of microbial and host specific 
signals. Cell wall and extra cellular products of S. aureus such as 
peptidoglycan, teichoic acids and protein A are all involved. The major signal 
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results from activation of the complement system which is triggered by these 
products. 
4.1.4 Opsonisation. 
Recognition of the micro-organism by the phagocytes is mediated by: 
i) their receptors for the Fe fragment of the IgG immunoglobulins; 
ii) receptors for the activated subunit of C3b; 
iii) and possibly other components of complement. 
In some strains of S. aureus opsonisation may reqmre highly specific 
antibodies; however, in most, complement opsonisation will override this 
specificity.86 In serum from non-immune subjects complement activation via 
the classical or alternate pathway provides the major part of the opsonic 
activity :87 In hyper-immune serum, opsonisation is largely a result of IgG 
activity. 
The peptidoglycan matrix is also a major determinant of opsonisation and it 
can trigger opsonisation in the absence of immunoglobulin by activation of 
either the classical or alternate complement pathway. 
Protein A plays a triple antiphagocytic role in the bacteria-cell opsonisation 
process by its binding to the Fe portion of IgG. Extracellular soluble protein A 
can react with the Fe terminals of the IgG molecules of human serum 
producing immune aggregates that consume complement. It may also bind to 
the Fe portion of specific anti staphylococcal antibodies coating the organism 
with their Fab fragment, thereby preventing any further interaction of the 
complex with the Fe receptor of phagocytes. Cell bound protein A binds to 
the Fe fragment of any IgG molecule eliminating both non-specific and 
specific antibodies. The capsule of S. aureus which may be present in as 
many as 50% of human isolates will also impair phagocytosis, probably by a 
mechanism of steric hindrance. 86 
25 
4.1.5 Intracellular killing. 
Once phagocytosed, the staphylococci are rapidly killed and degraded in the 
phagocytic vacuole. Prolonged survival may occur in some organisms and 
this may account for the high recurrence rate of S aureus infections. 88 
Oxygen dependent bactericidal mechanisms including 0-2. H202 and other 
free radicals are most important, although the low pH within the vacuole, 
lactoferrin and granular cationic proteins may also play a role. 
4.2 Ps. aeruginosa. 
Ps. aeruginosa rarely causes disease in healthy persons and usually behaves 
like an opportunistic pathogen, requiring a breach of host defences to cause 
infection. This usually involves disruption of the physical barriers such as 
skin or mucous membranes, or their circumvention by intravenous lines, 
urinary catheters or endotracheal tubes. They are therefore infrequent causes 
of community-acquired infection. Its adaptability to a wide range of physical 
conditions and its resistance to antibiotics allows it to exist in large numbers 
close to its prospective host, and this accounts for its pathogenicity. The fact 
that the pathogenicity of Pseudomonas is multifactorial is suggested by the 
number of potential virulence factors as well as the broad spectrum of disease 
that it causes. Of most relevance in pneumonia is its association with chronic 
lung disease, particularly cystic fibrosis. 
Pseudomonas infections usually comprise three distinct, consecutive stages: 
i) bacterial attachment and colonisation; 
ii) local invasion; 
iii) dissemination and systemic disease. 
4.2.1 Colonisation 
Bacterial adherence to epithelial cells is crucial for colonisation of the 
respiratory tract. Protein structures on the surface of the bacterium called pili 
are responsible for adherence on all epithelial cells. 89 Fibronectin in contrast 
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to S. aureus infections, usually protects against adherence by Pseudomonas 
aeruginosa. Sputa from patients with chronic lung disease or cystic fibrosis 
contain high levels of protease which breaks down the fibronectin coating 
leading to adherence. Cellular injury may also play a role as Pseudomonas 
like S. aureus also adheres to epithelia damaged by viral infection. 
Pseudomonas pili are attachment organelles or adhesins as both purified pili 
and antibodies to these structures block bacterial adherence to epithelial cells. 
It is likely that specific molecular sequences on these structures act as ligands 
that react act with complimentary sequences or receptors on host cells. 
Galactose or mannose -bindings lectins of Pseudomonas may represent such 
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ligands. The mucoid exopolysaccharide of mucoid strains and the pili of 
nonmucoid strains of Pseudomonas represent adhesins for tracheal epithelial 
cells. 
4.2.2 Local invasion 
Invasion follows colonisation and factors involved in this progression include 
cell wall associated structures that resist phagocytosis, or interactions with 
complement and antibodies, and also the ability of its extracellular enzymes or 
toxins to break down physical barriers. 
Elastase and alkaline protease are the best characterised of the cellular 
proteases and both are clearly associated with virulence causing necrosis in the 
lung, skin, and other structures. These enzymes lead to disruption of 
connections between cells and specifically degrade basement membrane 
associated laminin leading to disruption of respiratory cilia as well as cleaving 
type ill and IV collagen, and solubilising human lung elastin. 90 They may 
also make nutrients available for further bacterial growth thus further aiding 
invasion. Pseudomonas protease may also inactivate complement and the 
cleavage of IgG. 
Cytotoxin another toxin widely produced by Pseudomonas is largely cytotoxic 
to neutrophils. 
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Haemolysins, one a heat labile protein phospholipase c , and another a heat 
stable glycolipid, act synergistically to break down lipids and lecithin leading 
to tissue necrosis. Phospholipase may also contribute to Pseudomonas 
pneumonia by degrading lung surfactants.91 
4.2.3 Dissemination and systemic disease. 
Dissemination from local sites of infection is aided by the same cell associated 
and extra cellular products responsible for invasion. Pseudomonas is 
inherently resistant to phagocytosis because of the mucoid exopolysaccharide, 
as well as by having direct bactericidal resistant mechanisms. Pseudomonas is 
however susceptible to natural antibodies or IgM, activation of classical and 
alternate complement pathways, and an adequate number of functioning 
neutrophils. These stringent criteria for adequate clearance by host defences 
are further tested by complement inactivation and immunoglobulin-cleaving 
by the organism itself, which may surpass the capacity of the host immune 
system. 
Systemi_c illness or death, is most likely to result from excessive uncontrolled 
inflammatory mediator release largely caused by the lipid A moiety of the 
lipopolysaccharide endotoxin, and also exotoxin A. In addition to causing 
shock Exotoxin A also mediates local as well as metastatic disease by its 
ability to cause tissue necrosis, including dermonecrosis. 
28 
CHAPTER3 
PATHOLOGY OF PNEUMONIA 
Introduction 
Bacteria, viruses and other agents enter the lungs by various routes and, should the 
lung defences fail to clear the organisms, they will invade the lung tissue and cause 
inflammation. Differing forms of tissue damage and cellular responses are initiated 
by the different pathogens which results in distinctive pathological changes. These 
identifiable features led to the pathological classification of pneumonia, by causative 
organisms, first suggested by Cecil in 1922, and still in widespread use. The 
radiological classification into broncho or lobar pneumonia is also evident 
pathologically, and although also used, is of less value. 
In bronchopneumonia the damage occurs primarily in the terminal and respiratory 
bronchioles. Here the walls are damaged to a variable extent with spread of 
inflammation into the surrounding peri-bronchiolar alveoli. In lobar pneumonia the 
organisms produce copious, watery, inflammatory exudate that spreads directly into 
the air passages and related alveoli. This spread extends to involve adjacent lobules 
and segments of lung. Although there is bronchial and bronchiolar wall involvement 
the spread is largely along the lumen of the air passages rather than through the walls 
of the terminal air passages.92 
Interstitial pneumonia or pneumonitides m contrast to both lobar and 
bronchopneumonia which involve varying degrees of airspace consolidation , cause 
mostly interstitial inflammation confined to the alveolar walls and connective tissue 
around bronchovascular structures. There is little airspace exudation. Organisms that 
produce this type of inflammation include M. pneumoniae, viruses, Chlamydia spp., 
Coxiella bumettii and Pneumocystis carinii. This pattern of inflammation may also 
however be seem with many noninfectious causes including drug reactions, radiation 
pneumonitis, hypersensitivity pneumonitis and collagen vascular diseases. Mixed 
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patterns of airspace consolidation with interstitial inflammation may also occur 
frequently. This can be due to superimposed bacterial and viral infections creating a 
fibropurulent airspace inflammatory reaction with mononuclear interstitial 
inflammation and bronchiolar epithelial necrosis. Viral cytopathic changes and 
identification of bacteria with Gram staining, may provide diagnostic clues.93 
The development of abscesses, gangrene or haemorrhage in association with 
pneumonia is also dependent on the causative organism e.g. pneumolysin which is 
produced by pneumococci. 94-97 
It is also important to note that with modern day intensive care and antibiotic therapy, 
most of the classical pathological changes are seldom seen. Prolonged ventilatory 
support frequently precedes death. The pathological changes seen are modified by 
this ventilatory therapy and resemble non specific diffuse alveolar damage. The 
pathological process produced by certain organisms is relevant to the diagnosis and 
therapy, and a detailed description in certain pneumonias is warranted. 
1. Pneumococcal pneumonia 
Pneumococcal pneumonia, which is most frequently lobar in nature is caused by a 
number of different serotypes of pneumococci including, in order of decreasing 
frequency, type 1, 3, 2, 5, 7, 8 and 4.72 The early spread of pneumonia is caused by 
the outpouring of serous oedema fluid usually far beyond the initial focus of 
infection. 92,98 This response is dependent on: 
1) the size of inoculum of organisms; 
2) excessive mucus production in airways; 
3) presence of the inter-lobar septae which act as barriers to spread of infection; 
4) virulence of the organism; 
5) and the reaction of the host.99 
The most important factor in determining spread appears to be the ability of the 
different pneumococci to produce cytoplasmic proteins such as nuraminidase and 
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pneumolysins which are released during autolysis. Pneumolysin has been shown to 
disrupt the integrity of human respiratory epithelium and cause slowing of the 
cilia.72. 
The distribution of the pneumococcal pneumonia usually favours the posterior basal 
segment of right upper lobe and the apical segment of right lower lobe, both 
dependent regions and this suggests that aspiration of organisms is the most likely 
route of infection, although aerogenous infection undoubtedly also takes place as 
evidenced by outbreaks of pneumococcal pneumonia in men's shelters.100 
Classical sequential pathological changes are seen in the evolution of pneumococcal 
pneumonia in the absence of antibiotic therapy. 
Macroscopically the pathology may be divided into three distinct phases: a) spreading 
inflammatory oedema - this resembles any form of ARDS but the oedema fluid 
contains numerous organisms. b) red hepatisation - the lung is firm, airless and brick 
red in colour with petechiae and fibrin casing the pleura. The cut surface is congested, 
airless, and the smaller bronchi are plugged with fibrin. c) Grey hepatisation - the lung 
is firm, non-crepitant and covered with a thick film of fibrin. The cut surface is 
greyish yellow. d) Resolution - this stage shows a return of the normal red colour, 
though aeration and re absorption of fibrin will still take a longer time. 
Microscopically the lung progresses through the same four phases seen 
macroscopically. The early phase, though seldom seen as it progresses rapidly over a 
few hours, consists of oedema fluid, a few polymorphonuclear leukocytes and 
abundant pneumococci. This is followed by red hepatisation characterised by alveoli 
filled with red blood cells, fibrin and a few polymorphonuclear leukocytes. Alveolar 
capillaries are intensely congested and bronchial arteries may become obstructed 
proximal to the pneumonia. Grey hepatisation follows with the alveoli becoming 
choked with fibrin, large numbers of polymorphonuclear leukocytes and a few red 
blood cells. Pulmonary arterioles may become thrombosed and alveolar capillaries 
are inconspicuous. The thrombosis is probably caused by toxins produced by the 
pneumococc1. This phase is followed by resolution which is characterised by 
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infiltration of macrophages with phagocytic leukocytes and their entrapped 
pneumococci. 
Failure of the macrophages to function adequately causes persisting infection and 
incomplete resolution. Abscess formation, gangrene of the lung, and empyemata are 
well recognised late sequelae of incomplete resolution. Incomplete resolution with 
fibrosis is seen more commonly in the post antibiotic area and has been found to occur 
in 3.2% of 125 autopsies in patients with lobar pneumonia.101 Radiological 
resolution may be delayed for weeks or months, but by six months the majority of 
cases have resolved.9 More recently with effective mechanical ventilatory support, 
rapid spread of pulmonary infiltration is seen beyond the confines of the lung lobes on 
the radiograph. Histologically this is shown to be pulmonary oedema, typical of early 
ARDS, without the presence of numerous pneumococci. 
2. Staphylococcal Pneumonia 
Staphylococcus aureus is an uncommon cause of community-acquired pneumonia 
occurring in 3 to 8% of cases. It is nevertheless important as it has a high mortality 
particularly when associated with influenza infections; and its incidence has increased 
over the past few decades.102-104 These organisms used to be invariably sensitive to 
penicillinase resistant antibiotics, however more recently a small number, particularly 
in the hospital environment, are sensitive only to vancomycin, fucidic acid and 
clindamycin. This change in sensitivity pattern has paralleled a significant increase in 
the number of these methicillin resistant S. aureus isolates in nosocomial infections, 
and these organisms have also gradually appeared in the community, but fortunately 
still remains uncommon ( < 10% ). The route of acquisition of S. aureus pneumonia 
may be either aerogenous, endogenous following micro-aspiration, or haematogenous; 
The different routes of infection tend to result in two distinctive patterns of 
infection. 68,103,105,106 
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2.1. Aerogenous or micro-aspiration staphylococcal pneumonia. 
This type of pneumoma usually occurs in adults and frequently follows viral 
infections. It may also be associated with other factors such as old age, bronchial 
neoplasms or immunosuppression with steroids or other drugs. It may present with 
either a fulminant acute, or sub acute illness, characterised by bloody sputum with 
numerous gram positive cocci in clusters present on Gram's stain. The chest 
radiograph·has no typical features. Staphylococcal pneumonia complicating influenza 
has a mortality of over 40%.105 A preceding viral infection favours growth 
conditions for bacteria and S. pneumoniae, H. influenzae and S. aureus are commonly 
involved in secondary infection.107 S. aureus and viral co-infection however has the 
highest mortality, and this may be due to a protease secreted by some strains of S. 
aureus which can cause cleavage activation of the virus, and haemagglutination, 
resulting in rapidly increased viral proliferation and pathogenicity. 64 
Macroscopically the lungs are heavy, plum coloured, and the bronchi are filled with 
fluid that drains away leaving very inflamed bronchial mucosa. The larger bronchi 
often have a fibrinous pseudo-membrane that resembles a diptheretic membrane. 
Haemorrhages are widespread and parenchyma resembles haemorrhagic pulmonary 
oedema. The brunt of the disease is in the bronchi and bronchioles, but this spreads 
rapidly with necrotic bronchitis leading to thrombosis of adjacent lobular pulmonary 
arteries, with surrounding parenchymal oedema typical of ARDS. A less acute but 
more common form of the disease shows focal patches of peri-bronchial, greyish 
yellow areas of consolidation, which break down rapidly to form abscess cavities 
which are filled with sticky yellow pus, and are connected with small bronchi. These 
abscesses enlarge rapidly with pus spreading along the bronchi, demonstrating the 
tissue necrosing and pus promoting properties of S. aureus. These abscesses resolve 
slowly, becoming lined with granulation and fibrous tissue, and the adjacent 
parenchyma is extensively damaged and fibrosed, whilst the vessels may develop 
obliterative vasculitis. The cavities remained filled with pus with extensive 
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inflammatory cell reaction of the walls which gradually resolve. Staphylococcal 
infections of the lungs are frequently accompanied by a pleural reaction which may 
lead to an empyema in 7 to 27% of cases.102,106,108 
2.2. Haematogenous staphylococcal pneumonia 
Haematogenous staphylococcal pneumonia usually occurs less frequently than 
aerogenous or endogenous infection, however certain populations particularly young 
children in third world countries like South Africa, and drug addicts, have an equal or 
greater incidence of haematogenous staphylococcal infections.68,69,109 These 
usually present with classical radiological features typical of septic emboli, which 
usually include a number of discrete pulmonary infiltrates varying from 3 to more 
than 5 cm in size, are lobular in distribution, and may progress to more confluent 
opacification , or even diffuse opacification typical of ARDS in severe cases. The 
initial infiltrate frequently cavitates with walls which are initially 2 to 4 cm thick and 
which resolve into thin walled (less than 2 mm) cavities, which resolve completely 
with time.69,70,104 
Macroscopically the lungs appear similar to the previously described aerogenous 
pneumonia, however at a late stage there are characteristically multiple abscess 
cavities with almost complete destruction of lung parenchyma. Microscopically a 
pattern similar to endogenous infection is seen. Large pneumatocoeles are frequently 
seen in infants and young adults, and these may lead to pneumothoraces or 
empyemas. These occur more frequently with the haematogenous forms of the 
disease. They do occur in adults where they are seen less frequently than in the 
younger age group. 
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3. Klebsiella pneumonia (Friedlander pneumonia) 
This disease was described in 1882 by Friedlander who recognised a characteristic 
lobar pneumonia caused by a gram negative encapsulated bacillus. It is now 
uncommon in developed countries occurring in less than 1 % of community-acquired 
pneumonias. This organism has forty species plus serotypes, and includes Klebsiella 
pneumoniae, serotype 3; Klebsiella ozaenae, serotype 2,3 and 4; Klebsiella atlantii, 
serotype 1; Klebsiella edwardsie, serotype 1 and 2.92 The majority of cases of 
pneumonia (more than 80%) are caused by serotype 1 whereas the remainder are 
caused by serotype 2. Serotypes 1,2 and 3 are frequent commensals in the mouth and 
oropharynx of patients with carious teeth; 5.8% of unselected people may however 
also be colonised.110 
Primary Klebsiella pneumoniae pneumonia presents as an acute pneumonic illness, 
seen particularly in men over the age of 50 years, with poor dental hygiene or 
diabetes. 75% of cases are unilateral, occurring particularly in the posterior segment 
of the right upper lobe or the apex of the right lower lobe, which is a dependent area 
of lung and a characteristic site of inhalational infection. The disease usually starts in 
a lobular segment and spreads rapidly to involve the entire lobe. 
Macroscopically the lung appears consolidated, is a greyish red colour, and has a 
characteristic sticky exudate. Smears show numerous large encapsulated Gram 
negative organisms, and abscess formation usually occurs within a few days. 
Outpouring of this oedema fluid, and mononuclear cells with organisms, is seen 
microscopically. Alveolar destruction follows with a polymorphonuclear cell 
reaction, and, later granulation and fibrous tissue formation occurs. During the early 
stages acute alveolar inflammatory oedema occurs in the perivascular region, and 
peribronchial lymphatic channels are distended, and there is severe oedema of the 
interlobular septae. 
In the chronic stages, multiple abscess formation with granulation and fibrosis and 
secondary bacterial infection are seen. A quarter of these cases are associated with 
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empyema and again the posterior segment of the right upper lobe is commonly 
affected. 
4. Legionella pneumonia. 
All species of Legionella may produce a fibrinopurulent lobar or bronchopneumonia. 
Macrophages and neutrophils are the predominant inflammatory cell types within the 
alveoli and leucocytoclasis is a common feature. Organisms can often be found near 
areas of cell debris. Thrombosis of small vessels, septic arteritis, and alveolar wall 
necrosis occur and there is frequently a heavy mixed interstitial inflammatory pattern 
together with airspace inflammation.111 
5. Mycoplasma pneumonias. 
Pathologically these orgamsms all produce and interstitial pattern of pneumonia. 
Mycoplasma may produce a highly variable pattern ranging from lobar or lobular 
consolidation, to a diffuse interstitial pneumonitis. The microscopic picture is non-
specific with a mixed interstitial inflammatory infiltrate including lymphocytes, 
plasma cells, and histiocytes. There may be an associated acute necrotising 
bronchiolitis and tracheobronchitis and microscopic peribronchiolar abscesses. Large 
collections of lymphocytes with or without follicle formation may be found around 
airways. The cytological atypia of viral interstitial pneumonitis is not a feature. 
Infrequently in severe disease diffuse alveolar damage with hyaline membrane 
formation may occur. 
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5. Viral pneumonias. 
Viral agents produce an interstitial pattern of pneumonia similar to that of 
Mycoplasma pneumoniae. The lung responds in a similar way to the common viruses 
causing pneumonia, including Influenza A and B, Respiratory syncytial virus (RSV), 
Adenovirus, Rubeo/a and Varicella. The pneumonic disease may be patchy or diffuse. 
Macroscopically the lung appears congested and subcrepitant, without obvious 
consolidation. The pleura is smooth and pleuritis or effusions uncommon. 
Microscopically the alveolar septa and interstitium is widened with mononuclear 
inflammatory cells and oedema. Neutrophils may be seen in very acute cases. The 
alveoli are frequently filled with proteinaceous acellular material, and hyaline 
membranes occur heralding diffuse alveolar damage or ARDS. Ulcerative bronchitis 
and bronchiolitis , haemorrhage, or a superimposed bacterial infection may also be 
present. 
A few viral agents have specific cytopathic changes which may aid in diagnosis:-
i) Adenovirus produces amphophilic intranuclear inclusion bodies within bronchiolar 
epithelial cells. There is frequently bronchiolitis characterised by necrosis of 
bronchiolar epithelium and airway plugging with mucus, desquamated cells, fibrin 
and neutrophils. Pneumonitis, bronchiolitis or mixed patterns may occur. 
ii) Measles virus pneumonitis is characterised by large multinucleated, syncytial 
epithelial cells within air spaces. These giant cells have up to 100 intact or pyknotic 
nuclei and eosinophilic cytoplasm. 
iii) Respiratory syncytial virus infection results in necrosis of bronchiolar epithelium 
and cytopathic changes to infected parenchymal cells such as nuclear enlargement and 
chromatin dispersion. The regenerating reserve cells containing the virus form a 
syncytium for which the virus was named. It produces a necrotising bronchiolitis 
with mucopurulent plugging. 
iv) Cytomegalovirus has characteristic cytopathic changes. The infected cells are 
large with abundant cytoplasm and megalic, pleomorphic nuclei harbouring 
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eosinophilic inclusion bodies surrounded by a clear halo. Smaller basophilic 
cytoplasmic inclusions are present and represent viral coat protein or complete viral 
units. These changes occur in bronchiolar epithelium, alveolar lining cells, intra-
alveolar histiocytes and endothelial e:ells. 93 
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CHAPTER4 
AETIOLOGY OF PNEUMONIA 
Pneumonia is usually caused by a relatively small number of different bacterial and 
viral organisms, and less commonly it may even be caused by other types of 
organisms including spirochetes, nematodes or a variety of other potentially 
pathogenic species. The type of pathogenic organism will be influenced by a number 
of factors including regional, seasonal, exposure, and host differences. Using a 
classification which incorporates these factors, which is easily applicable, and which 
thus helps to define the spectrum of pathogenic organisms is important for clinical 
management decisions. The commonly used classification dividing pneumonia into 
community-acquired infection, nosocomial infection, post aspiration infection, and 
infection in immunocompromised patients is thus appropriate and useful. In 
community-acquired infections in particular, a number of additional factors may all 
influence the incidence of different pathogens, and these include age, the presence of 
underlying disease, domicile of patient and seasonal and regional differences. The 
nature of the disease itself in particular the tempo of onset, and the severity of the 
disease, may also be important in helping to determine the causative agent.44 
Factors influencing aetiology in community-acquired pneumonia. 
1. Age 
Age is one of the most significant factors to influence the incidence of different 
aetiological agents, and both the paediatric age group, and the elderly, have a different 
pattern of agents causing infection.. Children under the age of 3 months are much 
more likely to be infected with Respiratory syncytial virus, whereas in those under the 
age of 5 years, bacterial infections are common, but a high incidence of viral 
infections still occur, . In non-immunised populations, measles may be a major cause 
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of morbidity and mortality. The elderly, particularly those over the age of 65 years 
not only have more severe disease, but are more likely to develop Gram negative 
infections.112, 113 A number of recent epidemiological studies have corroborated the 
higher incidence of Gram negative infections in the elderly.58,114 There is also an 
increase in the incidence of H. influenza, M. catarrhalis and S. aureus pneumonia in 
the elderly, and this is thought to be due to an increased likelihood of micro-
aspiration. In contrast however, in a recent carefully conducted study from 
Nottingham which included serological investigations, a spectrum of agents similar to 
a normal population was found in the elderly. It is noteworthy that even in this study, 
40% of patients had no identifiable pathogens.115 
Tuberculosis has also been noted to occur more frequently in the elderly population, 
however these infections may be more prevalent in patients living in old age 
homes.114 
2. Pre-existing disease. 
Patients with chronic obstructive pulmonary disease have been shown to have an 
increased incidence of pneumonia caused by Haemophilus influenzae or Moraxella 
catarrhalis, an agent which is increasingly being recognised as a cause of pneumonia. 
In these patients more than one pathogen is frequently isolated and with currently 
available techniques it is impossible to determine whether one or both organisms are 
causing the pneumonia.44 One or other of these agents could be a coloniser but it 
would seem more likely that both are probably acting as true pathogens.116 
Patients with cystic fibrosis are frequently colonised by Ps. aeruginosa or S aureus 
and either of these micro-organisms are likely causes of pneumonia in these patients. 
Various abnormalities of host defence mechanisms may be associated with a higher 
incidence of specific infecting organisms. Complement deficient states which can 
occur in disease such as SLE will lead to an increased rate of infection with S. 
pneumoniae and Meningococci. Humoral defence abnormality such as 
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immunoglobulin deficiency will result in increased infection with Pneumococci, 
Streptococci, H. influenzae and Meningococci spp. 
Other immunosuppressive diseases such as transplant patients, AIDS patients etc. will 
all have a major influence on the spectrum of pathogens causing pneumonia. These 
patients form a distinctive group who although likely to develop pneumonia with the 
usual spectrum of ordinary bacteria, will in addition be subject to developing 
opportunistic infections; each different type of immunocompromising disease will 
produce a specific pattern of infections. 
Certain diseases or clinical situations by either altering host response, or facilitating 
colonisation are likely to predispose to infection with specific micro-organisms. These 
are illustrated in table 3. 
Table 3: Conditions associated with an increased rate of infection with specific 
IDicro-organisIDs 
Condition Micro-or anisID 
Elderl Gram -ves, H.in uenzae, M. catarrhalis and M. tuberculosis 
Children <3 months RSV 
Children <5 r. viruses 
COPD H. in uenzae and M. catarrhalis 
C stic Fibrosis Ps. aeru inosa and S. aureus 
Diabetes Candida s tococcus neo ormans and Nocardia s 
Sickle cell disease C* s. neumoniae, Menin ., and H. in uenzae 
C* s. neumoniae, Menin ., and H. in uenzae 
Renal disease C* s. neumoniae, Menin ., and H. in uenzae 
Com lement deficienc Menin ococcusl s 
*C = predominantly complement deficiency. 
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3. Regional and seasonal factors. 
Regional differences have only minor effects on the incidence of the most common 
pathogens including S. pneumoniae and H. influenzae, however marked differences 
may occur with organisms such as Legionella pneumophila and possibly Mycoplasma 
pneumoniae. The reported incidence of Legionella pneumophila varies from 15 to 
20%, in series reported from France and the United Kingdom, whereas in a study of 
community-acquired pneumonia in Cape Town no cases were found in 80 patients 
with CAP 9, and subsequent surveillance, information at a time of a cluster of cases 
would suggest that the incidence is less than 10% (Goveia,C; The Incidence of 
Legionella pneumonia in Cape Town; Master of Medicine Thesis, University of Cape 
Town). An analysis of cases that occurred in Cape Town indicates a very low 
incidence in hospitalised patients and these cases have been shown to occur in 
unrelated clusters.117 This almost certainly reflects a real difference in the incidence 
between the northern and southern hemisphere, although it may be possible that 
some of the reported series in the northern hemisphere may represent the effect of 
seasonal differences, or clustering of cases during a study period rather than the true 
incidence and this is supported by recent studies.33,52,115. 
Seasonal variations in the incidence of different organisms are also particularly 
important, and it is now well recognised that Mycoplasma pneumoniae frequently 
occurs in epidemics in a four year cycle.118 Epidemiological studies which are 
performed during one of these episodes of increased infection rates may well over 
emphasise the importance of these agents as a cause of pneumonia. 
The influence of aetiology on severity of illness 
The infecting agent has a definite influence on the severity of the pneumonia, a factor 
which has not been previously adequately appreciated. A confounding factor is 
however that the severity of disease may be influenced by co-morbid disease or other 
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prognostic factors, and these factors may also have an effect on the incidence of 
different causative organisms. This influence may be relevant the elderly where Gram 
negative micro-organisms are more likely to cause pneumonia. 
In pneumonias caused by S. aureus and K. pneumoniae the mortality is significantly 
higher. Although these pathogens are both uncommon causes of CAP, they are seen 
much more frequently in patients with more severe disease requiring ICU admission. 
Similarly the incidence of Legionella pneumonia is higher in these more severe 
cases.1,3,32 The incidence of different pathogens in hospital based studies are 
compared with those from ICU patients which illustrates these differences. (figure 
1).1,9,33 These differences in the types of infecting organisms are not usually 
appreciated because of the small numbers of patients with these infections in most 
studies. We have recently shown that there is a fourfold increase in the incidence of 
infection by Gram negative micro-organism and a doubling of S. aureus infection in 
patients with severe pneumonia requiring ICU admission. I In the same survey we 
noted an incidence of Legionella pneumophila pneumonia of 5%, and an increased 
incidence of 9 to 15% was also noted in a study in the United Kingdom.3,51 This 
incidence of Legionella pneumonia is considerably higher than that seen in general 
hospital based studies in both regions. 
Mycoplasma pneumoniae, a common pathogen in general hospital based studies 
occurs in 2 to 15% of cases, whereas it is extremely uncommon for a patient with 
Mycoplasma pneumonia to require intensive care admission.1,9 ,33,52, 119 
Figure 1: Aetiology of mild verses severe pneumonia 
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It is important to recognise all the different factors which may influence the spectrum 
of pathogens causing pneumonia and when one analyses epidemiological data it is 
essential that one takes into account the type of patient, age, presence of underlying 
disease, immunocompromising factors, seasonal influences, site of acquisition, 
severity of illness, and the possibility of seasonal variations, minor epidemics, and 
clustering of certain infections which may influence the incidence of different agents. 
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CHAPTERS 
DIAGNOSIS OF PNEUMONIA 
The diagnosis of pneumonia serves two purposes; firstly to identify patients with 
pneumonia, and secondly to determine the aetiological agent involved so that 
appropriate therapy can be instituted. The former is usually straightforward, however 
the latter presents more problems. 
CLINICAL DIAGNOSIS OF PNEUMONIA. 
The accurate clinical diagnosis of pneumonia is important, as early appropriate 
therapy has an important influence on successful outcome.120 The diagnosis of the 
disease will be . made in over 90% of cases using accepted clinical criteria, including 
signs of sepsis, purulent bronchial secretions, auscultatory signs of parenchymal 
consolidation, and standard radiological and haematological investigations. Acute 
bacterial pneumonia usually presents with an acute onset of fever, frequently with 
rigors and chills, a cough which may either be dry or productive of purulent sputum, 
with or without chest pain and shortness of breath. On examination the patient is 
usually pyrexial with a rapid respiratory rate and an area of crackles with bronchial 
breathing on auscultation of the chest. About 10% of cases have an associated pleural 
effusion, and the chest radiograph will usually show evidence of alveolar 
consolidation. The common radiological features may be either patchy consolidation 
i.e. bronchopneumonia, or lobar distribution i.e. lobar or segmental pneumonia, and 
occasionally in haematogenous infections, a lobular appearance may occur. In non-
bacterial pneumonias or atypical pneumonias radiological features similar to bacterial 
pneumonias occur, although an interstitial pattern is more common, particularly early 
in the disease. 
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While incorrect diagnosis is uncommon, such conditions as pulmonary embolism, 
pulmonary tuberculosis, and rarer conditions such as an eosinophilic pneumonia or 
cryptogenic organising pneumonitis (COP) may occur with features clinically 
indistinguishable from pneumonia. The most frequent and difficult differential 
diagnosis is between that of pulmonary embolism and pneumonia, and it is important 
to remember that in pulmonary embolism the temperature can frequently be higher 
than 3goc, and the white blood cell count more than 12,000 cells/ml. The white 
blood cell count may even be as high as 20,000 cells/ml, however it seldom rises 
higher, and a left shift in the morphology of the leukocytes is unusual in pulmonary 
embolism. 
Other conditions which occur in about 5 - 15% of patients also need to be considered 
in the differential diagnosis and include: 
1) Pulmonary embolism/infarct 
2) Pulmonary tuberculosis 
3) Pulmonary vasculitides 
4) Eosinophilic pneumonias 
5) Cryptogenic organising pneumonia (COP), or bronchiolar obliteration and 
organising pneumonia (BOOP). 
6) Sarcoidosis 
7) Pneumonitis (chemical, inflammatory e.g. Leptospirosis, collagen-vascular 
disorders, or gas inhalation.) 
8) Congestive cardiac failure 
In a prospective study in our emergency unit designed to determine the aetiology of 
commu~ity-acquired pneumonia, initial misdiagnosis occurred in only 5% of cases 
and similarly in a study by Fang et al, in only 3% of cases, however in two other 
studies where this aspect was reported the diagnosis was incorrect in 17.4% in the one 
and the diagnosis was unproved in 47% of cases in the other.7,9,52,121 
In most of these conditions the diagnosis usually only becomes evident with the full 
evolution of the disease, or when the patient fails to respond to treatment. 
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In cases of rapidly developing pneumonia, the chest radiograph may underestimate the 
extent of the pneumonic process, and early radiographs may even be interpreted as 
being completely normal, and only subsequent radiographs will show the presence of 
consolidation. 
The white cell count may be either very low (less than 4,000 cells/ml), very high 
(more than 40,000 cells/ml), or within the normal range. It is perhaps of more value 
to look at the morphology of the white blood cells, where a left shifted pattern 
irrespective of absolute count invariably indicates acute infection. 
Determining the Severity of Pneumonia. 
The ability to determine the severity of pneumonia using readily available clinical 
criteria is of paramount importance when making early management decisions such as 
where the patient should be treated ( either as an outpatient, or hospitalised in a general 
ward, or require intensive care unit admission); or will conservative treatment suffice 
or will supportive treatment including intubation be necessary. 
While the question of which patients require ICU admission remains undefined, the 
clinical criteria determining the severity of pneumonia are well accepted. It is 
however important to note that severity of disease doesn't necessarily relate to an 
adverse outcome. Many patients with severe disease defined by pathophysiological 
abnormality will have a good outcome given appropriate therapy. This is seen in 
patients with Varicella or Legionella pneumonia where the ICU outcome is 
excellent.(see chapter 10) A study by Macfarlane and the report of the British 
Thoracic Society (BTS) delineating risk factors for severity of illness provide useful 
guidelines (see table 4).17,122 The BTS study has shown that a combination of two 
of the following three criteria : respiratory rate= or> 30/min, renal failure (Urea> 7 
mmol/1), and a diastolic blood pressure = or < 60 mm Hg predicted a twenty-one- fold 
increase in mortality. Two "rules" that predict a poor outcome, were also proposed as 
criteria for ICU admission. Rule 1 was the presence of two or more of: respiratory 
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rate of 30 breaths per minute or more, a diastolic blood pressure of 60 mm Hg or less, 
and a blood urea of > 7 mmol/1. This rule had a 93% sensitivity and 94% specificity 
when used to identify which patients would die. Rule 2 substituted confusion for 
blood urea and it had a 93% accuracy and 94% specificity; however, it only identified 
34% of patients who died. It can nevertheless be applied immediately on assessing a 
patient.17 
In a subsequent retrospective study by the British Thoracic Society (BTS) group in 25 
British general hospital ICUs, 60 patients were studied and rule 1 was found to 
identify 75% of the ICU cases, however its positive predictive value is only 19%. 
They were however unable to identify any individual clinical or laboratory features, 
duration of illness, prior disease, prior antibiotic therapy, early ICU transfer, or 
aetiological pathogen that was significantly associated with death. 3 
A number of studies have now been performed to attempt to validate the findings of 
the BTS. Farr et al in a study of 245 patients of whom 20 (8.2%) died found 8 of 42 
previously identified factors to be predictive of death. In multivariate analysis only a 
respiratory rate of 30/min or more, a diastolic blood pressure of 60 mm Hg or less and 
a blood urea of > 7 mmol/L remained predictive. A discriminative rule of these 
factors was 70% sensitive and 84% specific in predicting mortality yielding an overall 
accuracy of 82%.22 Karalus et al in a study of 92 patients including elderly patients, 
found a 16 fold increase in mortality if they had 2 or more of the following clinical 
criteria present on admission: a respiratory rate of 30/min or more, a diastolic blood 
pressure of 60 mm Hg or less and either confusion or a serum urea of > 7 mmol/L. 
There were only 6 deaths and the positive predictive value of death was only 22.7% 
which limits the value of these findings.19 
Other studies from ICU populations including patients with pneumonia, suggest that 
the widely accepted AP ACHE IT severity of illness scoring system, does not 
accurately predict outcome in individuals, however with appropriate adjustment for 
the disease, it can reasonably predict group mortality.123 
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Van Eeden et al compared ordinary ward admissions with patients requiring ICU ad-
mission in a retrospective study of only 34 patients and suggested that the APACHE 
II Score was an unreliable predictor, whereas a complicated scoring system including 
weighting (10 points) for a Pa02 <7.5 on Fi02 .4 , respiratory rate of >30 
breaths/min, and bronchopneumonia with 2 or more lobes involved, and 5 points for 
abnormal liver function tests and low albumin, clinical septicaemia (3 of the 
following: SBP <75 mm Hg, confusion, serum HC03 <20 mmol/1, pre-renal uraemia, 
or a central venous pressure of <3 cm), and pre-existing factors for poor prognosis in 
pneumonia, was of value. This is an interesting concept , however the data that it is 
based on is totally inadequate to draw any conclusions. 20 A recent study from 
Baragwanath hospital (Soweto) evaluating the effect of steroid therapy on cytokine 
levels in severe pneumonia found no influence on cytokine levels, inflammatory 
response, or outcome; of interest there was no relation between cytokine levels and 
severity, however the APACHE II score accurately predicted severity.65 
In a study from our own ICU, Hammond et al, demonstrated that an APACHE II 
score of more than 21, septic shock (SBP <80 mm Hg), a white cell count of less than 
4,000 cells/ml, and a gram negative micro-organism (either K. pneumoniae, E. coli, or 
Ps. aeruginosa), or S. aureus causing the pneumonia, were all individually predictive 
of a poor outcome, and found no value in applying the previously described scoring 
system (South African Pulmonology Society Congress 1989). This increased 
mortality from pneumonia caused by Gram negative organisms, and also S. aureus , 
has been found in a number of studies in hospital and ICU patients.52,124,125 
Support for the importance of recognising "high risk" organisms was also 
demonstrated in a study designed to detect treatment failure in patients treated as 
outpatients, where infections with these organisms again predicted a high risk of 
treatment failure. Additional factors in this study designed particularly to define low 
risk patients, five factors predisposing to a complicated course were identified by 
logistic regression models, which included age >65 years (odds ratio 2.7), co-morbid 
illness (odds ratio 3.2), temperature >38.3°C (4.1), immunosuppression (12.0) and for 
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high risk organism an odds ratio of 23.3. The risk of a complicated course increased 
linearly with the number of risk factors from 12% with none to 100% with four.18. 
The clinical criteria used to define when a patient should be hospitalised, are now 
reasonably well defined, although not well scientifically proven, and the study by 
Macfarlane et al , the report of the British Thoracic Association study on pneumonia 
delineating risk factors, with the other papers discussed above provide acceptable 
guides (see table 4 risk factors).3,17-19,22,52,124-126 
Table 4: Risk factors for a poor outcome. 
AGE >60 - 65 years 
CO-MORBID DISEASE 
TEMPERATURE >38.3 
CONFUSION 
TACHYPNOEA >30 breaths/min. 
Pa02 <6.6 kPa 
DIASTOLIC BP <60 mm Hg. (SBP<80 or 90) 
UREA > 7 mmol/1 
wee <4,000 cells/ml 
MULTILOBE INVOLVEMENT 
MICRO-ORGANISM - Gm -ve 
- S. aureus 
HYPO-ALBUMINAEMIA 
BACTERAEMIA 
IMMUNO-SUPPRESSION 
Definitions of terms: 
i) Sensitivity = true positive/true positive + false negatives. 
ii) Specificity = true negatives/true negatives+ false positives. 
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iii) Positive predictive risk= true positives/true positive + false positives. 
iv) Overall accuracy= no of outcomes correctly identified/ no tested. 
DETERMINATION OF THE AETIOLOGICAL AGENT. 
Precise bacteriologic diagnosis of the infecting organism 1s difficult, and as a 
successful outcome depends on early effective antibiotic therapy, empiric therapy 
covering all the likely pathogens should be initiated immediately in severely ill 
patients. Pneumonia usually follows a benign course responding to the usual empiric 
antibiotic therapy, and extensive microbiological investigation to identify the 
pathogenic micro-organism in the majority of cases is unnecessary. Confirmation of 
the causative organism is however important, should the patient fail to respond 
appropriately, or in cases with severe pneumonia where very broad antimicrobial 
cover has been initiated. Once a causative agent has been identified, antimicrobial 
therapy should be tailored according to the antibiotic sensitivities of the micro-
organism to avoid unnecessary side effects and cost. The accurate identification of 
the infecting agent is far more problematic than the clinical diagnosis of the disease, 
and the causative agent still remains undiagnosed in as many as 50% of cases in spite 
of modern microbiological techniques. 8,9, 19 ,52, 122 
The clinical features of pneumonia are of little value in determining aetiology, and can 
only be used as a broad guide as to the nature of the infecting organism, provided all 
clinical features are utilised. Previously, much reliance was placed on clinical 
features such as the age of patient, presenting symptoms, sputum, and chest 
radiograph in trying to predict the infecting agent. However recent studies negate this 
view, and one study showed that by using discriminant function analysis of age, 
duration of illness, bloody sputum, white blood cell count and lobar infiltration on the 
chest radiograph only 42% of infecting agents were correctly predicted 127, and in 
addition numerous individual clinical features and even radiographic features are 
unreliable in differentiating between atypical and typical pneumonia. 31,128 This still 
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remains controversial however, as there are still other studies being reported that 
indicate some value in clinical features, particularly the immediate Gram's stain and 
chest radiograph used in combination.33,129 
Table 5: Clinical features of typical and atypical pneumonia. 
Typical Atypical 
Onset Abrupt Insidious 
Respiratory symptoms ++++ + 
Constitutional symptoms + ++++ 
Extra pulmonary manifestations + ++++ 
Fever High Low 
Sputum Purulent/Copious Mucoid/Scanty 
Radio graph Lobar Interstitial 
Response Good Failure 
Diagnosis Easy Difficult 
Previously a lot of emphasis has been placed on the clinical features of so called 
"typical versus atypical pneumonia". Atypical pneumonia is defined as a pneumonia 
caused by viral, Mycoplasma, Chlamydia or Legionella organisms, which have been 
thought to have a presentation different to classical bacterial pneumonias. The clinical 
features distinguishing these two types of pneumonia are shown in table 5, however 
current opinion is that this classification is of little value as there is significant overlap 
in the clinical setting. Much of the criticism of this classification has been generated 
from studies of either Mycoplasma pneumoniae or Legionella pneumophila 
pneumonias, and the individual characteristics such as radiological changes and 
clinical features which were thought to differentiate them from other bacterial 
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pneumonias. These studies have shown poor correlation with these individual features 
and the aetiological agent involved.31,128 Clearly considerable overlap does occur, 
however the original clinical features first recognised in the 1920's, and subsequently 
reported by Reimann in 1938, when taken in concert are probably still useful in 
alerting clinicians to the possibility of the infection being caused by either viruses, 
Mycoplasma, Chlamydia and similar organisms.61,130 Legionella pneumonia should 
probably not be included in this category as the pathology, chest radiograph and 
clinical features resemble ordinary bacterial pneumonia more closely than the original 
atypical micro-organisms. 93 
Detection of the aetiological agent relies heavily on microbiological samples and 
techniques, and these include blood culture (the gold standard); Gram's stain, 
microscopy and culture of sputum, tracheal aspirate, transtracheal aspirate, lung 
aspirate and specimens obtained by fibreoptic bronchoscopy using a special sheathed 
brush, or broncho-alveolar protected catheter lavage; open lung biopsy; or 
serology .11-15, 131-139 The essential requirements for any microbiological test is 
that it should be reliable and sensitive, have few false positive or false negative 
results, be quick and cheap; and the specimens should be easily obtainable with little 
risk to the patient. 
The value of microbiology is entirely dependent on the quality of specimen to be 
processed, and the following guides need to be adhered to: 
1) the specimen should come from a normally sterile area 
2) there should be no contamination by endogenous flora (not possible with sputum). 
3) sufficient specimen should be obtained particularly in situations where the microbe 
load is small. 
4) the specimen should be promptly and correctly transported 
5) accompanied by relevant clinical information 
6) promptly examined and cultured 
7) preferably before antibiotic administration (NB therapy must not be delayed) 
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MICROBIOLOGICAL TECHNIQUES 
1. Blood culture 
This remains a most valuable technique and provides the gold standard for the 
determination of the causative agent. Unfortunately it is positive in less than 20% of 
cases although in severe pneumonia requiring ICU admission it can be positive in as 
many as 35% of cases33,125. Macfarlane and most other authors recommend that 
blood cultures should always be done even though the yield is only 30%.11,122 
Others have suggested that because the yield is so low, particularly in mild 
pneumonia, that blood cultures should be reserved for patients with severe pneumonia 
only.33,116,139 Specificity is high, and a blood culture seldom gives false positive 
results, unless the technique of obtaining the specimen is poor. It may also be 
misleading in situations where dual pathogens are present, a situation which is now 
recognised more frequently. 8,33. There is also some delay in the culture of organisms 
being detected, however by utilising the BACTEC system in which culture is detected 
by gas chromatography which identifies release of C14, 30% of positive results can be 
obtained within 24 hours, and 90% by 48 hours. (BACTEC Instruments, Johnson 
Laboratories). Other similar automated systems may also provide similar results 
however the BACTEC system is more widely used. 
2. Sputum 
Culture of sputum 1s generally unreliable as the specimen may be frequently 
contaminated by endogenous flora from the oropharynx. If the initial sample is of 
good quality, and the culture is of a predominant organism which was present in 
reasonable numbers on the Grams' stain its predictive value is high. Well obtained 
sputum samples where oropharangeal contamination is minimal, can provide a quick 
guide to the presence of gram negative bacilli and gram positive diplococci or cocci in 
clusters which are highly predictive of Klebsiella pneumoniae, S. pneumoniae and S. 
aureus pneumonia.129,140-142 Rein in a study specifically designed to identify S. 
54 
pneumoniae by Gram's stain and microscopy, with >10 lancet shaped Gram positive 
cocci being considered diagnostic, defined 18 (62%) of 29 specimens containing 
pneumococci; only 2 false positive specimens were recorded; however there were 11 
(38%) false negatives.142 Gleckman, in a study of 59 bacteraemic patients showed 
that a physician could correctly determine monotherapy in 94% of cases using clinical 
criteria and morphology of Gram stained sputa. In 3 of 5 patients with H. influenzae 
pneumonia however, alternative pathogens were suggested.131 In the majority of 
patients with pneumonia suitable sputum is unobtainable, or even with careful 
collection falls far short of the standard generally considered adequate for examination 
and further processing. Two studies found that samples collected by nurses were 
better than those collected by house staff in 38 to 42% of cases33, 143 
No uniform criteria for culture of sputum exist however the majority agree that a 
specimen containing more than 25 WBCs per low power field (LPF) and less than 10 
squamous epithelial cells (SECs) /LPF is good; a specimen with <10 SECs and 10-25 
WBCs /LPF is satisfactory and should be cultured; > 10 SECs and > 10 WBCs poor; 
>10 SECS <10 WBCs unsatisfactory. Specimens with >10 SECS are heavily 
contaminated by oropharyngeal secretions and not considered to be representative of 
lower respiratory secretions as judged by transtracheal aspirate.12,138,140. Applying 
the above criteria for suitability for processing resulted in 75% of samples being 
discarded in a study from the Mayo Clinic.12 
Quantitative culture of sputum has proved little better than routine culture in 
predicting true pathogens, and washing of the specimen is time consuming and has 
likewise proved oflittle value.135,139 
Prior antibiotic therapy will significantly influence the results of sputum examination 
with both fewer positive findings and an increased number of false positive 
results.134 Spencer in a study of community-acquired pneumonia found a 29% 
incidence of S. pneumoniae and H. influenzae infection ,and only 8% with no 
pathogen in patients who had received no antibiotics. Of 52 patients who had 
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received antibiotics coliforms were found in 29% and no micro-organisms in 69% 
suggesting a major antibiotic influence.144 
3. Transtracheal aspirate 
A transtracheal aspirate first described in 1959, where a catheter is passed via a needle 
introduced through the cricothyroid membrane into the trachea, is suggested as an 
ideal way of obtaining uncontaminated lower airway secretions, which allow culture 
results to be more easily evaluated.145 Although it is a technique said to have few 
side effects, it remains widely recommended but seldom used.12,135,138 Bartlett in a 
study of 488 procedures found a positive culture in 369 procedures and negative 
results in 119 patients. Of these negative procedures 71 were considered to have no 
infection on subsequent clinical grounds, and 48 parenchymal infection and were 
considered false negatives. Of these 44 had received prior antibiotic therapy. In 23 
cases of bacteraemic pneumonia the companion transtracheal specimen yielded the 
same pathogen.134 In this study only one patient developed a side effect which was 
severe self limiting haemoptysis, however there have been reports of fatal 
complications .146, 14 7 
It is however an uncomfortable procedure, even if carefully performed using local 
analgesic techniques. The instillation of local analgesic solution into the trachea, as 
well as the introduction of the catheter produces excessive coughing, which in a 
critically ill patient can lead to significant hypoxaemia. The position of the catheter is 
also uncontrolled and it may even be coughed into the oropharynx rather than going 
down into the trachea and bronchus. Aspirated specimens are usually scanty, and 
frequently have to be collected following a small saline installation, which may 
further dilute the specimen. Although it has a low incidence of bleeding and surgical 
emphysema, it is not a technique that should be routinely recommended as the 
complications are uncontrolled, and can lead to significant hypoxaemia. It has also 
been superseded by newer fibreoptic bronchoscopic techniques, which are safer and of 
particular value in patients with non-responding pneumonia.148 
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4. Tracheal aspirate 
A tracheal aspirate taken immediately on intubation of the trachea is extremely 
valuable and should be regarded as an essential requirement following every 
intubation for severe pneumonia. In a recent report on 18 patients with severe 
Klebsiella pneumonia, 16 out of 17 had numerous Gram negative organisms present 
on the Gram's stain of the specimen obtained immediately after intubation, and the 
aetiological diagnosis was confirmed on culture of the tracheal aspirate or blood.129 
A tracheal aspirate may however be contaminated by oropharyngeal secretions before, 
or immediately after intubation, as many of these patients already have an 
incompetent larynx immediately preceding intubation because of the associated 
severity of illness. The presence of the endotracheal tube allows rapid colonisation of 
the lower airways following intubation, emphasising the need for early collection of 
specimens. Tracheal aspirates taken even hours later, are only of value in detecting 
infections by organisms unlikely to be colonising the oropharynx, e.g. Mycobacterium 
tuberculosis, or should be regarded as surveillance cultures which may be of value in 
detecting new nosocomial colonisation. 
5. Lung aspirate 
Percutaneous lung aspirate with an ultra fine needle (23 to 25 gauge)(FNAB) clearly 
provides an uncontaminated specimen. The yield is excellent in spite of the small 
inoculum and Zavala in a group of immunocompromised patients reported a 100% 
positive yield with only an 8% incidence of pneumothoraces.149 The incidence of 
pneumothorax varies from 3 - 10% in other series, and the risk of empyema is as yet 
undetermined in community-acquired pneumonia. The risks of this technique would 
be considered too high for routine use in pneumonia, particularly in severe 
pneumonia, however it is justified in those cases who fail to respond, or who show 
progressive deterioration, or who are likely to have an unusual organism. This 
technique has also been used successfully in epidemiological studies. 8 In a study of 
18 cases of pneumonia who failed to respond FNAB under ultrasonic guidance 
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yielded positive results in 72.2% on culture and 50% by direct microscopy,150 A 
recent study tested the efficacy of pneumococcal and Haemophilus influenzae type B 
latex agglutination testing as well as pneumococcal antigen detection in the urine 
identified a causative organism in 88% of cases, the needle aspirate antigen test 
increasing the yield from 50 to 78%.151 
6. Fibreoptic bronchoscopy. 
Fibreoptic bronchoscopy has become widely used for the diagnosis of many 
pulmonary diseases.152 It is an extremely valuable tool for diagnosing pulmonary 
tuberculosis, and other opportunistic infections particularly where the presence of the 
micro-organisms in the specimen invariably mean infection.153,154. Its routine use 
in the diagnosis of community-acquired pneumonia is however limited, both because 
of cost, and because the suction channel of the flexible bronchoscope becomes 
contaminated with endogenous organisms from the nose and oropharynx, resulting in 
difficulty with interpretation of the results.155 Various techniques have been 
developed to limit the effects of oropharyngeal contamination of specimens, initially 
by quantitative culture of specimens obtained by FOB through the suction channel, 
and subsequently by using protected specimen brushes (PSB), or protected lavage 
with quantitative culture.14,19,156,157 Bronchoalveolar lavage using 100 to 240 ml 
of saline and a quantitative culture where 104 cfu/ml which represents 105 or 106 
organisms/ml is considered diagnostic, has been suggested as a better way of 
obtaining a more representative sample than either PSB or small sample protected 
lavage techniques;. The same oropharyngeal contamination may occur as in ordinary 
bronchoscopic samples however.13,14,132,133 BAL using the presence of 
intracellular organisms to define the presence of infection may however prove a more 
valuable means of differentiating pneumonia from contamination, and an advantage is 
that it gives a more rapid result.158-160 BAL in the presence of hypoxaemia is 
potentially hazardous as it invariably results in hypoxaemia, and it has also been 
shown to produce sepsis-like systemic effects in patients with pneumonia.161 
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The use of a special sheathed brush (PSB)130 and also a protected wedge catheter 
lavage14,162 with quantitative culture, which avoids the problems of oropharyngeal 
contamination, provides valuable microbiological specimens, and may be regarded as 
a "gold standard " in the setting of ventilator-associated pneumonia.157 Their use in 
community-acquired pneumonia has been inadequately investigated and in one 
prospective study of severe community-acquired pneumonia, in which an attempt was 
made to improve and speed up the diagnosis by using a comprehensive protocol, an 
etiologic diagnosis was obtained in 81 % of patients, in 53% within 72 hours. 
Bronchoscopy was performed in 29 of these patients, all of whom were receiving 
antibiotics, and using BAL and PSB specimens, cultures were positive in 48%. 
compared with 42% with sputum, suggesting that it played a useful role.163 In 
another recent study where 40 patients with moderately severe CAP underwent 
bronchoscopy prior to antibiotic therapy, and comparing BAL (180 ml) with PSB 
specimens, a positive diagnosis defined as 103 cfu/ml was made in over 70% of 
patients with both techniques performing equally welt 164 In a recent study of 
patients with community-acquired pneumonia, limited to those patients who failed to 
respond to treatment, we made a positive diagnosis in only 3 of 35 patients. I Ortqvist 
in a study of FOB in 24 patients with CAP showed that in the setting of early 
antibiotic failure ( <72 hours) PSB would seem to be of limited value as it gave a 
positive diagnosis in only 1 patient (16.6% ), although a true negative may be 
considered useful. The value of PSB in the late failure group was also disappointingly 
low, with only 1 positive diagnoses in 11 procedures. The yield in patients not 
receiving antibiotics with 4 of 6 positive was much more rewarding.156 
In cases of truly non-responding pneumonia (i.e. no response after 5 days of therapy) 
where the organism is commonly an unusual pathogen, or another pathology is 
present FOB is of undoubted value. I 56,165 
The failure of this technique to diagnose ordinary bacteria may be due to antibiotic 
therapy as is . seen in ventilator-associated pneumonia where the use of these 
techniques following antibiotic therapy has been shown to be of little value.162. 
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Ortqvist showed that the yield from PSB specimens in patients with CAP admitted to 
ICU the was reduced from 80 to 12% following the administration of antibiotics 156 
The side effects of FOB are minimal unless transbronchial biopsy is used, when the 
incidence of pneumothorax and haemorrhage is around 5%.166 The cost of this 
procedure, particularly if a PSB is used (more than US $150), needs to be considered 
and weighed up against benefits. 
Protected specimen brush or BAL specimens are essential if direct fluorescent 
antibody techniques for the detection of L pneumophila. are to be used. This 
investigation may have a sensitivity of 70% and specificity of as high as 99%.167,168 
Fibreoptic bronchoscopy is therefore a useful tool in patients with community-
acquired pneumonia in whom no diagnosis has been made, and where L. pneumophila 
or opportunistic infection is suspected. It is also valuable where additional pathology 
needs to be excluded, but it should not be regarded as a routine investigation. 
7. Open lung biopsy 
This technique should not be considered routinely in any case of community-acquired 
pneumonia except those who have failed to respond, and in whom other tests have 
failed.14,169 It may also be considered where the diagnosis of pneumonia is in 
question, and where the progression of the illness will not allow time for a second 
investigation. It does however produce the largest specimen and the area of lung for 
biopsy can be selected. An area of lung with clear involvement and an adjacent piece 
of relatively normal lung should be selected, as grossly abnormal lung may show only 
non-specific end stage disease.43 
8. Serological techniques 
Serological bloods tests are of most value in the atypical pneumonias including 
Mycoplasma, Legionella and Chlamydia, where other microbiological techniques 
have a low yield.14 In Mycoplasma pneumoniae pneumonia the rapid specific IgM 
test is most useful and is positive in 86% of patients on admission. Cold agglutinins 
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occur in 57% and a fourfold rise in the complement fixation titre occurs in 26% of 
patients. 31 In Legionella pneumophila pneumonia a fourfold rise in antibody titre is 
also considered diagnostic, however it may be necessary to repeat the test six weeks 
after the initial sample to confidently exclude an infection. 5, The use of immediate 
immunofluorescent staining and microscopy of bronchoscopically obtained PSB 
specimens is of value in obtaining an early diagnosis.5,14 
Antigen detection is recognised as a possible way in which a rapid diagnosis may be 
made in community-acquired pneumonia, and may be of particular value in patients 
receiving antibiotics.15 Polysaccharide antigens to the cell walls of micro-organisms 
are specific and may be identified as being potential markers of a recent infection by 
the organism, and the identification of the infecting organisms is therefore possible by 
identifying these antigens m var10us body fluids by either 
counterimmunoelectrophoresis (CIE), coagglutination, or enzyme linked 
immunosorbent assays (ELISA).16 Guzzetta et al investigated 101 patients with 
community-acquired pneumonia in an attempt to detect S. pneumoniae, H. influenzae, 
K. pneumoniae or Ps. aeruginosa antigens in sputum, using both CIE and 
coagglutination techniques to diagnose the causative pathogen. Coagglutination 
detected the appropriate bacterial pathogen in 16 of 17 patients (94%) with a definite 
aetiological diagnosis whereas CIE identified only 11 (64%). Only one pathogen was 
identified in 19 control patients indicating a high specificity for both tests.170 
Detection of pneumococcal antigens in blood, urine, pleural fluid, and sputum, has 
been used and in some studies, have increased the yield of identified pneumococcal 
disease. In a recent study using detailed microbiological investigations including CIE 
for antigen detection with pneumococcal omniserum and 19 mono-specific antiserum, 
Macfarlane found S. pneumoniae in 76% of patients with community-acquired 
pneumonia. 51 These pneumococcal antigens are distributed widely in many body 
fluids including sputum, pleural fluid, serum and urine during acute pneumococcal 
infections, and usually the more antigenic the sicker the patient, but they may persist 
for a prolonged period of months. Not all patients are antigenemic and the exact 
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specificity and sensitivity are not known, but are not absolute. Oropharyngeal 
colonisation by S. pneumoniae will influence sputum and positive antigenemia has 
been found in 20% of healthy volunteers. Detection of antibodies to pneumolysin 
which is more specific of infection but the results are not immediate and are therefore 
only of value in epidemiological studies.16 These techniques are not freely available 
and have a significant false positive rate however they show promise for the rapid 
diagnosis of pneumococcal pneumonia and further studies on the sensitivities and 
specificity's are necessary. 
PRACTICAL APPROACH TO DIAGNOSIS. 
In practice the conventional clinical method of determining the likely causative agent 
in pneumonia requires a knowledge of the incidence of pathogens in different clinical 
settings, and interpretation of the Gram's stain of bronchial secretions. This is 
correlated with clinical features and a best "guess" empiric therapy to cover likely 
pathogens is selected. Both accurate cultures, and serological investigations take days 
or weeks. A number of studies have pointed out the unreliability in predicting 
causative agents by using clinical features such as history, radiological changes, 
nature of sputum, temperature and other signs in isolation.127,128 In a recent study 
of critically ill patients in the ICU, and a number of studies in less severe disease, 
moderately accurate prediction of the causative agent has been possible using all 
available clinical features, including a gram stain of well collected bronchial 
secretions, and severity of illness estimation. I, 11,33, 129,142 
In spite of extensive investigations the causative agent still remains undiagnosed in 
30% or more patients with pneumonia, and the role of prior antibiotic administration, 
and as yet undetected pathogens may play an important role. 
The practicality of management and expense of medical care, particularly in 
economically depressed regions, has determined that we should develop a cost 
effective approach to treatment. The clinical and bacteriological diagnosis of 
62 
pneumonia and its severity needs to be accurately defined to provide specific therapy, 
or appropriate cost effective empirical antibiotic therapy. To extend this philosophy, 
it is essential that we develop a protocol for immediate empirical antibiotic therapy, 
and the clinical and biochemical investigation that will provide minimal, essential 
information, without adding any risk to the patient. 
A recent paper by Levy et al reporting the practical approach to diagnosis in a cohort 
of patients with community-acquired pneumonia, has added significantly to our 
understanding of the value of different diagnostic procedures in modern practice. The 
results of the different tests are shown in the following table.33 
Table 6: Diagnostic procedures for pneumonia.( adapted from Levy et al )33. 
+ve -ve Total Poor quality** 
Sputum* 44 12 90 34** 
PSB 1 6 7 0 
Protected catheter 12 6 20 2*** 
Blood culture 14 102 110 -
Pleural asp. 4 29 33 -
* Gram stain and quantitative culture 
** Poor quality= >10 squames or <20 leukocytes/LPF; ***contaminated specimen. 
Critical to the decision about what investigations and treatment are necessary, is the 
determination of the severity of the pneumonia; this will impact both on the selection 
of empirical antibiotics as well as the necessary investigations. The severity of 
disease will reflect the spectrum of pathogenic organisms, with an increased number 
of Gram negative and S. aureus infections in more severe disease. In fulminant 
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disease where there will be no time to institute second line antibiotic therapy should 
the patient fail to respond all potential pathogens need to be covered by the initial 
therapy. 
The Gram's stain and culture of sputum has long been regarded as an essential initial 
investigation, however its positive contribution in mild pneumonia is of questionable 
value. Numerous studies evaluating Gram's stain and culture of sputum have shown 
that 50% or more specimens are so contaminated by oropharyngeal secretions that 
they are of no value.12,141 Using specific criteria for evaluation of specimens such 
as the number of squamous cells and pus cells on microscopic examination, they 
suggest that if more than 10 SECs are present, the specimen should not be processed 
further. Even in those specimens that warrant further evaluation, particularly in mild 
pneumonia, the yield lacks specificity, and is so low that the overall influence on 
antibiotic selection is minimal. In the study by Levy where 35% of samples were 
unsuitable, concordance between the Gram's stain and quantitative culture was found 
in 86% of cases.33 This has led to the somewhat heretical recommendation that 
sputum should not be a routine investigation in patients with mild pneumonia. 
The value of sputum or tracheal aspiration may also depend on the type of pathogen 
identified. In the case of S. aureus and K. pneumoniae the results are likely to be 
more sensitive and specific than S. pneumoniae or H. influenzae. 
Blood culture has also come under similar scrutiny in the group with mild pneumonia, 
because of the low positive yield of between 12 to 14%33,51, and the fact that the 
positive blood culture which is usually, S. pneumoniae, seldom leads to a change in 
antibiotics. This has led to the suggestion that blood cultures should also be reserved 
for patients with severe disease only, where the culture may be positive in as many as 
35%, as a cost saving exercise even though the result is 100% specific. In patients 
with severe disease the yield with both tests is much increased, and a positive test is of 
great value in determining therapy, both antibiotic and supportive measures. It is 
however important that in this setting the specificity of a positive blood culture may 
be lower than expected. Fagon has recently suggested that 58% of positive blood 
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cultures, particularly in patients with nosocomial pneumonia, may arise from non-
pulmonary sources and not be representative of the pulmonary infection.171 
In any patient following intubation an immediate tracheal aspirate sample, before any 
contamination from the oropharynx has occurred, is of great value for immediate 
Gram's stain and culture. Hammond, in a study of 18 cases of K pneumoniae 
pneumonia requiring intubation, found numerous Gram negative bacilli on 
microscopy of tracheal aspirates taken on intubation in 16 patients, and a positive 
correlation between tracheal aspirate and blood culture in all 6 bacteraemic 
patients.129 
Pleural fluid which is often considered to be useful hasn't been adequately evaluated, 
however in the study by Levy, pleural fluid was found to be positive on culture in 
only 4 of 33 pleural specimens. 
A practical algorithm for a diagnostic approach to pneumonia is given in the 
following flow diagram.(see Figure 2) 
Figure 2: Diagnostic approach in community-acquired pneumonia. 
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The investigation and therapeutic path taken initially is determined by the severity of 
the pneumonia, and subsequent decisions by the response to therapy, decided after 48 
hours and subsequently at 5 days. 
Mild pneumonia is considered to be disease without any of features that would 
suggest a poor prognosis including:- age >60 - 65 years, co-morbid disease, 
Temperature > 38.3, confusion , tachypnoea >30 breaths/min. Pa02 <6.6 kPa, 
Systolic <90 mm Hg., urea > 7 mmol/1, wee <4,000 cells/ml, multilobe 
involvement, · Gm -ve or S. aureus, hypo-albuminaemia, bacteraemia, and 
immunosuppression. 
Severe pneumonia would include patients with any of the above features which 
suggest a poor prognosis as well as one of the following: confusion and/or inability to 
cough, inability to oxygenate on mask oxygen and inability to maintain alveolar 
ventilation, or shock (SBP <90 mm Hg) i.e. those requiring immediate intubation. . 
.t. 
r Fulminant disease would be sevef/_cases where there is an inability to oxygenate on 
Fi02 <0.5 or with unresponsive shock. 
The patients who fail to respond after 5 days particularly those patients with less 
severe disease form a distinctive subgroup, the "non-responding" pneumonias and are 
considered in chapter seven. 
In patients who show progressive deterioration or no improvement within 48 to 72 
hours, more invasive investigation is warranted. Although fibreoptic bronchoscopy 
has a low positive yield, the detection of Mycobacterium tuberculosis, fungi or 
Legionella spp. is of critical importance for antibiotic management, and a true 
negative, the most likely result, will avoid unnecessary expensive antibiotic changes, 
and focus therapy on supportive measures such as fluid and ventilatory therapy, and 
host factors. 
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CHAPTER6 
TREATMENT OF COMMUNITY-ACQUIRED PNEUMONIA 
Introduction 
Pneumonia may vary from a very mild illness to a fulminating life threatening disease 
The treatment should therefore be tailored to the severity of the disease; this may vary 
from home therapy in mild cases, to hospitalisation in general wards or an ICU in 
more severe or fulminating life threatening disease. Determination of the severity of 
illness is therefore once again of paramount importance in determining if and where 
the patient should be admitted, and what therapy should be given. The widely 
accepted criteria from the BTS study group used to determine the severity of 
pneumonia are useful in determining therapy, and when used in conjunction with 
other studies of severity including a recent study that showed which factors were 
likely to be associated with failure of home therapy, can successfully predict which 
patients may be treated as outpatients.17,18,122(see table 4, chapter 5) 
Criteria for ICU admission still need further validation, however if the accepted 
features of severe pneumonia including any of the following : significant confusion, 
septic shock, unresponsive hypoxaemia, a low WCC <4,000 cells/ml, inability to clear 
secretions, or an extending pneumonia despite treatment are present, ICU admission is 
mandatory. Additional factors such as Gram negative or S. aureus infection and co-
morbid disease must also need to be considered. 
Thus using these criteria we are thus able to divide pneumonia into those who can be 
treated at home (mild disease), those requiring hospitalisation (moderate disease), and 
those requiring ICU admission (severe/fulminant disease). 
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ANTIBIOTIC THERAPY 
1. Selection of Antibiotic. 
a) Empiric antibiotic therapy. 
Initial selection of antibiotic therapy will depend on the severity of the pneumonia. In 
mild disease oral agents with a spectrum of activity that includes S. pneumoniae are 
indicated. In certain instances in young people from communal living environment 
e.g. army barracks, during known epidemics of Mycoplasma or in similar situations, 
an agent that includes activity against both S. pneumoniae and M. pneumoniae may be 
more appropriate, however these antibiotics are invariably more expensive and could 
be reserved for cases that fail to respond within 48 hours.118 Optimal oral agents 
would include amoxicillin, erythromycin or the newer macrolide antibiotics such as 
clarithromycin. In the latter the cost is considerable, and no additional benefit in 
efficacy has been shown although side effects may be reduced.172 A practical 
approach in the hospital outpatient setting is the combination of initial parenteral 
administration, followed by oral antibiotics; a combination of penicillin G 
intramuscularly, followed by oral amoxicillin has proved highly effective in our 
emergency unit. (Dr A. Aboo, personal communication). Many of these patients 
would remain overnight because of inadequate transport or home settings and as 
compliance may be suspect intramuscular agents may be preferable. 
The concern of emerging penicillin resistance in S. pneumoniae may influence initial 
empirical antibiotic selection, however this problem appears exceedingly rare in adult 
pneumonia in Cape Town. In other areas such as Johannesburg, Israel, Spain and 
southern Europe, this may be more of a problem.98,173 The incidence of 
pneumococcal resistance in patients with pneumonia however requires further 
accurate epidemiological evaluation before major antibiotic policy changes are 
recommended. 
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The empirical antibiotic selection for severe pneumonia should again include agents 
effective against S. pneumoniae but parenteral administration is the route of choice. 
Intravenous penicillin 1-2 million units six hourly is likely to be effective against the 
vast majority of infections, however if the Gram's stain of the sputum suggests S. 
aureus, intravenous cloxacillin 2 grams six hourly should be used instead, and if a 
Gram negative micro-organism morphologically resembling enterobacteriaciae is 
seen, an aminoglycoside (initial starting dose twice the standard dose calculated by 
weight) should be added.44,174,175 
In a severe infection when time will not allow for additional antibiotics to be added 
following initial failure, intravenous penicillin, cloxacillin, and an aminoglycoside, 
should all be commenced immediately. In view of our low incidence of Legionella in 
Cape Town and the high cost, intravenous erythromycin is not recommended unless 
the clinical picture is suggestive of Legionella infection. 
A number of special circumstances may dictate a somewhat different approach. In 
patients with COPD, H. influenzae is a more common pathogen and although high 
dose intravenous penicillin appears to be effective, amoxicillin either oral or 
intravenous is a better choice.9,175 Beta-lactamase producing Haemophilus spp. is 
relatively uncommon in our region and again because of cost, a cephalosporin would 
only be recommended in cases where there is failure to respond. In known epidemics 
of M. pneumoniae or in young army recruits or similar situations oral erythromycin is 
more appropriate as empirical therapy .118 In the presence of renal dysfunction a third 
generation cephalosporin should be substituted for the aminoglycoside.29,30 
b) Specific Antibiotic therapy. 
Once the causative micro-organism has been identified the antibiotic therapy should 
be tailored appropriately. In cases of K. pneumoniae infection, a combination of an 
aminoglycoside and third generation cephalosporin may be more effective than 
monotherapy, and has been recommended.129,176 Ps aeruginosa infections similarly 
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should also be treated with a combination of an aminoglycoside and anti-pseudomonal 
penicillin or ceftazidime.177, 178 
The role of dual or multiple pathogens causing pneumonia has been recognised more 
frequently with the use of more discriminatory invasive and serological 
microbiological tests. With only 50% or fewer cases of pneumonia having definite 
pathogens identified it is not surprising, given the difficulty with diagnosis, that 
multiple pathogens have not previously been recognised. Once an agent has been 
identified, no further search for additional pathogens is usually attempted, and both 
the identification of further pathogens, and the determination of significance is 
extremely difficult. The significance of infection with multiple pathogens has only 
recently been fully appreciated.9,116 It may therefore be prudent to broaden 
antibiotic cover, and intensify the search for an additional pathogenic organism in a 
situation with a "known" pathogen where there is failure to respond to appropriate 
antibiotic therapy. 
In our region as with Singapore, Hong Kong, and even France, a high incidence of 
Mycobacterium tuberculosis is found and this pathogen should always be 
considered.9,33, 179,180 
c) Failure to respond within 48 hours. 
In any patient who has failed to respond within 48 hours, additional antibiotic or 
supportive therapy should be considered. If no pathogen has been identified, the 
initial penicillin therapy should be changed to an agent that includes the atypical 
pneumonias in its spectrum of activity. In cases of severe pneumonia, an 
antimicrobial agent that covers Gram negative micro-organism should be added in 
addition to cover for atypical micro-organism. Further microbiological investigations 
including serology are mandatory in these cases. 
The following algorithm (figure 3) is a useful guide for antibiotic therapy in 
community-acquired pneumonia. 
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Figure 3: Antibiotic Therapy. 
SEVERITY OF MILD MODERATE/ FULMINANT 
PNEUMONIA SEVERE 
INITIAL Penicillin G or Penicillin G and Penicillin G, 
PRESENTATION Amoxicillin or Aminoglycoside or Aminoglycoside 
Erythromycin Cephalosporin. and Cloxacillin 
Investigation Gram's stain Blood culture, Ditto 
sputum Gram's stain and 
sputum culture 
48-96HOURS Change to Exchange Erythromycin in 
NO RESPONSE Erythromycin Erythromycin for place of Penicillin. 
Penicillin 
Investigation Serology FOB* with FOB* with 
** PSB Serology ** PSB Serology 
Serum antibiotic Serum antibiotic 
levels levels 
Are antibiotics Are antibiotics 
appropriate? appropriate? 
Worsening Consider as---> Consider as Cover all potential 
severe fulminant -----------> pathogens 
Cloxacillin, 
Quinolone or 
3rd Generation 
Cephalosporin 
Investigation FOB with PSB and 
Lavage 
Serolof!v 
*FOB= fibreoptic bronchoscopy. 
**PSB = protected specimen brush for Gram's staining and immunoflurescent 
staining for Legionella spp. 
71 
SUPPORTIVE TREATMENT 
In cases of mild pneumonia patients may be treated at home as outpatients . It is 
however important to ensure compliance with antibiotic medication, and there should 
be no factors present which may adversely influence absorption of the drugs. Long 
acting parenteral penicillin or cephalosporins may overcome these problems, however 
close supervision is necessary. Supervised care is essential, and time should be taken 
to instruct the supervisor in detail as to when the patient should seek further medical 
care. Deterioration of the patients condition will present with increasing dyspnoea, 
confusion, or failure of the febrile illness to defervess and any of these features must 
be considered serious, and an absolute indication for the patient to return for further 
medical evaluation. 
Similarly, in severe disease close monitoring for features indicative of deterioration is 
essential. The respiratory rate, pulse rate and blood pressure, level of consciousness, 
and fluid balance should all be monitored regularly. Oxygen therapy is frequently 
necessary and in cases of deteriorating clinical features, pulse oximetry or regular 
blood gas analysis may be indicated. In this situation frequent radiological 
monitoring is necessary to detect spread of disease with increasing consolidation 
which is indicative of a need for increasing respiratory support. Careful fluid balance 
will be essential to avoid aggravating renal dysfunction with too little fluid, or 
worsening hypoxaemia with excessive fluid administration. 
Features such as unresponsive hypoxaemia, confusion, renal dysfunction, a high risk 
micro-organism, failure to respond, and an inability to clear secretions are all 
indicators that ICU admission and intubation may be necessary. Septic shock 
(Systolic Blood Pressure < 90 mm Hg despite adequate fluid resuscitation) even in the 
presence of acceptable blood gases requires urgent intubation and cardio-respiratory 
support. 
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1. Ventilatory Support 
The extent of the ventilatory support required will depend on the severity of the 
pneumonia, and invariably if hospitalisation is needed, some form of oxygen therapy 
is usually indicated. This may vary from face mask oxygen only, in severe cases, to 
constant positive pressure ventilation in patients with refractory hypoxaemia. The 
goals of ventilatory support are to maintain a PaO of> 8 kPa, and a PaC02 of< 5.3 
kPa. 
Ventilatory support may be : 
1. Oxygen by face mask. 
This is usually indicated where the patient is fully conscious, capable of 
clearing secretions, maintaining alveolar ventilation, and where adequate oxygenation 
is achieved with an inspired oxygen (Fi02) of 40%. 
2. Continuos Positive Airway Pressure (CPAP.) 
If adequate oxygenation cannot be maintained by face mask oxygen, CP AP by 
face mask provides more efficient and controlled oxygenation. It is however essential 
that upper airway reflexes are intact and that the patient can protect his own airway, is 
co-operative, and clear secretions.24,181 Patients treated by face mask CPAP require 
particularly close monitoring and the use of pulse oximetry is mandatory as dangerous 
hypoxaemia may occur very rapidly. These patients should never be off oxygen, and 
if eating or drinking, should be on oxygen by nasal prongs. 
3. Mechanical Ventilation. 
Indications for constant positive pressure ventilation (CPPV) in severe 
pneumonia include unresponsive hypoxaemia, confusion, inability to clear secretions, 
septic shock, exhaustion, and inadequate alveolar ventilation. The nasotracheal route 
of intubation is preferred in many hands as it is recognised to have a number of 
advantages in this situation including: 
1. Ease of intubation without sedation or muscle relaxants using a blind nasal 
technique and topical analgesia. 
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2. More secure fixation than the oral route. 
3. Better patient comfort than oral tubes. 
4. Size of tube limited by size of nostril. 
Disadvantages include an increased risk of sinusitis, and potential compression of tube 
by turbinates that may make suctioning difficult. An early tracheostomy is indicated 
when copious thick secretions make suctioning difficult, or when a prolonged ICU 
course is predicted. 
IPPV with positive end expiratory pressure (PEEP) is invariably indicated, except 
when active air trapping with airflow obstruction is present 182,183 Occasionally with 
unilateral disease PEEP needs to be carefully tailored, or independent lung ventilation 
with the level of PEEP determined for each lung may be necessary. The ventilator 
should be set to approximate the ventilatory pattern of the patient prior to intubation. 
This will avoid the necessity for heavy sedation and paralysis in most cases, but will 
mean a respiratory rate in the region of 18 to 25 breaths per minute, with a reasonably 
fast inspiratory flow rate of around 50 I/min. The tidal volume should be adjusted to 
provide 10-12 ml/Kg body weight, but should the inspiratory pressure be too high, the 
volume may be reduced to maintain the pressure below 50 cm H20. The PEEP should 
be adjusted to allow an inspired oxygen (Fi02) of 50% or less. It is however essential 
that the Sa02 is > 90 % at all times, and it may therefore be necessary to maintain a 
higher Fi02 for a period of time.184 If adequate oxygenation is not achieved, sedation 
with muscle relaxation may be necessary, and an even higher respiratory rate, with 
ventilation using an inverse inspiratory to expiratory ratio (inverse ratio ventilation) 
may improve the situation.185 
Regular suctioning and position changes are necessary to prevent postural atelectasis, 
and where this may cause desaturation a special sheathed suction catheter (Steri Cath, 
Portex Ltd., U.K.) which reduces suction hypoxaemia should be used. 
2. Circulatory Support. 
a) Fluid therapy. 
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In cases of severe pneumonia, pre-existing dehydration may be present, and in 
addition distributive circulatory changes secondary to sepsis will further aggravate 
this situation, creating an increased need for intravenous fluid therapy. The adequacy 
of fluid therapy can be assessed by ensuring an adequate urine output of .5 cc/ kg 
/hour, however it should be remembered that excessive fluids will aggravate lung 
oedema and gas exchange. 
b) Inotrope therapy. 
A small number of patients with fulminant pneumonia will develop septic 
shock and require inotropic support. Dopamine in a "renal" dose ( <10 
micrograms/min ) is usually commenced when urine flow falls, and should the 
systolic blood pressure fall below 90 mm Hg, it is necessary to commence additional 
inotropic support. Either adrenaline ( 4 ampoules/200 ml saline) or Dobutamine ( 10 -
30 micrograms/min ) an expensive alternative, may be used in a dose sufficient to 
achieve an adequate systolic blood pressure. Excessive fluid therapy and inotropes 
used in an attempt to achieve "optimum goals" ( 02 delivery >600 ml/min -m2 or 02 
consumption >170 ml/min-m2) suggested by Shoemaker186, have yet to be shown to 
improve outcome in this setting, and may even cause harm. A pulmonary artery 
catheter is however indicated for ventilatory and fluid management in patients 
requiring PEEP of 15 cm H20 or more, or where urine output is compromised. 
PREVENTION OF SECONDARY INFECTION 
These patients with pneumonia are at particular risk of developing secondary infection 
because of the additional immunosuppressive effects of the illness, as well as the 
effects of the antibiotic therapy. All the usual methods for reducing exogenous 
infection should be implemented, but in addition methods of selective gastro-intestinal 
decontamination should be considered. A subgroup analysis of patients with 
75 
community-acquired pneumonia determined "a priori" were shown to have a 
significantly reduced incidence of secondary infection, and although no deaths 
occurred in this group the numbers were too small to show a significant reduction in 
mortality.(Potgieter,P.D, Hammond,J.M.J Abstract 18th ICC, Stockholm, 1993) This 
is very suggestive that SDD may be of benefit in these patients, and if not all the 
components are used, at least oral topical anti fungal therapy should be used. 
IMMUNOTHERAPY. 
Immunotherapy has long been considered for the treatment of severe sepsis including 
pneumonia, and early attempts at using corticosteroids have failed to show any 
improved outcome.187, 188 Our understanding of the cascade from sepsis to multiple 
organ dysfunction and death, has however greatly increased over the past few years. 
With this increased knowledge a number of exciting new therapeutic options, 
particularly monoclonal antibodies against the various mediators of sepsis, or their 
receptors have been developed. 
There have been a number of clinical studies evaluating the use of different forms of 
immunoglobulin preparations in the prevention of the spiral from the systemic 
inflammatory response syndrome to multiple organ failure. One of the more recent 
advances was the development of mouse and then human monoclonal antibodies 
directed at Gram negative sepsis and in particular endotoxins. 
Initial use of pooled human anti-endotoxin immunoglobulin or J-5 antibodies had to 
be abandoned because of the fear of associated transmission of blood-borne diseases 
189. This line of intervention has been followed by the development of the E-5 
murine monoclonal anti-endotoxin antibody and the human monoclonal HA-lA 
antibody. Such forms of therapy are directed at the lipid A component of the wall of 
Gram negative bacteria which limits their spectrum of efficacy. Reports of the 
administration of the E-5 monoclonal antibody to 486 patients with suspected Gram 
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negative sepsis in a double blind randomised study have been published 190. The 30 
day survival in. those who received E-5 was 60% compared with a non-significantly 
different 59% in those who received placebo. In 316 patients, the presence of Gram 
negative sepsis was confirmed, 54% (179 patients) of this subgroup with the presence 
Gram negative bacteraemia; in these patients the 30 day survival in those who 
received E-5 was 55% compared with 60% in those who received placebo. The 137 
non-shocked patients showed an apparently significant benefit from the administration 
of E-5 and in those who received the active drug the 30 day survival was 70% 
compared with 57% in those who received placebo. 
The 28-day survival in the widely publicised HA-lA multi-centre study conducted by 
Ziegler 191, in which this immunoglobulin or placebo were administered to patients, 
has earned this drug acceptance as first line therapy for presumed Gram negative 
sepsis. The mortality of the initial 543 patients enrolled in this study was not different 
between the two groups (39% in those who received HA-lA vs. 43% in the placebo 
group), 200 were confirmed to have Gram negative bacteraemia, and 70% of those 
who received HA- lA survived to day 21 compared with a statistically significant 
fewer 51 % of those who received placebo. However, the 28 day survival was not 
significantly different between the groups, being 60% in those who received placebo 
compared with 55% in those who received the drug; the lack of efficacy in the patients 
with Gram negative infection, but without bacteraemia is difficult to explain, as 
endotoxaemia may often occur without bacteraemia. This observation also contrasts 
with the experience with the administration of E-5 where the outcome was improved 
in both bacteraemic and non-bacteraemic patients, but while HA- lA was apparently 
effective in both shocked and non-shocked patients, E-5 was ineffective in those who 
were shocked. 
Since the publication of this study, there have been numerous criticisms of the 
methodology and the conclusions reached. The patients in the placebo group were 
sicker, older and more received inadequate antibiotic therapy than those in the active 
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group. While individually such factors may not have been significant, the combination 
surely did not favour as good an outcome and probably means that the groups were 
not entirely comparable. Recent evaluation of the studies has shown that the 
empirical administration of HA-lA to patients with Gram positive sepsis may actually 
worsen their outcome, and this prompted further trials to be initiated by the American 
Federal Drug Administration (FDA), to establish the role of this substance. The 
recently completed multi-centre CHESS study which evaluated the efficacy of HA-lA 
has confirmed these earlier suspicions and the drug has been withdrawn.192 
Tumour necrosis factor and related cytokines have been identified as playing a central 
role in all forms of the systemic inflammatory response (SIRS) which leads to the 
development of multiple organ failure, and agents which are able to block the cascade 
at this point may prove still more useful, as they are less specific 193,194. Since the 
anti-endotoxin studies, antibodies directed at anti-tumour necrosis factor, and 
interleukin receptor antagonists, both of which have been developed. These new 
drugs have an increased spectrum of activity and theoretically block both Gram 
negative, Gram positive, fungal, and viral mediators of sepsis. A number of large 
multi-centre studies have been initiated in patients who have severe sepsis, and while 
some results are equivocal although a recent European multi-centre study (lntersept 
Study Group; Lancet 1996. in print) shows a 17% reduction of mortality. 
Other modalities, still largely in the experimental phase at present, include inhibitors 
of thromboxane A2, leukotrienes, and prostaglandins 14. Part of the difficulty in 
developing this type of therapy, is the extreme complexity of the inflammatory 
cascade which is subject to numerous positive and negative regulatory feedback 
controls, and numerous alternative pathways may trigger the final insult. Not only are 
there receptors for many of the cytokines, but there are also naturally occurring 
antibodies to these receptors, and until greater understanding has been achieved in this 
field, more harm than good may be done by disturbing the balance between these 
factors. 
78 
The role of these agents in specific infections such as pneumonia will have to be 
evaluated independently. 
VACCINATION. 
Vaccination against bacterial pneumonia was first described by Sir Almroth E. Wright 
in a seminal paper published in the Lancet on January 3, 1914_195 In the introductory 
paragraph in reference to the treatment of pneumococcal pneumonia he states: "-our 
task is to supply to the organism substances which are specifically bacteriotrophic-
that is substances which make chemical attack specifically on the microbes of disease. 
We saw that in connexion with each saveral disease two paths of research open out 
before us. On the one hand there is the path of pharmacotherapy. Following this we 
may come to an effective and non-poisonous specifically bacteriotrophic drug. There 
is, on the other hand, the path of immuno-therapy. Following this, we may come to a 
effective vaccine- i.e. to a vaccine which will, when administered in a proper dose, 
stimulate the chemical machinery of the patient to elaborate the required specifically 
bacteriotrophic substances." In this paper he firstly defines that in newly recruited 
South African gold miners, S. pneumoniae was the cause of pneumoniae in 25% of 
cases, using blood culture, and in 70% of cases, using lung puncture. He then 
described the preparation, standardisation, and final testing of this vaccine. Results of 
this vaccine showed a reduction of episodes of pneumonia. These studies were started 
in 1912 and he used whole bacteria cultured on newly devised culture media which 
were then killed and purified. These vaccines were developed before the knowledge 
of the different pneumococcal types. In 1930 the immunogenicity of pneumococcal 
capsular polysaccharides was discovered, and since then monovalent and polyvalent 
vaccines have been successively developed from capsular polysaccharides to provide 
the widest possible cover for most common pneumococcal infections. There are 82 
capsular types of Pneumococci known, however 84% of bacteraemic infections and 
77% of deaths associated with bacteraemia, are caused by 12 serotypes (types 
79 
1,2,3,4,5,6,7,8,12,14,18,19) m adults, and, m children, eight serotypes 
(l,3,6,7,14,18,19,23) account for 70% of infections.196 
The first, a 6 valent vaccine was investigated in gold miners. In this selected group 
who are at increased risk because of "recruit disease" (with an incidence of 200 per 
1000 per annum) the vaccine was found to be 78.5% effective in preventing 
radiological proved pneumococcal pneumonia (76% by 6-valent and later 92% by 12-
valent) and 82.3% effective in preventing bacteraemia caused by the types in the 
vaccine. An increase in antibody levels of between 6 and 25-fold occurred, and 
minimal side effects were shown.197 Subsequent studies with 8-valent vaccines in 
sickle cell disease and asplenic patients have also shown a reduction of pneumococcal 
infections.198 
The vaccine is prepared from purified capsular antigens and the currently available 
preparation consists of 14 common individual types of pneumococc1. 
(PNEUMOV AX, MSD) The protective effect of vaccination may last for up to 5 
years and immunisation should not be repeated more frequently than every 3 years. 
Current recommendations for immunisation are patients over the age of 2 years with 
sickle cell disease, and individuals who have had a splenectomy or who have impaired 
splenic function; the use in the elderly and patients with chronic heart, renal or lung 
disease, and diabetes or other metabolic disorders is not as clearly defined as yet. 
A recent report of the utilisation of pneumococcal vaccine in elderly medicare 
beneficiaries found that it had been administered to over 1.4 million beneficiaries at a 
cost of 14.3 million$. The level of administration peaked in 1985 and by year 2000 
an estimated goal of 60% of the elderly will be immunised. Unfortunately no efficacy 
was measured but Medicare believes that it is cost effective and encourages 
vaccination as no copayment is necessary and the deductible limit is not affected.199 
23-valent pneumococcal vaccine is now in widespread use in the USA. 
lnfluenzae vaccine is used widely but probably has little effect on community-
acquired pneumonia per se, although it is very effective in preventing influenzae 
epidemics. 
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Other bacterial vaccines can easily be prepared but the incidence and significance of 
these microbes in community-acquired pneumonia do not warrant their development. 
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CHAPTER 7 
NON-RESPONDING PNEUMONIA 
Pneumonia is a common infection in adults affecting approximately 1.5/100 of the 
population annually. 200 Although community-acquired pneumonia may lead to death 
in 1 to 5% of patients, it usually responds well to antibiotic therapy with 
defervescense of the acute febrile symptoms within a few days, and complete 
resolution within a week or two. Those who die usually run a fulminant course and 
the pneumonia is caused by the common community-acquired pathogens including S. 
pneumoniae, Staph.aureus and K. pneumoniae.9,43,52,122,200 A small number of 
patients fail to respond within 5 to 7 days of initiating therapy, and these cases usually 
form a distinct group which are considered non-responding pneumonia. More 
recently this group has been subdivided into slow-resolving and non-resolving; this 
-----distinction may be of value although there are only subtle differences. Outcome is 
similar but aetiology may vary with the non-resolving group more likely to result 
from an incorrect diagnosis of pneumonia, whereas slowly resolving disease more 
likely to be due to pre-existing disease including anatomical abnormalities of the lung 
parenchyma or airways, other host defence deficiencies, unusual organisms resistant 
to the antibiotics, necrotising pneumonia or development of an empyema or lung 
abscess. 
The incidence of non-responding pneumonia in an outpatient-based population is 
unknown, but re-analysis of the data from Prout et al9, suggests that the incidence 
may be in the region of 15%. In this study a clinical diagnosis of pneumonia was 
made in 86 patients attending the emergency room. Those patients who may have 
responded slowly, or in whom the initial diagnosis was incorrect are illustrated in 
figure 4.9 
Figure 4: Potential non-responding pneumonia group 
37 
31 
CAUSES OF NON-RESPONDING PNEUMONIA 
Unusual micro-organism 
1 AMOEBIASIS 
1 EOS. PNEU. 
3 PULM. EMB. 
5 MTB 
B MYCOPLASMA 
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These organisms usually form a distinct subgroup of community-acquired pneumonia, 
the "atypical pneumonias". While some may be slow resolves or fail to resolve, 
others will behave in a manner identical to other bacterial pneumonias. The most 
frequent causes of an atypical pneumonia are Mycoplasma pneumoniae, and 
Mycobacterium tuberculosis (MTB).43,179,180,201 Epidemiological surveys in the 
United Kingdom and United States have shown that Chlamydia, particularly 
Chlamydia pneumoniae (TW AR agent) is becoming prominent, and although usually 
causing a mild acute illness, may cause an indolent pneumonia52,202-204; in our 
region we have yet to identify this pathogen as a cause non-responding pneumonia, 
however it has been reported to have been responsible for 6% of community-acquired 
pneumonias in a recent survey (Gary Maartens, South African Society of Infectious 
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diseases Conference 1993) The full spectrum of agents causing atypical pneumonia 
are shown in table 7. 
Table 7: Causes of atypical pneumonia 
Bacteria 
Fungi 
Viruses 
Mycobacterium 
M. pneumoniae 
Chlamydia spp. 
Coxiella bumetti 
Bacillus anthracis 
Leptospirosis 
Histoplasmosis 
Coccidiomycosis 
Cryptococcus 
Influenzae 
Para-influenzae 
Mycobacterium tuberculosis 
Others (MOT) 
Atypical pneumonia is characterised by an unusual clinical presentation. These agents 
may produce a relatively low-grade infective pneumonia which resolves slowly, or not 
at all, even if appropriate antibiotics are given. Multi-organ involvement is common 
and diagnosis is difficult. They are fastidious and difficult to culture requiring special 
media. Diagnosis is usually dependent on the detection of antigen or antibody 
response and this may take weeks or even months before the diagnosis can be 
adequately confirmed. The clinical features differentiating atypical from typical 
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pneumonia are shown in table 5, chapter 5. However, it must be noted that in a large 
proportion of cases the clinical presentation is identical to other bacterial pneumonias 
as is the time course of the disease.. A recent study indicates that no features are 
classical of these organisms and suggests that the classification "atypical pneumonia" 
be abandoned and this may not be unreasonable as the term "atypical pneumonia" was 
coined in 1938, a time when Mycoplasma pneumoniae was the only atypical pathogen 
that had thus far been identified and the original clinical descriptions don't necessarily 
fit the clinical features caused by the newly described micro-organisms particularly 
Legionella spp.52 
Mycoplasma pneumoniae is the most common cause of an atypical pneumonia in our 
population (see figure 4).9 Mycoplasma pneumoniae pneumonia produces no 
diagnostic clinical or radiological features. Duration of symptoms vary from 1 day to 
more than a month, and although younger patients are predominantly affected, the 
elderly are not spared. The disease is often subclinical or self limiting and passed off 
as influenza, and a large number of infections probably remain undiagnosed.. Extra 
pulmonary manifestations including haemolytic anaemia (17%), Steven's Johnson 
syndrome ( 4% ), neurological abnormalities ( 4% ), arthritis, hepatitis and pericarditis 
are common. Diagnosis relies on serological tests and the most useful is the rapid, 
specific IgM test which is positive on admission in 86% of patients. Cold agglutinins 
are present in 57% and a fourfold rise in complement fixation titre occurs in 26%.31 
The clinical features of Legionella pneumophila pneumonia, an agent discovered 40 
years after the first description of atypical pneumonia, was initially thought to mirror 
the criteria for atypical pneumonia. Recent experience, however, suggests that the 
pathological and radiological changes resemble other bacterial pneumonias more than 
the atypical pneumonias. 93 There are some distinctive features and it frequently has a 
fever higher than pneumonia from other aetiologies, and is often associated with 
haematuria, renal and hepatic dysfunction, confusion, diarrhoea and hyponatraemia52 
It occurs infrequently in our region, but has been noted to occur in small unrelated 
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clusters.117 The incidence is increased in patients requiring ICU admission (5% to 
30% of community-acquired pneumonia) but the mortality remains relatively 
low.1,52,205 Extra pulmonary manifestations are again common and response is 
usually slow and diagnosis difficult. Characteristically no pathogens are found in the 
sputum and blood culture is negative and the diagnosis depends on a four fold rise in 
antibody titre. Direct imunoflurescent antibody staining of protected brush or lavage 
specimens have recently been introduced and are highly sensitive and specific if 
uncontaminated specimens are examined. 
Mycobacterium Tuberculosis (MTB) occurs frequently in our community and 
although it usually presents with characteristic clinical and radiological features, it 
may mimic acute community-acquired pneumonia in up to 5% of patients diagnosed 
as having community-acquired pneumonia.9 Recent studies from Hong Kong and 
Singapore have reported an incidence in similar circumstances as high as 12% and 
21 % respectively 179,180 Pulmonary tuberculosis not infrequently presents with a 
short history and radiological opacification of the lungs involving regions other than 
the classical upper zone infiltrates, particularly in patients with underlying 
immunocompromising conditions such as immunosuppression or AIDS. It is also 
important to consider the role of dual aetiology which is becoming increasingly 
recognised with the use of more discriminative diagnostic tests.116,206 In our survey 
of community-acquired pneumonia one patient presented with a viral pneumonia and 
associated pulmonary tuberculosis.9 
Necrotising Pneumonia (Chronic destructive pneumonia) 
Aspiration pneumonia is a distinct entity resulting from inhalation of large quantities 
of oropharyngeal or gastric contents. It usually occurs in patients with an underlying 
predisposition to aspiration including dysphagia or unconsciousness, and results in 
either a chemical pneumonitis or bacterial infection. Bacterial infection may either 
present early, with features indistinguishable from other forms of acute pneumonia, 
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which may or may not resolve, or one to two weeks later with suppurative 
complications including necrotising pneumonia, lung abscess or empyema. 59 
Necrotising pneumonia itself may present with an acute suppurative illness, or a more 
indolent protracted course, with chronic symptoms of low grade fever and copious 
foul smelling purulent secretions. The chest radiograph may show a single lung 
abscess, but more typically multiple pulmonary cavities less than 2 to 3 cm in 
diameter, usually in dependent regions of the lung. The bacteriology of this disease 
consists of multiple pathogens particularly the anaerobic bacteria, Peptostreptococcus, 
Fusobacterium spp., and Bacteriodes spp. commonly, and less frequently, the aerobic 
bacteria S. pneumoniae, H. influenzae, Staph.aureus and Gram negative bacilli.6,59 
The diagnosis is usually confirmed by exclusion of other indolent pneumonias such as 
MTB or Nocardia asteroides, and pulmonary neoplasms. These necrotising 
pneumomas respond slowly to antibiotic therapy and 30% may require surgical 
treatment. 6 
Empyema or Abscess Formation 
Although the majority of lung abscesses follow an aspiration pneumonia, a number of 
common pathogens including S. pneumoniae, S. aureus and K. pneumoniae have a 
predilection to cause necrosis, with abscess formation or empyema. This 
complication must be considered in any patient who fails to respond, as tube 
thoracostomy or surgical drainage of the pus may be necessary. 207 Computerised 
tomograph (CT) scanning of the thorax is a very useful way of differentiating between 
pleural and intrapulmonary disease and is valuable in planning surgery.26 Most 
empyemas can however be diagnosed clinically, and on the plain chest radiograph, 
and pleural drainage should never be delayed. 
Table 8: Host defence abnormalities 
Mechanical 
Humoral 
Non-specific 
Host Defence Abnormalities 
Aspiration 
Cilia abnormality 
Systemic disease ( diabetes or collagen 
vascular disease) 
Transplant patients 
Immunosuppressive drugs 
AIDS 
Advanced age 
Smoking 
Malnutrition 
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These may either be due to mechanical or humoral factors (see table 8).60 The usual 
spectrum of pathogens seen in community-acquired pneumonia occur in the same 
frequency in these patients, but opportunistic infections are much more common, and 
their incidence depends on the type of concomitant disease and regional differences. 
In our region diabetics and transplant recipients frequently develop Nocardia 
asteroides pulmonary infections and transplant recipients have a high incidence of 
Mycobacterium tuberculosis and fungal infections, particularly invasive 
aspergillosis.154. Although Pneumocystis carinii is common in patients with AIDS 
in Europe and the United States, in endemic areas for MTB many of these patients 
present with Mycobacterium tuberculosis infections. 
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Anatomical Abnormalities 
Anatomical abnormalities may lead to non-response or slow-response particularly 
where normal bronchial clearance of secretions is obstructed. These anatomical 
defects may also lead to repeated infections with the usual spectrum of agents, or by 
the micro-organisms which have colonised the anatomical deformity. 
Response in these cases is either slow, or there may be complete failure to respond. 
These abnormalities may be broadly categorised into parenchymal, or bronchial 
lesions, but in both inadequate drainage is the main cause of infection (see table 9). 
Table 9: Anatomical abnormalities leading to slow response 
1.Parenchymal 
2.Bronchial 
Incorrect Diagnosis 
COPD 
Lung cysts 
Interstitial Lung disease 
Hydatid disease 
Tumours 
Sequestrated Lung 
Bronchiectasis 
Foreign body 
Tumours (benign and malignant) 
Stenosis 
Compression (nodes, etc.) 
A number of pulmonary diseases, which will require specific therapy for resolution, 
may present with clinical and radiological features indistinguishable from acute 
pneumonia. Whilst the majority are uncommon, some such as pulmonary infarct or 
embolism, occur frequently, and occasionally closely mimic pneumonia. Clinical 
features of infection such as a pyrexia, increased white cell count and sputum 
production occur with either disease, and although a white cell count of more than 20 
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000 cells/ml is uncommon in pulmonary embolism, it can frequently be elevated to 
levels between 10 000 to 20 000 cells/ml, and special investigations including 
venography, lung scanning and pulmonary angiography may be necessary to 
differentiate. Another less common but otherwise indistinguishable condition, is a 
pulmonary infiltrate with eosinophilia (PIE) where a differential white cell count 
should usually clinch the diagnosis. Other diseases including the pulmonary 
vasculitides such as Wegener's granulomatosis may need lung biopsy to confirm the 
diagnosis, however serum antineutrophil cytoplasm antibodies (ANCA) 
measurements may be helpful. Table 10 lists conditions which may be misdiagnosed 
as an acute pneumonia. 
Table 10: Diseases mimicking pneumonia 
1. Pulmonary embolism/infarct 
2. Pulmonary neoplasm 
3. Cryptogenic organising pneumonia or bronchiolitis obliterans and organising pneumonia 
4. Pulmonary Infiltrate with Eosinophilia (PIE) - Eosinophilic pneumonia, etc. 
5. Lipoid pneumonia 
6. Collagen vascular diseases - Systemic lupus erythematosis, Rheumatoid arthritis 
7. Alveolar haemorrhage syndromes 
8. Pulmonary vasculitides 
9. Necrotising sarcoidosis 
10. Drug reactions - Amiodarone, Furadantin, Bleomycin, etc. 
11. Neighbourhood pathology-Amoebiasis, Mediastinitis 
90 
MANAGEMENT OF NON-RESPONDING PNEUMONIAS 
Diagnosis 
An accurate diagnosis is paramount for the correct management of a pneumonia that 
fails to respond. 
The following . diagnostic approach should be followed in all patients who fail to 
respond to therapy after 5 to seven days of antibiotic therapy. (Figure 5) 
Figure S: Diagnostic approach in a pneumonia failing to respond after S to 7 
days of therapy 
Likely diagnosis Incidence Investigations 
MTB ++++ FOB* with PSB**, 
Atypical pneumonia +++ Lavage,Transbronchial biopsy 
CA Bronchus ++ and cytology. 
Anatomical abnormality ++ CT scan 
Ernpyema ++ 
-
Abscess + 
-
Foreign body + Rigid bronchoscopy 
* FOB = Fibreoptic bronchoscopy 
** PSB = Protected specimen brush for ZN staining, direct immunofluorecent 
staining and fungal stains. 
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Antibiotic therapy 
If after 5 to 7 days of conventional antibiotic therapy no response has occurred 
atypical pneumonia should be considered, and appropriate treatment instituted if this 
has not already been started. Antibiotic therapy should be organism specific and care 
should be taken to give adequate doses. The antibiotic should be continued for 48 to 
72 hours after resolution of all clinical features of infection. 
Mycoplasma pneumoniae should be treated with erythromycin in an oral dose of 250 
mg, 6 hourly . Legionella pneumophila should be treated with erythromycin lg, 6 
hourly intravenously, however if no response occurs rifampicin or ciprofloxacin, 
which have been shown to improve cure rate, may be added. 
PART2 
SEVERE COMMUNITY ACQUIRED PNEUMONIA REQUIRING 
INTENSIVE CARE 
CHAPTERS 
RESEARCH PROTOCOL 
INTRODUCTION 
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Although community-acquired pneumonia is a common disease which leads to death 
in 13.1 per 100,000 of the American population, and has the highest age adjusted 
death rate of any infectious disease, little has been described about the aetiology, 
severity of illness, or critical care management of severe pneumonia admitted to an 
ICU. A number of different aspects have previously been addressed in these patients 
and guides for determination of the severity of illness, indication for admission, and 
use of fibreoptic bronchoscopy in the diagnosis, have been suggested. These 
recommendations are however based on small numbers of patients, and these findings 
require further validation. This descriptive prospective study of all patients with 
community-acquired pneumonia admitted to a teaching hospital, respiratory intensive 
care unit over a six year period reviews aetiology, clinical features, complications and 
therapy in an attempt to define current practices in caring for severe pneumonia 
requiring ICU admission. Included are also longer studies of less common specific 
etiologic pneumonias as well as specific therapeutic studies within this cohort of 
patients. 
93 
OBJECTIVE 
1. To define the population of patients with different types of severe pneumonia 
requiring ICU admission. 
2. To determine the aetiology of severe community-acquired pneumonia (CAP). 
3. To evaluate different diagnostic techniques in severe community-acquired 
pneumonia. 
4. To determine factors that might predict increased mortality in severe community-
acquired pneumonia. 
5. To evaluate ICU complications and causes of death in severe community-acquired 
pneumonia in an attempt to determine ways in which these may be reduced. 
6. To characterise severe community-acquired pneumonia of specific aetiology 
including Klebsiella pneumonia, Staphylococcal pneumonia, Varicella pneumonia 
and Pneumococcal pneumonia .. 
PATIENTS 
All patients with a clinical diagnosis of acute pneumonia defined on admission, and 
with ultimate evolution of the disease confirming this diagnosis are included in the 
study. The criteria for the diagnosis included a clinical history of an infective illness 
suggestive of pneumonia; pyrexia or hypothermia; clinical signs of lung consolidation 
including crackles or bronchial breathing; an elevated white cell count or a left shift in 
the morphology of the neutrophils, and evidence of an infiltrate on the chest 
radiograph. Patients with pulmonary or disseminated tuberculosis were excluded. 
Patients admitted with pneumonia but only after a cardiac arrest resulting in 
irreversible neurological damage were also excluded. 
No specific criteria for admission to the ICU existed and all patients who were 
considered likely to benefit, were admitted depending on bed availability. Patients 
were usually seen in the medical wards prior to admission, and therapy instituted 
immediately and transferred to the ICU when a bed became available. No patients 
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were excluded because of old age or any other clinical features suggesting a poor 
outcome. 
METHODS 
Clinical Diagnosis 
The diagnosis of pneumonia was determined on admission by the attendant physician 
and confirmed with subsequent evolution of the illness in problematic cases. All 
associated diseases present on admission were recorded. The pneumonia was 
classified as : 
Community-acquired pneumonia (CAP):-
Pneumonia that occurred in the community without any major comprising 
factors. Patients with COPD, diabetes, and similar underlying diseases were included. 
Nosocomial pneumonia:-
Pneumonia acquired after 48 hours of hospital admission or in a patient who 
has been in hospital within the previous month. 
Aspiration pneumonia:-
Pneumonia following observed aspiration or a very likely clinical setting e.g. 
after a fit; and further classified as either community-acquired or nosocomial. 
Pneumonia in an immunocompromised patient:-
Pneumonia in a transplant patient; patients on immunosuppressive drug 
therapy e.g. azathioprin, methotrexate, cyclophosphamide, steroids > 30 mg/day, and 
cancer chemotherapy; diseases including haematological malignancies, lymphomas, 
collagen vascular diseases and HIV infections. 
The data on community-acquired pneumonia only is reported, other than in chapter 9 
where an overview of all admissions to the ICU are presented, and those with all types 
of pneumonia are further described in terms of aetiology, treatment and outcome to 
give an overall perspective. 
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Demographics and Severity of Illness. 
Patient demographics were recorded and the severity of illness was calculated using 
the AP ACHE II scoring system with the worst physiological parameters in the first 24 
hours being used. (See appendix 2)208 The organ failure score was assessed daily for 
the first 5 days following admission using the following critetia for defining organ 
failure: 
Respiratory -
Renal -
CVS-
Respiratory rate <6 breaths/minute or >49 /minute or 
PaC02 >5.9 kPa or 
AaD02 >46 kPa (Pi02 - Pa02 - PaC02) or 
Dependent on ventilator for >3 days. 
Urine output <480 ml/24 hours or <160 rnl/12 hr or 
Serum creatinine >300 micro mol/1 or 
Serum urea >20 mmol/1. 
Mean blood pressure <50 mm Hg or 
Heart rate <55 beats/minute or 
pH <.7 .25 with PaC02 <6 kPa. 
Haematological -
wee <1000 cells/ml or 
Platelets <20,000 cells/ml or 
Haematocrit <21 % 
Neurologic 
Unconscious Glasgow Coma Score <7 (no sedatives for 24 hr) 
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Diagnosis 
The diagnostic procedures used were those that were considered to be good clinical 
practise and the following approach was used for ~ommunity-acquired pneumonia. 
1. On admission: 
Blood culture plus sputum Gram's stain and culture 
2. Immediately on intubation: 
Sputum Gram's and Ziehl-Neelsen stain and culture 
3. Gram's stain unhelpful and clinical features suggestive of an atypical pneumonia: 
Serology for Legionella and Mycoplasma. 
4. At 48 hours: 
Clinical response - no further investigation. 
No response Empiric antibiotic change and PSB (including 
immunoflurescent staining and microscopy for L. pneumophila), if additional factors 
suggested the possibility of an unusual organism or another diagnosis. Serology for 
Legionella and Mycoplasma was performed 
5. No response at 5 days: 
Fibreoptic bronchoscopy with PSB and transbronchial biopsy if indicated. 
In patients with nosocomial pneumonia a similar approach was used except that in 
fulminant disease fibreoptic bronchoscopy and a PSB were used on admission . 
In the immunocompromised group of patients invasive methods of diagnosis were 
performed on admission. 
Microbiological Methods. 
Microbiology was performed in the routine laboratory using standard laboratory 
methods. 
Blood cultures were processed by the Bactec system using both aerobic and anaerobic 
bottles 
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Sputum specimens. 
1. Specimens were examined macroscopically, and if unsuitable (e.g. salivary), were 
discarded except in the case of neutropenic patients. Sputum was described 
macroscopically as salivary, mucoid or purulent, and the presence of blood noted. 
2. A Gram's and Ziehl-Neelsen (ZN) stain was prepared using a sterile swab. The 
Gram's stain was evaluated for pus cells (graded 1 +,2+ or 3+ ); epithelial cells ( graded 
as >1+ to signify salivary specimens.); and predominant organism (i.e.> 1+), mixed 
organisms, or a pure single organism. 
3. The specimen was inoculated onto Boiled Blood Agar and Columbia Gentarnicin 
Agar, both inoculated at 37° C overnight under CO2 conditions and McConkey agar 
incubated at 37° C overnight. 
4. Pathogens were identified according to standard laboratory protocols. Disc 
sensitivity testing was done using NCCLS specifications for all organisms with the 
exception of cloxacillin. Cloxacillin was initially tested by the disc method and 
subsequently the cut off method was adopted.209 
During the time of this study however a number of specific studies were conducted 
including selective decontamination of the digestive tract, and evaluation of cefpirome 
and perfloxacin where additional microbiology was performed. 
Bronchoscopy Specimens. 
Bronchoscopic specimens were taken during fibreoptic bronchoscopy. Minimal local 
anaesthetic (lignocaine 2%) was used to anaesthetise the airways, and the 
bronchoscope was introduced through a special swivel adapter that permitted 
uninterrupted IPPV. The Fi02 was increased to 1.0 during the procedure, and the 
EKG, pulse, and oxygen saturation, was monitored continuously. Specimens were 
taken either by a bronchial brush, or a PSB if indicated, or a lavage trap specimen, and 
transported to the laboratory immediately. PSB specimens were agitated on a rotator 
to release material adhering to the brush, and then handled in a similar way to trap and 
other brush specimens. These were centrifuged at 4000 r.p.m for 15 minutes, and the 
supernatant then carefully removed and retained in a sterile tube, using a sterile 
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Pasteur pipette. A Gram's and ZN stain of the deposit were prepared and evaluated 
for micro-organ.isms and pus cells. Ziehl-Neelsen stains were done for all specimens, 
and direct immunoflourescence staining for Legionella spp. when this became 
available, The specimen was inoculated onto Boiled Blood Agar and Columbia 
Gentarnicin agar, and both were incubated overnight at 37°C under CO2 conditions; 
and a McConkey agar was incubated at 37°C overnight. Additional anaerobic culture 
was performed using a Vancomycin/Neomycin agar plate and a Nalidixic acid agar 
plate which were incubated anaerobically at 37°C for 48 hours. Further identification 
was done by standard laboratory methods as for sputum. All remaining deposit and 
supernatant fluid was forwarded for further processing for fungi and for Kirschner to 
exclude Mycobacterium spp. These organisms were identified according to standard 
laboratory protocols. In certain cases for study purposes quantitative culture of PSB 
specimens was performed however the results reported here consider all growth from 
the PSB to be significant. 
Definitions of Pathogenic Micro-organisms. 
Causative organisms were defined as those that were cultured from blood; those that 
were seen on the Gram's from sputum or tracheal secretions and cultured in pure 
growth; a predominant heavy growth of a pathogen, and all micro-organisms cultured 
from the PSB (quantitative culture was not used routinely). Mixed flora on the 
Gram's stain and mixed growth were considered as contaminants. Serology showing a 
fourfold rise in antibody titre was considered positive. 
99 
MONITORING 
Continuous EKG and oxygen saturation monitoring using a pulse oximeter and intra-
arterial blood pressure monitoring was used for the frrst few days until stable, and 
thereafter routine two hourly nursing monitoring of pulse, respiratory rate, blood 
pressure and temperature recordings were done. Urine output was measured hourly 
initially and subsequently two hourly. Routine monitoring of ventilatory variables 
was performed as indicated, and all ventilator alarms and EKG monitor alarms were 
appropriately adjusted. The duration of ventilation and different ventilatory 
modalities were documented. 
The patients were under the direct care of a registrar in training ( either anaesthetics or 
internal medicine), and the management was supervised by a specialist intensivist or 
pulmonary physician on routine twice daily rounds, or more frequently if necessary. 
Regular clinical monitoring and daily chest radiographs were performed. A special 
note of all procedures and their complications, and all other complications was 
recorded. Drug therapy was also documented. 
Microbiological surveillance of tracheal aspirates, and urine if catheterised, was done 
routinely twice weekly; and all IV catheters were cultured on removal. Other 
specimens were obtained when clinically indicated. 
In cases who died the cause of death and particularly the relationship to the 
pneumonia was doc;;umented. The relationship to secondary infection was determined 
clinically as far as possible. An autopsy was performed in all cases in whom consent 
was available, and an attempt was made to determine the causative organism and 
factors leading to death. 
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THERAPY. 
Antimicrobiol Therapy 
The antibiotic protocol used for the duration of the study was as follows: 
Empirical therapy in severe fulminant disease was commenced with intravenous 
Penicillin 5 million units 6 hourly, amikacin 15 mg/kg body weight 12 hourly (or 
gentamicin 1.5 to 2 mg/kg, 8 hourly), and cloxacillin 2 g, 6 hourly, until a pathogen 
was isolated. In less severe disease cloxacillin was omitted. In patients with renal 
dysfunction a third generation cephalosporin was substituted for the aminoglycoside. 
In cases where a causative organism was isolated, organism specific therapy was 
instituted. For S. pneumoniae, penicillin only; for H. influenzae if no response had 
occurred, intravenous ampicillin only; for S. aureus, cloxacillin and the 
aminoglycoside or in the case of cloxacillin resistance, vancomycin was given alone; 
for K. pneumoniae, a combination of aminoglycoside and third generation 
cephalosporin; and for Ps. aeruginosa a combination of an aminoglycoside and anti-
pseudomonal penicillin or ceftazidime. If the organism was resistant to any of the 
usual antibiotics an agent to which the organism was sensitive was substituted. All 
patients with Varicella zaster pneumonia (chickenpox pneumonia) received acyclovir 
in addition to broad spectrum antibiotics. In cases with aspiration pneumonia, and 
occasionally in primary community-acquired pneumonia, metronidazole was added. 
In the immunocompromised group of patients invasive diagnostic procedures were 
performed whenever possible to define the causative organism and allow specific 
antimicrobial therapy. 
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Ventilatory Therapy. 
The majority of patients needed intubation and mechanical ventilation however a few 
were treated with continuos positive airway pressure (CP AP) by face mask. 
CPAP by face mask. 
Indication for this form of therapy was persisting hypoxaemia (Pa02 <8 kPa), despite 
40% oxygen by mask, adequate alveolar ventilation (PaC02 <5.5 kPa), with an 
effective cough, and fully co-operative and capable of protecting the airway. 
A free-flow design CPAP apparatus with an oxygen blender and heated 
humidification designed in the respiratory ICU was used. (Cape CPAP system.). 
Intubation and IPPV with PEEP. 
Failure to meet the above criteria for adequate respiratory function, and also any 
evidence of septic shock (Systolic Blood Pressure <90 mm Hg in spite of adequate 
volume replacement), were both individually, indicators for immediate intubation. 
High volume low pressure cuffed endotracheal tubes were used exclusively (Portex 
profile, Portex LTD. Hythe, Kent, England.), and these were usually introduced 
transnasally using a blind nasal technique. In cases where suctioning was difficult, or 
where ventilation and oxygenation were difficult, or where a prolonged course was 
anticipated a tracheostomy was performed using a cuffed tube (Portex LTD, Hythe, 
Kent, England). Cuffs were all inflated to minimal occlusion pressure, adjusted two 
hourly, and monitored on an air pressure manometer. 
Patients were ventilated using constant volume ventilators (Bear 2 or 2e or CPU 1) 
with heated humidifiers (Fisher-Paykel), at an inhaled temperature of 32-350C 
incorporated into a standard circle circuit. The respiratory rate was set between 15 to 
25 breaths /minute, a tidal volume of 10 to 15 ml/kg body weight, a flow rate of 40 to 
50 I/min, and a positive end expiratory pressure (PEEP) level of 5 or more cm H20 as 
dictated by oxygenation. 
Goals of ventilation were: 
1. Pa02 
2. PaC02 
3. Peak Inspiratory Pressure (PIP) 
4. Fi02 
>8kPa 
<6kPa 
< 50cmH20 
<.50 
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The aim was to maintain oxygenation above 8 kPa at all times, and if it were 
necessary the goal limits particularly Fi02, were exceeded for as long as was 
necessary. If the PIP was exceeded, the tidal volume was reduced, and if the problem 
persisted, the patient was sedated and paralysed. If in spite of appropriate ventilator 
adjustment, hypoxaemia persisted, and the patient failed to adjust to ventilation, heavy 
sedation and paralysis was used. 
In cases of refractory hypoxaemia, PEEP levels of > 15 cm or inverse ratio ventilation 
at a rate of 20 to 30 breaths/minute were used. The rate was increased to meet the 
patients respiratory demands using minimal sedation if possible. In these difficult 
cases pulmonary artery catheters were inserted to monitor oxygen delivery and 
optimise fluid balance. 
Standard weaning criteria were used to decide when to initiate weaning: these 
included an adequate Pa02, Vital Capacity > 12-15 ml/Kg body weight, and reversal 
of the pneumonic process. The patients were weaned using techniques of Intermittent 
Mandatory Ventilation (IMV) or increasing time on CPAP. 
Respiratory circuits including the humidifier bowel were changed twice weekly. 
Standard nursing procedure was carried out in all these patients, which included 
routine monitoring and charting of blood pressure, pulse, respiratory rate; intake-
output fluid and urine charting including 1-2 hourly urine volumes plus S.G. and 
glucose estimations; ventilatory pressures, tidal volumes, suctioning and tracheostomy 
care; mouth care; positioning, and turning, and pressure care; feeding and all other 
personal hygiene. Care of the endotracheal and tracheostomy tubes, cuffs and 
endotracheal suctioning was shared by the nurses and physiotherapy teams, and 
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ventilator aspects with the ICU/Respiratory technologists. There was an ICU trained 
intensive care nurse responsible for this care whenever possible. 
Physiotherapy was performed by two physiotherapists ( on a 6 monthly to a year 
rotation), usually with one experienced in ICU care. Their responsibility was largely 
chest physiotherapy, respiratory care, and mobilisation of patients, which was usually 
done twice daily. Their role was also supervisory and teaching to enable the nursing 
staff to continue the physiotherapy programme more frequently. 
All these procedures in particular suctioning, was carried out with EKG and pulse 
oximetry monitoring to avoid causing hypoxaemia. If necessary the Fi02 was 
increased before suctioning, and if still inadequate, a special sheathed suction catheter 
which allows uninterrupted ventilation was used.(Steri-Cath, Portex LTD, Hythe, 
England) 
Supportive Therapy. 
Patients were given full circulatory support with intravenous fluids and inotropic 
support where indicated. Dopamine was used in a dose of <10 micro-
grams/kg/minute in cases of decreased urine output, and if further inotropy was 
necessary an adrenaline infusion was used in a dose of 10 to 100 micro-grams/hour. 
Patients were fed as soon as possible, by balanced enteral tube feeds with the majority 
receiving 1000 to 1,500 kcals/day (Ensure), or where diarrhoea was a problem, 
Osmolite (Abbott/Ross Laboratories, South Africa). Supplementary vitamins were 
given to all patients. 
No routine prophylaxis was used for stress ulceration. 
DATA COLLECTION. 
All data was collected by the registrars in training during the patients stay in the ICU, 
and this was recorded on a data collection form which was reviewed at a weekly 
clinical meeting convened by PDP or a deputy, to ensure the correctness of the data. 
The data collection forms and Apache II forms are in appendix 1 and 2. Data was 
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stored on a DBase 4 programme (Ashton-Tate) specifically designed for this ICU 
information (developed by PDP), and further analysis was performed using the DBase 
program, Epi Info Program and Epistat (Centres for Disease Control,USA). 
STATISTICAL METHODS. 
Numerical data is reported as mean and standard deviation. Comparison between data 
was done by Students t for nominal data, and Chi square testing for categorical 
variables where appropriate using the Epi-Info and Epistat statistical packages. 
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CHAPTER9 
PNEUMONIA REQUIRING ICU ADMISSION - AN OVERVIEW. 
INTRODUCTION. 
This chapter reviews all patients admitted to the ICU in whom a diagnosis of 
pneumonia was the primary indication for admission. These patients with pneumonia 
are classified according to the pathogenesis in immunocompetent patients, or as a 
specific group in those who are severely immunocompromised. This classification 
can be determined on admission and may be useful to provide a guide for further 
antibiotic management in pneumonia requiring ICU admission.210 The total number 
of ICU admissions are presented according to the primary admission diagnosis to give 
some perspective of the relative importance of pneumonia in the overall ICU case 
mix. 
PATIENTS. 
A total of 2385 patients that included 1436 patients with medical diseases (60.2%), 
218 with general surgical disease (9%), 11 cardiac (.5%), 75 thoracic (3.1%), 87 
orthopaedic (3.6%), 69 (2.9%) other surgical, 160 (6.7%) obstetrical and 
gynaecological, and 326 (13.7%) following trauma were admitted during the study 
period . The disease profile of all admissions and mortality are shown in table 11. 
The mean age of admissions was 41.7 years ( range 11-87 years); 319 (13.4%) were 
black male, 278 (11.7%) black female; 248 (10.4%) white male, 192 (8.1%) white 
female; 641 (26.9%) male, and 707 (29.6%) female of mixed race. 
413 (17.3%) patients were admitted to the ICU with pneumonia during the six year 
study period from January 1987 to December 1992. This included 196 patients with 
community-acquired pneumonia, 75 nosocomial, 101 following aspiration and 41 
immunocompromised patients. 35 patients with pulmonary tuberculosis and 15 with 
disseminated tuberculosis were not included in the patients with community-acquired 
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pneumonia for analysis. One patient with dual infection with pulmonary tuberculosis 
and a bacterial pathogen was included in the analysis. 
Table 11: Different diseases with APACHE II and mortality. 
No. APACHE II MORT.% 
ASTHMA 223 11.2 0.45 
ARDS 192 14.8 23.4 
COPD 89 17.5 4.5 
PNEUMONIA 413 16.2 24* 
OTHERLD** 192 13 18.2 
POISONING 172 12 5.8 
NEUROLOGICAL 204 14.7 22.1 
SURGICAL 235 10.1 6.8 
TRAUMA 534 9.33 5.4 
OTHER DISEASE 131 28.2 52.7 
TOTAL 2385 13.5 14.8 
*x 2 p = .000001; **includes interstitial lung disease, carcinoma and bronchiectasis. 
The classification of the pneumonia; age, severity of illness, and outcome is shown in 
table 12. 
Table 12: Classification of pneumonia with severity and outcome. 
No AGE APACHE II MORT.% 
CAP 196 44.9+- l 7 .09 16.9+-7.95 25.5% 
Nosocomial* 75 46.3+-16.85 14.6+-7.77 20% 
Aspiration** 101 40.4+-16.29 15.3+-8.55 15.8% 
Immunocomp. 41 41+-14.89 17.5+-6.75 45% 
*Non ventilator associated pneumonia only. **Includes both community-acquired and 
hospital acquired aspiration. 
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AETIOLOGY. 
The aetiology of the different types of pneumonia is shown in Table 13. 
Table 13: Micro-organisms causing severe pneumonia 
CAP NOSOC*. ASPIR.** IMMUNO.*** 
% % % % 
S. pneumoniae 32.1 16 20 17.1 
S. aureus 8.7 16 11.9 17.1 
S. epid. 0.5 2.7 1 0 
OtherGm+ve 0.5 1.3 0 2.4 
H. infiuenzae 11.2 14.7 18.8 7.3 
Br. catarrhalis 0.5 0 0 0 
K. pneumonia 8.2 20 8.9 4.9 
E.coli 3.1 4 7.9 0 
Ps. aeruginosa 1 6.7 3 2.4 
Acinetobacter spp 1 1.3 2 0 
Enterobacter svv 0 2.6 2 0 
OtherGm-ve 1 0 2 0 
Anaerobes 1 1.3 2 0 
Candida svv 1 0 0 9.8 
Legionella spp 3.1 0 0 1 
Mycoplasma 0.5 0 0 0 
Viruses 3.6 0 0 9.8 
Others 1.5 1.3 4 9.8 
P. carinii 0 0 0 14.6 
Unknown 29.6 33.3 42.6 26.8 
* Nosocomial pneumonia; ** Aspiration pneumonia; *** Immunocompromised 
patients. 
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There was only one HIV positive patient admitted to the ICU with a pneumonia 
during this time period, and this patient was one of 5 patients with P. carinii infection; 
the others with P. carinii infections included 2 renal transplant patients, and 2 with 
haematological malignancies. 
SPECIAL INVESTIGATIONS 
A number of special investigations were performed which included fibreoptic 
bronchoscopy (73), transbronchial biopsy (9), open lung biopsy (5), lumbar puncture 
(23), bone marrow (15), lung or body scan (11), ECHO or MUGA scan of heart (43), 
angiography (6), and computerised tomography or ultrasound of the abdomen (79). 
Pulmonary artery catheterisation was used in 96 patients with 138 procedures being 
performed. The right internal jugular was used in 109 procedures, left in 16 , left 
subclavian 3, and right subclavian 1. Complications were largely technical, with 4 
patients requiring multiple attempts to find the vein, 3 attempts failed, 4 arterial 
punctures occurred, 5 balloon ruptures and in 1 it was impossible to obtain an 
adequate wedge, 3 patients developed arrhythmias that required treatment and in one a 
pneumothorax occurred. 
TREATMENT 
The majority of patients were in hypoxaemic respiratory failure and 215 patients were 
managed with endotracheal intubation, and 129 required tracheostomy. The 
indications for initial intubation were considered to be respiratory failure in 301, 
secretion retention in 19, and miscellaneous causes in 19 patients, whereas for 
tracheostomy 114 were for respiratory failure and prolonged intubation, 7 to assist 
weaning, 5 secretion retention, and 3 for upper airway obstruction following 
extubation. 316 patients were treated with CPPV, 31 with IPPV, 39 CP AP by face 
mask, and 27 oxygen by face mask only. The mean level of PEEP was 7.48 and 26 
patients required 15 cm H20, or more. 6 patients were treated with double-lumen 
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endotracheal intubation and independent lung ventilation. The duration of ventilation 
is shown in figure 6. 
Figure 6: Duration of ventilation 
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Additional supportive treatment included haemodialysis (73 patients), peritoneal 
dialysis (35), and total parenteral nutrition (70). All patients received enteral 
nasogastric tube feeding as soon as they could tolerate it (177 patients), starting with 
500 kcals and building up to a maximum of 1000 to 1500 kcals.( Ensure or Osmolite; 
Abbotts/Ross Laboratories) 
The antibiotics used in these patients are shown in table 14. 5 patients received one 
antibiotic only, 17 two antibiotics and the remainder more than two antibiotics. 
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Table 14: Antibiotic therapy that was prescribed. 
Antibiotic No of Patients 
n=413 
Penicillin G 228 
Amikacin 201 
Gentamicin 75 
Tobramvcin 3 
Cloxacillin 68 
Erythromvcin 65 
Cefotaxime 64 
Ceftriaxone 63 
Ceftazidime 28 
Cotrimoxazole 69 
Amoxicillin 39 
Piperacillin 18 
Clindamycin 27 
Amphotericin B 21 
Metronidazole 165 
Vancomycin 33 
Fucidin 7 
Quinolone 17 
Chloromycetin 5 
Tetracycline 2 
The duration of admission to ICU ranged from <1 day to 165 days (a patient with 
Guillain Barre' admitted with severe pneumonia), with a mean duration of 13.01 days 
(S.D. 14.69). The mean duration of admission in the 314 survivors was 14.29 +-15.93 
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days, and 8.92 +- 8.57 days; in the 99 non-survivors ( p = 0.00002). The duration of 
admission is shown graphically in figure 7. 
Figure 7: Duration of ICU admission of survivors and non-survivors 
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COMPLICATIONS OCCURRING IN THE ICU 
Complications occurred in 210 patients and these were usually related to the severity 
of the disease, and included secondary infections, gastro-intestinal haemorrhage and 
diarrhoea. A number of complications of ventilation occurred and included 27 
pneumothoraces, 6 blocked endotracheal tubes, 7 accidental extubations and 3 
tracheostomy bleeds. There were no cases of tracheal stenoses, even with long-term 
follow up. The frequency of different complications is shown in shown in table 15. 
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Table 15: Incidence of complications in the ICU. 
No of complications 
Gastrointestinal bleeding 32 
Pulmonary embolism 1 
DVT* 3 
Haemoptysis 7 
Pneumothorax 27 
Ventilatory complications 24 
Respiratory infection 47 
Septicaemia 11 
IV line sepsis 22 
Diarrhoea 23 
IV line complications 23 
Drug complications 25 
* Deep venous thrombosis 
MORTALITY 
The overall mortality was 24% (99 patients), with 25% of deaths occurring within 48 
hours. The time of death is illustrated in figure 8. 
Figure 8: Time to death following admission 
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Deaths were considered clinically to be due to septicaemia and multiple organ failure 
in 53 patients, respiratory failure in 27, hypoxic brain damage 9, pulmonary embolus 
1, and cardiac in 9. In 2 of these patients death occurred following withdrawal of 
active therapy because of no chance of meaningful recovery. The outcome of the 
different pneumonias are shown in table 12. 
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DISCUSSION 
Patients admitted with pneumonia contribute significantly to the patient load in our 
multidiciplinary ICU. The mortality varies considerably depending on the type of 
pneumoma. This classification seems useful . in clinical decision making and 
epidemiological studies of ICU admissions, as both mortality, and aetiology, are 
different in the different categories which allows planning of appropriate therapeutic 
strategies. Many previous ICU studies have combined pneumonia with other causes 
of ARDS which tends to lose these clinical distinctions, and will make evaluation of 
these studies and new therapeutic strategies difficult to interpret. 211 
In this study the aetiology of the pneumonia was determined using routine clinical 
methods, but because of the severity of the disease most patients had tracheal 
secretions sampled immediately on intubation, and other special procedures such as 
fibreoptic bronchocscopy were used more frequently. Not surprisingly because of the 
physiological decompensation prior to intubation with acidosis, shock and a depressed 
level of conciousness, the larynx was usually incompetent on intubation. Many of the 
secretions that the patients were unable to expel because of a weak cough appeared to 
be of oropharyngeal origin. This may also explain the many cases of unknown 
aetiology as these specimens would have been discarded as unsuitable for 
microbiological processing. The diagnostic approach that was used was also 
pragmatic and not all patients were subjected to all the tests particularly FOB and 
serology. This may have influenced the results and underestimated pathogens such as 
Legionella spp., or Mycoplasma pneumoniae, where the diagnosis is only possible 
using these techniques. The number of S. Pneumoniae infections may also have been 
increased had we used specific antigen detection, however this would have been 
unlikely to have influenced the incidence of Gram negative infections to any extent. 
The aetiology of infections in the immunocompromised group may also be altered by 
having other ICU's in the hospital where these patients are initially treated and only 
the worst often non responding cases are admitted to the RICU often after prolonged 
antibiotic therapy. 
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This classification which can be applied on admission to the ICU proved to be as 
useful in patients with severe pneumonia as it is in patients with less severe disease, as 
each different category appears to have a characteristic spectrum of causative micro-
organisms.210 This helped in empirical antibiotic and other therapeutic decisions 
such as what further diagnostic procedures were necessary. Whilst the general pattern 
was similar with S. pneumoniae remaining the most common organism, an increased 
number of Gram negative micro-organisms were seen in the nosocomial group, and 
more opportunistic infections occurred in the immunocompromised patients. There 
was a high incidence of S. aureus infections in all the categories, and interesting H. 
influenzae was also common in all groups; this agent was frequently identified as a 
second pathogen, and whether it truly contributed to infection was difficult to 
determine, however appropriate clinical response often only occurred after specific 
therapy for H. influenzae was instituted. There were no episodes of L. pneumophila 
other than in the patients with CAP. 
The nature of pathogens in these patients with severe CAP differ from those seen in 
less severe cases with an increased number of Gram negative infections, particularly 
K. pneumoniae, as well as an increase in S. aureus infections.17,125 
Pulmonary artery catheterisation had a low complication rate and in the majority of 
patients catheterised, the information from the procedure was considered most 
valuable, and contributed to decision making particularly with regard to fluid, and 
ventilatory therapy when high levels of PEEP were necessary. It was also helpful 
diagnostically in a small number of patients in whom a pulmonary embolism or 
cardiac failure was diagnosed vis a vie pneumonia. 
The mortality for the different diseases varied considerably, and the relationship 
between mortality and the AP ACHE II score is well illustrated showing how 
pneumonia has a high mortality relative to the AP ACHE II score. The mortality in 
pneumonia compared to all other admissions was significantly increased. ( p = 
.000001) (see table 11.) 
116 
CHAPTERlO 
SEVERE COMMUNITY-ACQUIRED PNEUMONIA 
INTRODUCTION 
Severe community-acquired pneumonia forms a clearly distinct category that accounts 
for the majority of patients with pneumonia who require ICU admission. This group 
includes all patients with community-acquired pneumonia, other than those who have 
had a clear episode of aspiration, or who are severely immunocompromised. It 
includes those with underlying diseases such as COPD, diabetes and neurological 
abnormalities. These patients with severe CAP differ significantly from those with 
milder forms of CAP, and also other types of pneumonia. As such these patients 
warrant separate analysis and in particular clinical features including aetiology, 
diagnosis, and determinants of severity require documentation to contribute further to 
our understanding of the clinical features and management of these patients. 
RESULTS 
There were 196 patients with CAP including 121 males, and 75 females. There were 
70 blacks, 18 whites, and 108 of mixed race (see figure 9). 
Figure 9: Race and gender of patients with CAP. 
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The mean age was 44.9 (S.D.±17 .09) years, and the distribution of age is shown m 
figure 10. 
Figure 10: Age distribution of patients with CAP 
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The APACHE II score was 16.9 (S.D.±7.95) and distribution of scores is shown in 
figure 11. 
Figure 11: APACHE II scores (Worst in first 24 hours of admission) 
Number of patients 
so ~-----------------------------~ 
1-5 6-10 11-15 16-20 21-25 26-30 31-35 >40 
APACHE II Score 
118 
The organ failure scored on day 1 showed that 88 patients had one organ failure, and 
57 with more than 1 organ failure (mean of 1.47, S.D.±1.04). 21 patients were 
admitted with septic shock (Systolic blood pressure [SBP] <80 mm Hg); 24 patients 
had renal failure (Creatinine >300 micro mol/1, or urea >20 mmol/1) on admission and 
a further 8 developed renal failure. 
Associated disease occurred in 100 patients and the relationship of this disease to age, 
severity of illness, and outcome is shown in table 16. 
Table 16: Concomitant disease related to age, APACHE II, and mortality. 
n AGE APACHE2 
COPD 42 54.15±15.12 18.95±9.22 
Asthma 13 36.15±15.52 15.54±6.09 
OldPTB 18 43.06±16.02 16.06±5.76 
Lung disease* 8 41.88±16.13 19.5±7.11 
Diabetes 21 54.57±13.64 17.81±6.65 
Cardiac 16 58.94±16.74 18.69±5.28 
Neurological** 8 36.63±15.52 14.63±5.73 
* Bronchiectasis ( 3 patients), Interstitial fibrosis ( 4 ), Kyphoscoliosis ( 1 ). 
** Myasthenia Gravis (4 patients), Myopathy (3),Tetanus (1). 
AETIOLOGY. 
MORT.% 
11 (27%) 
0 
4 (22%) 
3 (38%) 
6 (29%) 
3 (19%) 
1 (13%) 
The aetiology of the pneumonia was determined by blood and bronchial secretion 
cultures, and serology. The spectrum of aetiological agents is shown in figure 12, and 
the aetiology determined by blood culture only (58 patients) in figure 13. 
Figure 12: Aetiology of severe community-acquired pneumonia. 
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Figure 13: Aetiology of severe CAP determined by blood culture. 
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Blood culture was positive in approximately 50% of cases where causative organisms 
were identified. In H influenzae pneumonia it was significantly lower. ( 1 in 22 cases; 
x2 p = .039) 
The aetiology related to underlying COPD, diabetes and in the elderly ( > 60 years of 
age) are compared to the aetiology in all patients in figures 14,15,16. 
Figure 14: Aetiology of severe CAP in COPD 
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Figure 15: Aetiology of severe CAP in diabetics 
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Figure 16: Aetiology of severe CAP in the elderly 
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There were 23 patients who were considered to have pneumonia caused by dual 
infections; 1 by three pathogens, and one patient had active pulmonary tuberculosis 
and a blood culture positive bacterial pneumonia. The most common multiply 
occurring pathogen was H. influenzae in 11 cases, and anaerobes in 2. 
The severity of illness, duration of therapy and mortality in relation to pneumonia of 
different aetiologies is shown in table 17. 
Table 17: Relationship between micro-organism, severity of disease, and 
t ou come. (All l va ues J!lVen as mean an d (SD)} . .. 
No AGE APACHE II ORGAN DURATION 
(years) FAILURE ICU (davs) 
S. pneumoniae 63 44.7 18.4 1.56 9.09 
(16.88) (8.7) (1.06) (7.07) 
H. infiuenzae 22 41.6 18.5 1.33 10.6 
(18.49) (18.5) (0.97) (8.68) 
S. aureus 17 37.1 13.5 1.27 11.59 
(20.93) (7) (0.88) (7.95) 
K. pneumoniae 16 45.3 19.2 2.06 9 
(11.25) (7.77) (1.34) (9) 
E.coli 6 45 15.7 2.0 16.4 
(8.25) (5.28) (1.0) (30.16) 
Varicella 7 28.7 6.43 0 0 
(12.19) (5.09) 
L. pneumophila 6 47 16.67 1.33 13.5 
(13.3) (6.98) (1.03) (16.67) 
Unknown 54 47.8 16.12 1.34 8.63 
(16.8) (7.06) (0.96) (7.74) 
Total 196 44.8 16.89 1.47 9.5 
(17.09) (7.95) (1.04) (9.8) 
MORT 
13 
20.6% 
7 
31.8% 
6 
35.3% 
7 
43.8% 
2 
33% 
0 
0 
15 
27.8% 
50 
25.5% 
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CLINICAL FEATURES. 
The earliest clinical features documented on admission to hospital were recorded 
where possible prior to instituting therapy. 
Table 18: Clinical features on admission 
Clinical Feature No. of Patients Mean S.D. 
Confused n= 150 27/150 
Temperature oc 191 37.48 1.41 
Resp. Rate 183 30.99 12.36 
wee m111 185 17430 29612 
Polymorphs % 185 68.28 
Platelets rnl/1 185 219753 134254 
Na+ mmol/1 191 136.46 6.88 
K+ mmol/1 187 3.95 0.85 
P04.- mmol/1 158 1.14 0.85 
Uream mol/1 191 12.15 13.51 
Cr- micro mol/1 190 199 481.4 
ALT units/I 165 48.5 65.2 
AST units/I 165 80.52 87.8 
LDH units/I 156 590.9 774.9 
Alk. Phos. I U/1 166 116.3 84.7 
Bilirubin (Conj.) micro mol/1 170 9.8 13.6 
Bilirubin (Total)micro mol/1 175 17.7 16.2 
Protein (Total) g/1 169 58.6 9.7 
Albumin g/1 175 28.22 6.43 
pH 190 7.39 0.15 
PaO? kPa 190 12.87 7.62 
PaCO? kPa 190 4.48 1.54 
Pa0?1Fi0? 190 200.7 101.5 
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The level of oxygenation is also shown in the table above as the Pa02/Fi02 ratio to 
eliminate the influence of supplementary oxygen therapy. 
Radiological Features. 
The chest radiographs were classified on admission as either lobar or segmental, 
bronchopneumonia, interstitial, or lobular; the presence of an effusion; diffuse 
changes of rapid onset suggesting that there was ARDS were also noted. These 
features related to the different aetiologies of the pneumonia are shown in table 19. 
The radiographs were all viewed blindly by the author without any clinical history, 
and an aetiological diagnosis was attempted in 132 patients. The correct diagnosis 
was made in only 34% of cases. Whilst the patients with Chicken pox pneumonia, 
and those with haematogenous S aureus infection were all correctly identified there 
were many false positive diagnoses even in these groups. Only 11 patients had 
evidence of an effusion but most radiographs were taken in the supine or semi-erect 
anterior posterior projection. Those with effusions included S. pneumoniae 3, S. 
aureus 3, unknown aetiology 3 and 1 each for E.coli and H. influenzae. 
Table 19: Radiological features of pneumonia of different aetiologies 
n. Bilat. Lobar Broncho. Lobular Interstitial ARDS 
S. pneumoniae 37 26 28 3 2 4 7 
H. influenzae 12 11 5 5 2 0 3 
K. pneumoniae 10 5 9 0 1 0 3 
S. aureus 13 11 4 3 5 1 6 
Le~ionella spp. 5 3 4 0 0 1 3 
Unknown 43 36 23 7 6 7 13 
Total 120 92 73 18 16 13 35 
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SPECIAL INVESTIGATIONS. 
A number of special investigations were performed including fibreoptic bronchoscopy 
with bronchial brushing in 41 patients, transbronchial biopsy in 4 and open lung 
biopsy in one; 4 patients underwent blind bronchial brushing. Echo-cardiography was 
performed in 10, ERNA scanning in 6, abdominal ultrasound in 10, radio isotope body 
scan in 7, lumbar puncture in 5, and computerised tomographic scanning both chest or 
abdomen in 16. 
THERAPY 
Antibiotic therapy was instituted as soon as possible usually starting in the emergency 
unit and if the selection was considered suitable it was continued in the ICU, and 
antibiotics were changed when so directed by microbiology, or if the patient was 
considered to have failed to respond within 48 hours. Antibiotics were discontinued 
after 24 hours of resolution of the signs of infection. The antibiotics used in this group 
of patients are shown in figure 17. 
Figure 17: Antibiotic prescription in severe CAP 
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All patients required ventilatory support with 160 patients requiring intubation and 
mechanical ventilation, 22 CPAP by face mask, and 14 oxygen only. The indications 
for intubation were for respiratory failure in 155 patients and retention of secretions in 
5, and tracheostomy was done for prolonged ventilation in 50 patients, secretion 
retention in 4 and to assist weaning in 3. 
Different methods of ventilatory support, severity of illness, duration of support, 
complications, and mortality, are shown in table 20. Continuous positive pressure 
ventilation was used in 140 patients, and in 16 patients more than 15 cm H20 PEEP 
was required. · 20 patients were ventilated without PEEP because of associated air 
trapping due to obstructive lung disease. Four patients three of whom survived were 
intubated with double lumen endotracheal tubes (Broncho-Cath, National Catheter 
Corp., Mallinkrodt, Argyle, New York.), and ventilated using independent lung 
ventilation. Two of the survivors required pulmonary surgery. 
Table 20: Ventilatory therapy, complications, and outcome. 
No Duration Vent. Complies Mort 
(Pts.) ICU(davs) (davs) (total n.) 
MaskO? 14 4.14±1.46 - 3 0 
MaskCPAP 22 5.0±2.65 - 4 1* 
IPPV 20 6.9±6.73 4.55±5.2 11 5 (25%) 
CPPV 140 14.06±12.5 10.85± 223 44 (31.45%) 
10.07 
± =S.D. 
* Patient died of a pulmonary embolus. 
127 
Complications of the ventilator therapy occurred in 33 patients and the different 
complications are given in table 21. 
Table 21: Complications occurring in the ICU related to ventilation . 
No. of Complications 
Pulmonary Infection 8 
Barotrauma 13 
Accidental Extubation 3 
Ventilator Failure* 2 
Pulmonary Haemoptysis 4 
Tracheal Bleed 2 
BlockedETT 2 
CV A during CPPV 1 
* Total numbers of hours of ventilation= 37608 hours. 
Forty-four patients were admitted with acute renal failure and a further 15 patients 
developed renal failure of whom 40 were supported with dialysis; 25 patients by 
haemodialysis alone, 9 by haemodialysis and peritoneal dialysis, and 6 with peritoneal 
dialysis, of whom 28 (70%) survived. 
All patients received enteral feeding usually with either ensure or osmolite via a fine-
bore nasogastric tube if the gastro-intestinal function allowed, however in 32 it was 
necessary to institute TPN. 
Additional drug therapy included adrenaline (32 patients), and dobutamine (29 
patients) for inotropic support; dopamine in a dose of <10 micro gm/kg/min for renal 
protection (70 patients); H2 antagonists for active treatment or prophylaxis of pre-
existing ulcer disease or active gastro-intestinal bleeding (25 patients). Sedatives 
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usually diazepam ( 127 patients), fentanyl ( 31 patients), morphine ( 36 patients), and 
non-depolarising muscle relaxants used intermittently (33 patients). 
COMPLICATIONS 
The complications that occurred in these patients are shown in table 22. There were 
100 patients who had no complications, 42 with one complication and 54 with two or 
more complications. 
Table 22: Complications occurring in the ICU 
No of patients 
Gastrointestinal Bleeding 17 
Respiratory Infection 12 
Septicaemia 8 
Urinarv Tract Infection 8 
IV sepsis 9 
Cardiac Failure 10 
Arrhvthrnia 11 
Renal Failure 16 
DIC 16 
Hepatic Failure 6 
Diarrhoea ( enteral feeds) 6 
DVT 4 
Skin Reaction 8 
Delirium Tremens 8 
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MORTALITY 
There were 50 deaths ( 25.5% mortality), with the mean time to death being 7.62 (<l -
35) days after admission. with the time of deaths shown in figure 18. There were 15 
deaths in 58 bacteraemic patients and 35 deaths in 103 non-bacteraemic patients 
which was not significantly different. x2 p = 0.915) 
The majority of deaths were sepsis related and the cause of death as assessed clinically 
are shown in table 23. 
Figure 18: Relationship of time of admission to death 
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Table 23: Clinically assessed cause of death. 
No. of Patients 
Septicaemia 14 
Multiple Organ Failure 15 
Hypoxaemia 12 
Pulmonary Embolus 1 
Cardiac 4 
Neurological Damage 4 
DISCUSSION. 
The type of pathogens leading to severe disease differ significantly from those seen in 
less severe cases. The major difference is the increased number of Gram negative 
infections, particularly K. pneumoniae as well as an increase in S. aureus infections. 
A previous emergency room based study in our hospital showed the incidence of 
Gram negative pneumonia (excluding H. influenzae) to be less than 4% as compared 
with the present study with an incidence of 14%, and an incidence of S. aureus 
pneumonia of 2 and 9% respectively.9 A similar low incidence of Gram negative and 
S. aureus infections is noted in a number of community based studies from other 
regions.17, 125 
This high incidence of Gram -ve infections 27 patients (14.%), with 44% mortality 
and S. aureus with a 35.7% mortality in these patients with respiratory failure 
requiring ventilatory support, suggests that these pathogens may produce a more 
severe form of disease. This is supported by the high mortality with these infections 
in this study and in other studies of S. aureus infections and by the high mortality in 
17 patients with Klebsiella pneumonia previously reported.104,129 Previous general 
131 
hospital based studies of primary pneumonia and studies from intensive care units 
have failed to recognise this important influence of etiologic agent on the severity of 
disease because of insufficient numbers of patients with these infections, or have not 
evaluated aetiology as a prognostic indicator. 2, 17 ,20, 125 The severity of disease may 
not necessarily be entirely dependant on the micro-organism as it may be a reflection 
of the predisposition of patients with co-morbid diseases to develop specific micro-
organisms. This seems unlikely however as the AP ACHE scores of Klebsiella and S. 
pneumoniae infections are similar with very similar types of patients, and the low 
AP ACHE in S. aureus infections is largely related to the young age of the patients, yet 
the mortality is high.. A high incidence of Legionella pneumophila (30%) was seen in 
a previous ICU based study.119 Our incidence of 3% was considered high when 
compared with the usual low incidence in our region.9,117 Of interest, however, was 
that the mortality of this organism was low in both series in spite of requiring ICU 
admission, suggesting that although it causes a severe disease, appropriate therapy 
will result in a successful outcome. 
It is of interest that in this group of diabetics the spectrum of causative organisms is 
similar to the other patients with severe pneumonia. One of the three patients with 
fungal infections occurred in a diabetic whereas the other two were in patients with 
COPD. Almost half the cases with H. influenzae infection as would be expected 
occurred in the patients with COPD. 
The selection of antibiotics was appropriate in the majority of cases; there was 
however a tendency for excessive use of arninoglycosides and metronidazole prior to 
ICU admission, particularly in the less severe cases where a micro-organism known to 
sensitive to penicillin was present. An arninoglycoside was given in 130 patients 
whereas it could only be considered appropriate in only 27 patients with Gram 
negative and 9 with S aureus infections. It is questionable whether metronidazole is 
ever indicated as empirical therapy unless a patient has already failed to respond. In 
some cases there were considerable delays in the administration of the initial starting 
dose of antibiotic, and also in achieving early adequate serum levels because of 
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insufficient dosage particularly with aminoglycoside administration. In Gram negative 
pneumonia inadequate dosage has been shown to worsen outcome .212 This failure 
of appropriate aminoglycoside therapy was in spite of a clearly defined antibiotic 
policy, and in an attempt to overcome this the recommendation that the starting dose 
should be double the calculated dose has been made. This approach is supported by 
recent evidence of a very much increased volume of distribution in critically ill 
patients.213 Unexpected delay also occurred occasionally with staff waiting for 
specific time schedules before administering the starting dose. This was particularly 
relevant with drugs with more widely spaced dosage intervals and also with in 
hospital .transfer, and this is of concern with new dosage schedules for 
aminoglycosides as well as with newer agents with long half-lives requiring widely 
spaced dosing intervals.29 
Although a small number of patients were treated with face mask oxygen alone, the 
majority required PEEP either by CP AP mask in the milder cases, and CPPV in the 
more severe cases. Most patients received CPPV with a respiratory rate of in excess 
of 20 breaths/minute early on in the illness, which was effective in allowing 
comfortable ventilation in the majority of patients without having to use excessive 
sedation or muscle relaxation. To achieve this the pC02 was often between 3.5 and 
4.5 kPa and this appears to have no detrimental effect on either oxygen delivery or 
cardiac function. The benefits of a co-operative wake patient who can be actively 
mobilised seems to far outweigh the benefit of normocarbia and the potential adverse 
depressant effects of deep sedation. 214 Sedative drugs were used sparingly and 
usually only to help facilitate patients who were critically hypoxaemic, or requiring 
excessively high ventilator pressures. There has been a trend to limit the level of 
PEEP and maintain oxygenation initially by a high Fi02 and if insufficient 
improvement is seen, inverse ratio ventilation is applied. This is a global trend and 
appears effective as adequate oxygenation is invariably achieved. 
The indications for intubation are unclear and no guidelines are yet widely accepted. 
Our practice is to encourage early intubation particularly when septic shock is present, 
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even if by blood gas criteria there is no absolute indication. We would recommend 
that patients are intubated if they are confused; are in respiratory failure and have 
either refractory hypoxaemia or hypercarbia; are unable to clear secretions; or are in 
shock. In a number of cases delay in referral, or intubation may have contributed to an 
adverse outcome. This was often also associated with a delay in adequate fluid 
resuscitation and inotropic support. 
A number of agents that block various stages of the inflammatory cascade have been 
developed over the past decade and have shown promise. The use of anti-endotoxin 
immunoglobulin antibodies showed an improved outcome in severe sepsis, 
particularly if used prophylactically, however HN which may be transmitted with 
these preparations has rendered them obsolete.25,190 The recently developed human 
monoclonal antibody against endotoxin (HA-lA), despite initial encouraging reports 
has been shown to have little benefit 191 During this study period a number of 
patients were part of an international anti-TNF immunotherapy trial. The results are 
still being analysed but it was clear that more rapid accurate assessment of the patients 
by experienced medical staff, appropriate resuscitation, and early antibiotics seemed 
to hasten response and these agents may play an important role in the future. Other 
cytokine blockers may also have a protective effect and preliminary results will soon 
be available.191, 193 
Multiple organ failure proved to be the most frequent cause of death. This was either 
caused by the primary infective process, or nosocomial infection which proved to be 
the most common complication. Refractory hypoxaemia also occurred and 
contributed to death in a few cases. Gastro-intestinal bleeding occurred in 9% of 
patients and this complication was usually part of multiple organ failure, and was not 
seen more frequently following discontinuation of routine ulcer prophylaxis. 
Earlier literature suggests that therapy may play a very small part in determining 
outcome from severe pneumonia as death occurred early within 24 hours of 
admission, and ICU management had thus far not influenced outcome whatsoever. 
Hook et al reported a mortality of 76% for bacteraemic pneumococcal pneumonia 
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requiring ICU admission.99,215 Our results however, suggest that with modem 
intensive care the mortality of community-acquired pneumonia may be considerably 
lower, with mortality of less than 30% overall, and 35% for bacteraemic pneumonia. 
The cause of death and timing of deaths suggest that supportive therapy in ICU has 
played a real part in reducing early deaths, and that the cause of death is now largely 
due to multiple organ failure and not due to early respiratory failure or septic shock. It 
is however impossible to determine which aspects of therapy may have led to this 
reduced mortality. 
Any further improvement in mortality will have to be directed at the rapid removal of 
infection and prevention of organ dysfunction. Complications of ICU treatment which 
may contribute to organ dysfunction such as secondary infection will also have to be 
recognised and prevented. 
CHAPTERU 
FACTORS PREDICTING MORTALITY IN SEVERE COMMUNITY-
ACQUIRED PNEUMONIA 
Introduction 
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Prediction in medicine and particularly in critical care, is one of the most important 
clinical attributes for patient care. With recent changes in medical practice not only 
are we now expected to be able to accurately quantify the risk of death or long term 
outcome of different diseases for decisions on ratient's ICU therapy, but we are also 
expected to use shrinking medical resources where they will produce most benefit to 
society. As the cost of critical care contributes to more than 10% of hospital 
expenditure whilst benefiting only a small number of patients, and as most deaths now 
occur in this setting, it is not surprising that clinical predictions have become an 
important area of development in critical care. The APGAR and the Glasgow Coma 
Score are the forerunners of the "science" of outcome prediction, and they were 
followed by the therapeutic intervention score (TISS), the earliest general ICU 
severity scoring system which was developed by Cullen. This scoring system which 
measured medical and nursing intervention was soon superseded by methods that 
scored physiological parameters, and the APACHE (acute physiological and chronic 
health evaluation), followed shortly thereafter by AP ACHE II, [measures 11 
physiological variables, age, Glasgow Coma Score and chronic health (appendix 2)] 
and SAPS, (simplified acute physiology score) that measures 14 readily available 
physiological variables have received wide validation, and are in general use.208,216 
More recently an AP ACHE 3 system has been developed as a commercial venture, 
and the exact methodology have not been made available for general scrutiny. This 
system is very expensive and requires sophisticated in-house computerised analysis 
For these reasons it has not yet received general acceptance although it does offer 
additional advantages as it evaluates and updates risk on a daily basis. 217 
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Treatment decisions for a successful outcome in pneumonia, rely heavily on accurate 
assessment of the severity of the disease to determine antibiotic selection and the level 
of supportive and monitoring therapy necessary. There have been suggestions that the 
APACHE II may be a poor predictor of outcome in pneumonia,20 however we have 
shown good correlation between the AP ACHE II score and mortality in a group of 90 
patients with pneumonia.123 A number of independent clinical features are 
recognised to predict the severity of pneumonia in a community and hospital 
population, some of which, in combination may predict a 16 to 20 fold increase in 
mortality (>1 of diastolic BP:::; 60 mm Hg; respiratory rate ~30 breaths/min; Urea> 7 
mmol/1 or confusion substituted for urea on admission). These clinical features while 
being fairly sensitive are not particularly specific and unfortunately fail to predict risk 
accurately in individuals.17 ,22, 172 A recent study that evaluated patients who failed 
outpatient treatment added a number of additional risk factors that need to be 
considered.18 Patients with ARDS pose similar problems and once again the general 
scoring systems fail to give an accurate prediction of mortality particularly in 
individual patients.123 This has led to the lung injury score proposed by Murray 
however this also needs further refining. 218,219 The assessment of the severity of 
pneumonia and risk factors that may predict a poor outcome have not been adequately 
evaluated with large groups of clearly defined patients with severe pneumonia 
requiring ICU admission. This study will attempt to determine factors that may define 
the severity of disease and evaluate previously used predictors of outcome. 
Patients and Methods 
All patients with community-acquired pneumonia admitted over the study period 
(January 1987 to December 1992) are included. The definitions for diagnosis and 
methods evaluation of severity of illness scores and data collection are described 
previously in chapter 8. In addition the clinical parameters thought to predict a poor 
outcome (age, confusion, tachypnoea, renal function, physiological variables for 
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APACHE II (see appendix 2 and 3), serum chemistry and haematology, as well as 3 
parameters of the lung injury score [Pa02/Fi02 ratio, chest radiograph, and PEEP 
level (appendix 4)] were carefully documented at the time of ICU admission and 
stored on a D Base 4 or Epi Info data base. 
The BTS and other rules previously reported to be useful in determining the severity 
of pneumonia were tested in this population to determine their sensitivity and 
specificity .17 The young patients and those with low AP ACHE II scores who died 
unexpectedly were also evaluated separately to determine what factors were associated 
with to death. 
Results 
Severity of illness scoring systems. 
The AP ACHE II score determined from the worst physiological abnormalities in the 
first 24 hours of ICU admission showed a significant difference between survivors 
(15.05 ± 6.27), and non-survivors (22.28 ±. 9.78 p = <0.001). The individual 
AP ACHE II scores and mortality are related in figure 19. 
The AP ACHE II scores for total all ICU admissions from our unit over the study 
period are contrasted with those of patients with pneumonia.(figure 20.) 
Figure 19: APACHE II severity of illness score related to mortality 
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Figure 20: A comparison of APACHE II scores between pneumonia and all ICU 
admissions. 
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Organ Failure. 
The number of organs in failure on day one in survivors was 1.05 ± 0.77, and non-
survivors 2.22 ± 1.18 (P= <.0001). The number of organs in failure on day one are 
related to mortality in figure 21. 
Figure 21: Organ failure on day one related to mortality 
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ORGAN FAILURE 
Organ failure was assessed daily for the first five days of ICU admission in patients 
admitted from 1988. The overall relationship of organ failure to mortality from day 1 
to 5 is shown in figure 22. 
Figure 22: Organ failure on day 1 to 5 related to outcome 
(164 Patients) 
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The relationship of organ failure in survivors and non-survivors is shown in figure 23 
which shows a significant increase in mortality with 3 or more organ failure on 
admission. 
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Figure 23: Organ failure in survivors and non-survivors with CAP. 
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Lung Injury Score. 
The lung injury score proposed by Murray was retrospectively applied to these 
patients. A score of O to 4 given for extent of radiological involvement of the lung, 
Pa02/Fi02, compliance and PEEP with the total divided by the number of parameters 
scored.(see appendix 4) There was a significant difference in lung injury score 
between 98 survivors, mean score of 1.59 +-. 0.64, and in 27 non-survivors 1.97 +-
0.64 (p = 0.007). 
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Figure 24 Lung injury score related to mortality 
No of Patients 
~ Survivors 35 i-----~~""1-----------~-~-----l 
t"?..2:J Non-survivors 
30 1-------l 
25 >------I 
20 f-------1 
l5 t------
5 
< 1 1- 1.5 1.6-2 2.1-2.5 2.6-3 >3 
Lung Injury Score 
Clinical Features Predicting Outcome. 
A number of clinical features have become recognised as predictors of severe 
pneumonia and these together with serum chemistry and haematology, are shown in 
survivors and non-survivors.(Table 24) 
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Table 24: Clinical features related to mortality 
n Survivors n Non-survivors P= 
Age 143 42.9 ± 16.8 47 48.7 ± 18 0.045 
Temp.°C 144 37.6 ± 1.24 47 37.2 ± 1.7 0.142 
Resp. Rate 140 30.3 ± 12.68 43 33.3 ± 11.1 0.164 
Confused 117 17 33 10 0.068 
Shock (SBP <80 mm Hg 122 20 39 23 <.001 
wee m111 143 18975 ± 32896 42 12044 ± 12376 0.04 
Platelets ml/I 143 227503±120215 42 193366±172958 0.24 
DIC* 108 2 26 5 0.002 
Na+ m mol/1 145 136.6 ± 8.3 46 136 ± 7.13 0.66 
K+ mmol/1 144 3.9 ± .71 43 4.11 ± 1.2 0.282 
P04- m mol/1 124 1.01 ± .6 34 1.63 ± 1.34 0.018 
Urea m mol/1 145 10.86 ± 13.2 46 16.19 ± 14 0.019 
Cr micro mol/1 144 183 ± 538 46 247.4 ± 220.9 0.248 
ALT units/I 125 52.89 ± 71.86 37 33.46 ± 30.23 0.018 
AST units/I 129 84.02 ± 96.25 37 67 .97 ± 44.88 0.16 
LDH units/I 121 586.5 ± 850.3 35 606.2 ± 431 0.85 
Alk.Phos.IU/1 129 117.1 ±84.3 34 113.5 ± 87.4 0.83 
Bilirubin Conj. micro mol/1 131 8.51 ± 12.5 39 14 ± 16.36 0.063 
Bilirubin Total micro mol/1 136 16.6 ± 14.5 39 21.5 ± 21 0.18 
S albumin g/1 136 28.8 ± 6.5 39 26.2 ± 5.9 0.026 
* DIC = diffuse intravascular coagulopathy [platelets <80,000 cells/ml, prolonged 
partial thromboplastin time (PTT), fibrinogen degredation products(FDPs)] 
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Age both the very young and very old have long been considered major risk factors in 
pneumonia however in our population this has not been adequately investigated. The 
mean age difference only just achieved significance ( p = 0.046), but mortality was 
significantly increased in the 22 patients who were over 65 years of age (X2 p= 
0.005). The relationship between age and mortality is shown in the following figure. 
Figure 25: Correlation between age and mortality in CAP. 
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Urea and ALT were significantly elevated whereas albumin and the WCC were 
significantly lower in the non-survivors.(see table 24 ) Significantly more patients 
who died had a DIC. The higher P04 in non survivors is difficult to explain. The 
incidence of renal failure in those with a P04 of >1.5 (7/32 patients) was similar to 
those with lower P04 ( 44/159) but the level of urea was higher in the high P04 group. 
It was possible to test 2 modified predictive BTS rules (Rule 1; 2 of hypotension i.e. 
SBP <80 mm Hg, renal failure i.e. urea > 7 mmol/1 or respiratory rate of >29 
breaths/min; Rule 2 BTS rule 1 with confusion instead of urea to make it immediately 
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applicable) in 193 patients .(table 25). A systolic BP was used as it can be more 
accurately defined by multiple observers and has been used by the severe sepsis 
consensus committee. 220 
Figure 26: Serum albumin, ALT, P04 and wee in survivors and deaths. 
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Table 25: Rules and scoring systems predictive of outcome 
Positive Overall Sensitivity Specificity Youden's Relative 
predictive accuracy % % Index% 
value% % 
Rule 1 42 69 65 70 35 
Rule 2 41 68 71 67 38 
Shock 53 77 48 86 34 
APACHE 45 73 46 81 27 
Il>20 
MOSF>2 70 80 38 95 33 
Lung lnj. 31 69 21 85 6 
>2 
Positive predictive value = no. with positive function who died I no. with positive 
function. Overall accuracy = no. outcomes correctly identified I no tested with 
function. Sensitivity = no. with positive function who died I no. tested who died. 
Specificity = no with negative Junction who survived I no. tested who survived. 
Youden's index= specificity+ sensitivity - I.Relative risk= proportion who died with 
positive Junction I proportion who died with negative function. 
Risk% 
2.5 
2.4 
3.2 
2.5 
3.8 
1.3 
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Aetiology Related to Severity. 
The mortality for the different causes of pneumonia is shown in figure 27. 
Figure 27: Mortality related to CAP of different aetiologies 
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Surprisingly a number of deaths occurred in the younger age groups with 7 deaths 
occurring in 43 patients (mortality 16.3%) who were 30 years of age or younger and 
this number compared with 43 deaths in 153 patients aged 31 years or older showed 
no significant difference in mortality (p = 0.17). The demographic and clinical 
features of these patients are shown in table 26. 
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Table 26: Demographic and clinical features of younger patients 
SURVIVORS NON-SURVIVORS 
No of patients 43 8 
Black 18 4 
White 2 2 
Mixed 23 2 
Male:Female 23:20 3:5 
APACHE II* 11.79 +- 51.6 15.13 +- 8.08 
Organ Failure 0.84 +- 0.65 1.88 +- 1.13 
Renal Failure 1 1 
Septic Shock 2 3 
Bacteraernia 14 3 
IPPV 30 8 
Duration IPPV 10.1 +- 8.3 8.63 +- 7.01 
Duration ICU 11.8 +- 11.04 8.88 +- 7.34 
Complications** 45 n=19 14n=4 
* T test p=0.69 ** n = number of patients 
Deaths were due to brain damage following cardiac arrest in 1, respiratory failure 1, 
shock 1, multiple organ failure in 5. In 3 deaths the patients had severe underlying 
disease including a possible collagen vascular disease, a subarachnoid haemorrhage 
and a patient with Prader-Willi syndrome. In 2 of the patients there was over a weeks 
delay in seeking medical attention. 
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Table 27: Organisms causing pneumonia in younger patients 
Micro-or~anism No.(%) Mort.(%) 
S. pneumoniae 17 (39.5) 2 (12) 
S. aureus 6 (13.9) 2 (33) 
H. inf[uenzae 6 (14.0) 
K. pneumoniae 1(2.3) 1 
L. pneumophila 1 (2.3) -
Virus 6 (14) -
Other 2 (4.6) -
Unknown 8 (18.6) 2 (25) 
Candida spp 1 -
TB 1 (2.3) -
Dual infection 7 (16.3) 3 (43) 
There were 17 patients who were bacteraemic in this group compared with 41 in the 
older patients but this difference did not achieve significance (p = 0.15), and 
bacteraemia occurred equally in those who survive or died. There was however 
significantly more infections caused by S. aureus (p = 0.02), and all the patients with 
Varicella pneumonia occurred in this group. 
The patients with APACHE II scores of 12 or less points, who surprisingly died, are 
compared with those who survived in table 28. 
150 
Table 28: Demographic and clinical features of patients with a low APACHE II 
score (12 or less) 
SURVIVORS NON-
SURVIVORS 
No of patients 56 5 
Age 36.52 +- 15.64 40.40 +- 19.09 
Race 
Black 20 4 
White 5 1 
Mixed 31 0 
Male:Female 33:23 1:4 
APACHE II 8.95 +- 3.06 10.2 +- 1.48 
Organ Failure 0.75 +- 0.61 1.2 +- 0.45 
Renal Failure 6 0 
Shock 1 0 
Bacteraemia 12 (21.4%) 1 (20%) 
IPPV 31 5 
PEEPcmH?O 6.5 +- 3.8 10.8 +- 5.07 
Duration IPPV 9.76 +- 12.63 9.2 +- 10.99 
Duration ICU 10.25 +- 12.21 8.4 +- 8.71 
Complications* 33(n=17) 6 (n=4) 
* Number of complications. n= number of patients with complications. 
Deaths were due to multiple organ failure (MOSF) in all cases other than one who 
died of shock. 
The micro-organisms causing pneumonia in these patients with a low AP ACHE score 
with related mortality are shown in table 29. 
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Table 29: Organisms causing pneumonia in patients with a low APACHE II 
score (12 or less) 
Micro-organism No.(%) Mort.(%) % of Deaths 
S. pneumoniae 15 (26.8%) 2 (13%) 40 
S. aureus 8 (14.3%) 1 (13%) 20 
H. influenzae 5 (9%) 1 (20%) 20 
K. pneumoniae 2 (3.6%) -
L. pneumophila 1 (1.8%) -
Mycoplasma 1 (1.8%) -
Virus 6 (10.7%) -
Other 2 (3.6%) -
Unknown 19 (33.9%) 1 (20%) 20 
Candida spp. 1 1 20 
Dual infection 4 (7.2%) 1 (25%) 20 
There were 13 patients who were bacteraemic in this group. The one patient with dual 
infection who died had S. pneumoniae and H. influenzae identified. 
Discussion 
Pneumonia is well known to be one of the diseases where outcome prediction is very 
inaccurate and conventional scoring systems such as the AP ACHE II predict mortality 
poorly, and these patients usually have a higher than predicted mortality123,208 The 
unpredictability of the AP ACHE II score in individual patients and the increased 
mortality in this study is compared with the data for respiratory infections from Knaus 
et al. (see figure 28)208 The mortality in our series of patients is slightly lower than 
those with respiratory infections and higher than the whole group that were used by 
Knaus to validate the system. Individual prediction however was unreliable with the 
152 
group with scores of 20 to 29 being lower than the group with scores of 10 to 19 in 
our patients. 
Figure 28: A comparison of APACHE II scores from the validation cohort of 
non-operative cases, respiratory infection cases, and CAP. 
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In this cohort of carefully selected patients with severe CAP the poor predictability of 
AP ACHE II is again seen although the patients who died had a significantly higher 
AP ACHE II score as a group but a number of patients with low scores died. 
It is possible that review of this group could shed some light on the failure of 
AP ACHE II to predict these deaths. There didn't appear to be any striking differences 
between the patients with low APACHE II scores who survived and those who died. 
Three of the five patients who died were admitted from the hospital ward or another 
hospital, with treatment having been started, which may have stabilised the patients 
giving a false low APACHE II score. In the whole group however only 67 (35%) had 
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been admitted directly from the emergency unit thereby making it unlikely that the 
low scores in these patients who died was only due to prior stabilisation. Another 
explanation may be that there was failure to respond to initial therapy. There were also 
a number of young people who died and here again it was difficult to identify any 
specific causes other than an increased incidence of S. aureus which accounted for 
some of the deaths, but also pre-existing associated disease seemed to be an important 
factor leading to death in patients who were both young and who had low AP ACHE II 
scores. 
The organ failure score was the most reliable predictor of death and there was a 
significant difference in organ failure scores between those who survived and died. If 
assessed over the first few days of admission no patients with 4 or more organ failure 
on day 1 (8 patients) survived and all patients with 4 organ failure on subsequent days 
died. Applying an organ failure score of more than 2 organ failure on day one had a 
predictive value for death of 70% with an overall accuracy of 80% but it was only 
38% specific. 
The modified discriminate rules proposed by the BTS were also poor predictors of 
survival with rule 1 having a sensitivity of 65% and overall accuracy of 69%. This 
rule was modified by using a systolic blood pressure of 80 mm Hg rather than the 
diastolic pressure which I believe is a more objective measure and therefore more 
reliable particularly in sepsis where systolic pressures are currently used to define 
septic shock. 220 
The lung injury score also proved to be a poor predictor of individual outcome 
although there · was a significantly higher in those who died no score predicted 
individual mortality. 
Few clinical parameters only proved to be predictors of death on univariate analysis at 
a low level of significance and these included the presence of shock, a DIC, age, a low 
serum albumin, WCC and ALT and a high phosphate and urea. The high P04 were 
not all associated with renal failure and is difficult to explain but has been previously 
identified.32 None of these parameters were highly discriminative and no 
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combinations proved of value as discriminative rules to predict outcome.(see table 28) 
As only those parameters that may on clinical grounds have been predicted to be 
important, were analysed statistically no correction for multiple comparisons was 
considered necessary. If the Bonferroni correction is applied only the presence of 
shock or a DIC retain any significance. 
This high incidence of Gram -ve infections (27 patients, 14.3%) with 44% mortality 
and S. aureus with a 35% mortality in this group of patients with severe pneumonia in 
respiratory failure, requiring ventilatory support, suggests that these pathogens may 
produce a more severe form of disease. This is supported by high mortality with these 
infections in this study which surprisingly is not statistically significant in this selected 
group of patients. In other community based studies of S. aureus infections and in 17 
patients with Klebsiella pneumonia previously reported a significant increase in 
mortality was found.129 Previous general hospital based studies of primary 
pneumonia and studies from intensive care units have failed to recognise this 
important influence of etiologic agent on the severity of disease because of 
insufficient numbers of patients with these infections, or have not evaluated aetiology 
as a prognostic indicator.2,17,20,32,125 The importance of S. aureus, Gram negative 
micro-organisms and L. pneumophila as determinants of CAP requiring 
hospitalisation and also ICU care have recently been described. I, 18 Infections with 
these agents with a high mortality should alert the clinician to the need for early ICU 
admission with appropriate antibiotic therapy. 
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CHAPTER12 
DIAGNOSIS OF SEVERE PNEUMONIA IN PATIENTS ADMITTED TO ICU. 
Introduction 
Cost effective antibiotic treatment of pneumonia relies on the accurate diagnosis of 
the causative organism as empirical therapy is invariably more expensive as a broad 
spectrum of agents need to be covered. Pivotal to the antibiotic selection is a 
knowledge of the factors that may influence the spectrum of infecting agents and the 
accuracy of diagnosis using routine microbiological evaluation. Of more importance 
is whether these principles apply in the intensive care setting, where the spectrum of 
causative pathogens may differ significantly and where the more severe patients 
gravitate. This study evaluates the efficacy of routine bacteriological methods in the 
diagnosis of severe pneumonia requiring ICU admission. This chapter is adapted 
from a paper published in Chest. I ( Potgieter PD, Hammond JMJ. Etiology and 
Diagnosis of Pneumonia Requiring ICU Admission. Chest 1992; 101:199-203.) It is 
included as part of this thesis as the microbiological investigations were done in much 
greater detail than in the rest of the thesis, and as such can contribute to our 
understanding of the value of different diagnostic techniques. 
Patients and Methods 
All patients admitted to the respiratory intensive care unit (RICU) from January 1987 
to December 1989 were included in the study. The diagnosis of pneumonia was made 
on clinical grounds including pyrexia, cough and purulent sputum, crackles and 
bronchial breathing, an increased white cell count or a left shift in the morphology of 
the leukocytes, and an infiltrate on the chest radiograph. Patients with tuberculosis 
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(18 patients) and those with eosinophilic pneumonia (2 patients) and patients in whom 
the subsequent course excluded a pneumonic illness were not included. No specific 
criteria for admission to the ICU existed other than the clinical assessment of a need 
for intensive care treatment and this usually included an inability to clear bronchial 
secretions, confusion and respiratory failure necessitating either continuous positive 
airway pressure (CPAP) by face mask or intermittent positive pressure ventilation 
(IPPV). 
The pneumonia was classified as primary pneumonia, i.e. infection which occurred in 
the community and included patients with associated diseases such as diabetes and 
chronic obstructive pulmonary disease; as nosocomial pneumonia, i.e. a pneumonia 
developing 48 hours after the patients admission to hospital or a pneumonia in a 
patient who had been hospitalised within the previous four weeks; 
immunocompromised pneumonia included patients with major host defence 
abnormalities including immunosuppressive drugs, irresectable carcmoma 
haematological malignancies and collagen vascular disorders, of patients requiring 
high dose steroid therapy (>40 mg prednisone daily); aspiration pneumonia was 
diagnosed when there was a clear episode of aspiration or unconsciousness. The latter 
2 types were divided into community-acquired or nosocomial. The etiologic diagnosis 
was made on microscopy and culture of sputum, or tracheal aspirate taken 
immediately after intubation, blood culture (Bactec system) or serology. Sputum 
specimens were examined by a microbiologist and were only considered diagnostic if 
a predominant organism was present on Gram's stain in the presence of numerous pus 
cells without excessive epithelial cells, and if a respiratory pathogen was cultured in 
significant growth. Antibiotic sensitivity was tested using routine Joan Stokes' 
methods, and anaerobic culture was only performed on bronchoscopy specimens. If a 
patient failed to respond after 48 to 72 hours, or initially in immunocompromised 
patients, a fibreoptic bronchoscopy was performed and special sheath brush (PSB) 
specimens taken. A segmental lavage and a transbronchial biopsy was performed if 
oxygenation permitted. Open lung biopsy was done in two patients. Serology was not 
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performed routinely, but done only if no pathogen could be isolated, or if the patient 
failed to respond, or if the clinical presentation suggested an atypical pneumonia. A 
fourfold rise in antibody titre on paired samples of sera was considered diagnostic. 
Chlamydia and viral serology was also not routinely tested. The patients 
anthropometric data, severity of illness (AP ACHE II), ventilatory therapy, and course 
in hospital was documented and in cases that died the clinical cause of death 
determined and autopsies were performed where possible. 
Results 
1171 patients were admitted to the RICU from 1 January 1987 to 31 December 1989, 
of whom 178 were diagnosed as having acute pneumonia and admitted to the study. 
157 (88%) needed IPPV. 
Table 30: Demographic features, ventilatory therapy, and outcome. 
Classification Primary Immunocomp. Aspiration Nosocomial 
n= 95 n=24 n=28 n = 31 
Age (range) 46.7 (13-84) 41.3 (12-73) 41.54 (15-79) 44.32 (20-66) 
SexM:F 61:34 11:13 27:1 18:13 
Race White 12 10 5 15 
Black 30 7 7 10 
Mixed 53 7 16 6 
APACHE II 18.4 (1-46) 19.17 (9-32) 14.21 (1-28) 14.03 (2-37) 
Tracheostomv 39 2 15 13 
ETT 47 16 9 16 
IPPV (%) 86 (91) 18 (75) 24 (86) 29 (94) 
CPAP 5 3 2 1 
IPPV (range) 10.45 (1-46) 8.67 (1-42) 11.68 (1-68) 16.07 (1-107) 
ICU Stay 13.44 (1-68) 9.46 (1-43) 14.46 (1-77) 22.61 (1-165) 
Mortalitv ( % ) 28 (29) 12 (50) 4 (14) 8 (26) 
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These included 95 patients with primary pneumonia; 31 with nosocornial pneumonia; 
24 immunocomprornised patients and 28 following aspiration pneumonia. The 
incidence, demographic data and clinical details in the different types of pneumonia 
are shown in table 30. 
The aetiology of this group of patients made by all diagnostic methods is shown in 
table 31. . 
Table 31: Aetiology of pneumonia. 
Primary Nosoc Asp Immunocomp 
No. of patients 95 31 28 24 
Isolate n(%) n (%) n (%) n(%) 
S. pneumonia 31 (32.6) 8 (25.8) 6 (21.4) 5 (0.8) 
H. influenzae 12 (12.6) 3 (9.7) 4 (14.3) 2 
S. aureus 7 (7.4) 7 (22.6) 4 3 
K. pneumoniae 10 (10.5) 1 4 2 
E.coli 2 1 3 0 
Pseudomonas SfJfJ. 1 1 2 0 
Mycovlasma svv. 1 0 0 0 
LeJ?ionella SfJfJ. 5 0 0 0 
Viruses 1 0 0 2 
Fungal 2 0 0 1 
Other Gram +ve 1 2 1 0 
Unknown 24 (25) 16 (51.6) 10 (35.7) 8 (33.3) 
Other pathogens 2 0 0 2 
Multiple 11 3 8 3 
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All isolates of S. pneumoniae were penicillin-sensitive and one H. influenzae strain 
was resistant to ampicillin. One cloxacillin resistant S. aureus was cultured from the 
community, whereas 29% of those involved in nosocornial infections were 
cloxacillin-resistant 
An aetiologic diagnosis was made in 118 (70.1 % ) of the 178 patients by culture of 
sputum and or tracheal aspirate; 44 (25%) of 178 patients by positive blood culture; 6 
(15%) of 40 patients by serology; 7 of 35 by fibreoptic bronchoscopy and both 
patients who had open lung biopsies had a positive diagnosis made. Fibreoptic 
bronchoscopy was performed in 24 patients with primary pneumonia in whom no 
diagnosis had been made and who failed to respond to treatment or who had failed to 
respond despite appropriate treatment. A positive diagnosis was made in 3 patients 
with bronchial brushings; two patients underwent transbronchial biopsy and an 
incorrect presumptive diagnosis was made on histology in one patient. Fibreoptic 
bronchoscopy was performed in six immunocomprornised patients with a positive 
diagnosis in three. The method of diagnosis in the different types of pneumonia is 
shown in Table 32. 
Table 32: Method of diagnosis 
Diagnosis Primarv(%) Nosoc(%) Asp(%) Immunocomp(%) 
Total patients 95 31 28 24 
Sputum or TA 59 (62) 15 (48) 14 (50) 8 (33) 
Blood culture 33 (35) 3 (10) 3 (11) 5 (21) 
Serology (40pts) 6 (6) 0 0 0 
FOB (30pts) 1 1 0 3 
Open Lung Biopsy 0 0 0 2 
·Other 5 0 1 3 
No diagnosis 24 (25) 16 (52) 10 (36) 8 (33) 
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Blood culture was positive in 33 (35%) of the 95 patients with primary pneumonia. 
An identical pathogen was cultured in sputum or tracheal aspirate in 30 of these 
patients. The diagnostic accuracy for Gram's stain and culture of sputum and aspirates 
in patients with CAP and positive blood cultures is shown in Table 33. 
Table 33: Correlation between blood culture and Gram's stain and culture of 
sputum and tracheal aspirate. 
n= Gram's stain Culture 
Result +ve +ve -ve +ve +ve False False 
+ve +ve 
Type of Gm Gm Gm Gm Gm Gm 
Bacteria +ve -ve +ve -ve +ve -ve 
Sputum 19 9 6 4 8 6 1 0 
Trach. Asp. 15 5 3 7 4 3 1 0 
Total 31 14 9 8* 12 9 2 0 
* Three patients had both negative sputum and tracheal aspirates. 
Discussion 
This group of patients with severe pneumonia pre-selected because of respiratory 
failure that necessitated ICU admission comprise a group of patients with a high 
mortality. A high incidence of gram negative and S. aureus infections in patients with 
CAP was found, however the standard classification is as useful in this group of 
patients, as it is in those with less severe disease. The diagnosis of primary CAP 
Gram negative pneumonia (14 patients) was confirmed by blood culture in 11 
patients, and made on pleural aspirate (1) and culture of sputum/tracheal aspirates 
only, in 2. In 13 of the 14 patients the sputum or initial tracheal aspirate on intubation 
showed significant Gram negative organisms on Gram's stain and the cultures were 
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identical to the blood culture in all 11 cases. There were no false -ve sputum cultures 
in these patients. None of these patients had been intubated other than immediately 
prior to obtaining the bronchial secretions. In the 20 patients with blood culture 
proven S. pneumoniae infection; the identical diagnosis was made from Gram's stain 
of sputum (12) or tracheal aspirate (4) in 16 patients. These findings confirm the 
value of well processed Gram's stain for the diagnosis of community-acquired 
pneumonia shown in previous studies.33, 131 In three patients the additional culture 
of H influenzae from bronchial secretions was considered as dual pathogens a feature 
noted in recent studies.116 Fibreoptic bronchoscopy using a special sheathed brush 
and quantitative culture which differentiates between colonisation and pneumonia has 
been shown to be useful in diagnosing diverse pulmonary infections, was well as 
nosocornial pneumonia in ventilated patients.130, 137 This technique has been shown 
to be useful in patients in intensive care with undiagnosed pneumonia156 This study 
however found no pathogens in culture of brush specimens in seven patients with 
pneumonia that failed to respond to treatment within 72 hours, and considered this 
negative result valuable. In our study we only considered positive cultures valuable 
and in only three of 24 patients was a definitive diagnosis made. This new diagnosis 
did not however result in any change in antibiotic therapy, which suggests that 
fibreoptic bronchoscopy is seldom clinically useful in these patients. As in general 
hospital based studies the aetiologic diagnosis is not made in a large number of cases. 
In this study a diagnosis was not made in 25% of cases despite proceeding to invasive 
techniques including fibreoptic bronchoscopy with brushing and biopsy as well as 
serology for Mycoplasma pneumoniae and Legionella pneumophila. Serological 
investigation or viral studies were not performed routinely and also did not include 
Chlamydia , and no special techniques to detect antigens to pneumococci were 
performed. This may have underestimated the incidence of these infections. In those 
patients who died, however, autopsy did not suggest an alternative aetiologic 
diagnosis. It is also possible that in this study a number of infections with multiple 
pathogens were not recognised because once an identifiable pathogens was recorded 
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no further investigations were performed unless the patient failed to respond to 
therapy. The Gram's stain of well collected sputum samples or early tracheal aspirates 
provides an accurate guide for empirical antibiotic therapy and a definitive diagnosis 
is more frequently confirmed by blood culture in these patients with more severe 
disease than in less severe disease. More invasive procedures such as fibreoptic 
bronchoscopy add little to the diagnosis in primary pneumonia but is of more value in 
patients who are immunocompromised. 
CHAPTER13 
NOVEL THERAPY FOR COMMUNITY-ACQUIRED PNEUMONIA 
SURGERY IN THE MANAGEMENT OF COMMUNITY-ACQUIRED 
PNEUMONIA 
Introduction. 
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Most patients with community-acquired pneumoma will respond to appropriate 
antibiotic therapy. In 3 to 5% of patients, however, in spite of adequate therapy the 
disease process may progress to produce irreversible respiratory failure and 
death. 9, 17, 18 In a small proportion of these cases, frequently those in whom initiation 
of treatment is delayed, low grade infection may progress to involve the entire lung in 
a necrotic process, termed massive pulmonary gangrene. This may result in ongoing 
tissue damage, release of cytokines and persisting infection, septicaemia and multiple 
organ failure ensues.1,28 Occasionally in other instances the necrotising nature of the 
infection may lead to the development of acute lung abscess with similar effects.27 In 
such cases where adequate and appropriate antibiotic therapy has been given with 
inadequate response, there may rarely be instances where surgical management is 
indicated to prevent the progression to multiple organ failure and death.95,96 
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PNEUMONECTOMY IN SEVERE PNEUMOCOCCAL PNEUMONIA. 
Pneumonectomy was considered necessary in 2 patients who developed massive 
pulmonary gangrene secondary to pneumococcal pneumonia that failed to respond to 
appropriate antibiotics and ICU therapy, including mechanical ventilation with 
differential lung ventilation. 28 
Case 1 
A 39 year old man with a background of both heavy smoking and prolonged alcohol 
abuse was admitted to our Emergency Unit with a 2 week history of progressive 
dyspnoea, cough, blood-stained sputum, fever and pleuritic chest pain. On 
examination he was pyrexial 38.7°C, hypotensive and found to have clinical features 
of a right sided pneumonia. The white cell count was 5,800 cells/ml, platelets 28,000 
cells/ml with an ESR of 120 mm/hour. Arterial blood gases on room air: pH 7.41 
Pa02 7.4 kPa pC02 4.0 kPa with a standard bicarbonate of 20.6 mmol/1. Sputum 
culture grew S. pneumoniae sensitive to penicillin and blood cultures were also 
positive for this micro-organism. 
The patient was admitted to the ICU where he was treated with intravenous penicillin 
and tobramycin, and required intubation ventilation, and inotropic support. 
Over the next few days the pneumonia was noted on the chest radiograph, to have 
extended to involve the entire right lung, and this was associated with the 
development of a right sided bronchopleural fistula, and worsening of his respiratory 
function. Chest radiograph showed extensive consolidation of the right lung, with loss 
of volume, a persistent sub-pulmonic pneumothorax in spite of chest drains, and an 
area of breakdown in the midzone. The left lung was initially normal. The possibility 
of spread of infection to the opposite side prompted the insertion of a double lumen 
endotracheal tube, and the institution of independent lung ventilation. There was a 
concomitant deterioration in his renal function, and the development of disseminated 
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intravascular coagulation. Following 7 days of intensive supportive therapy during 
which he showed progressive deterioration with the development of multiple organ 
failure, and a Pa02 of 5.8 kPa, pC02 5.3 kPa pH 7.44 on 35% oxygen it was decided 
to perform a right pneumonectomy. 
At surgery the lung was noted to be oedematous and frankly necrotic, with breakdown 
of the anterior segment of the right upper lobe. Postoperatively he developed a right 
empyema that was treated with a thoracostomy, and then subsequently successfully 
closed. His recovery was otherwise uneventful and he was able to be discharged from 
the ICU after 35 days. 
Three month follow-up found him well with some reduction in his lung volumes and 
moderate airflow limitation. (FEV 1 = 1030 ml, FVC 2050 ml) He was still alive 5 
years later. 
Case2 
A 33 year old stable-hand with a long history of alcohol abuse presented to this 
hospital with a one week history of fever, cough, and dyspnoea. On examination he 
was found to have signs of left-sided consolidation and the chest radiograph showed 
dense, homogeneous opacification of the left lung; the right lung was uninvolved. 
Arterial blood gases on room air were pH 7.14, Pa02 7.6 kPa, pC02 of 10.1 kPa, and 
the white cell count was 12,800 cells/ml with a marked left shift in the morphology. 
His serum urea was elevated at 11.7 mmol/1 with a creatinine of 160 micro mol/1 and 
normal liver function tests. 
He was admitted to the ICU for ventilation. Antibiotic therapy was commenced on 
admission with both cefotaxime and cloxacillin. Gram's stain of the sputum showed 
numerous Gram positive diplococci and Gram negative cocco-bacilli, and culture of 
the tracheal aspirate grew S. pneumoniae and H. influenzae. 
His course in the ICU was stormy and he developed evidence of multiple organ failure 
over the next 6 days. A double lumen endotracheal tube was inserted on day 7 
because of copious secretions, and independent lung ventilation was commenced. His 
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condition remained critical with ongoing deterioration of his renal function, and need 
inotropic support was needed to maintain his blood pressure. On the 9th day he was 
taken to surgery for a left pneumonectomy as he was not responding to conventional 
therapy. 
The findings at thoracotomy were of a non-viable, infective process involving the 
entire left lung. His postoperative course was complicated by wound haematoma and 
a post pneumoi:lectomy empyema from which a cloxacillin resistant S. aureus was 
cultured. Three weeks later he was able to be discharged from the ICU. Eventually 
he was discharged from hospital with a thoracostomy in situ. 
Discussion 
Severe community-acquired pneumonia still has a mortality of between 29 and 54% 
despite intensive care and appropriate antibiotic therapy_l,119 A number of factors 
including septic shock , a white cell count <4 000 cells/ml and Gram negative 
organisms are recognised as indicators of an increased mortality with death usually 
occurring in the first few days after admission.17 ,32 The cause of these deaths is 
usually due to overwhelming infection and endotoxaemia leading to ARDS, septic 
shock and multiple organ failure. I 
Massive pulmonary gangrene resulting from both Klebsiella pneumoniae and S. 
pneumoniae pneumonia was recognised as a rare complication in the pre-antibiotic 
era, and successful outcome often relied on surgical management of such 
cases.95,96,221 Whereas the natural history of severe overwhelming pneumonia is 
usually rapid spread bilateral involvement, these 2 cases differ substantially in that 
the process remained confined to one lung for some days before spread to the 
opposite, uninvolved lung occurred. It was thought that this unusual course was due 
to the development of massive necrosis of the involved lung with subsequent spill-
over to the opposite side. 
167 
In both these cases the development of the typical late radiological features of 
pulmonary gangrene97, including the presence of a lobar sized cavity containing 
freely moveable tissue, were not seen, probably because its development was 
anticipated and treated with early surgery. 
Many cases of pneumonia which have been thought on radiological criteria to have 
unilateral involvement, are shown at autopsy to have involvement of both lungs -
especially in those where the progression to death is rapid; this makes the decision as 
to when to proceed to pneumonectomy difficult. Special investigations including 
computerised tomographic scans and perfusion scans of the chest may contribute to 
the clinical decision to proceed to surgery but these have not yet been adequately 
evaluated. Evaluation of the pulmonary reserve using lung function testing is 
impossible in this situation and a clinical assessment of pulmonary function needs to 
be made, taking the history of previous effort tolerance and co-existing lung disease 
into consideration. 
Serotype 111 pneumococci are recognised to cause more severe necrosis than other 
types; the mechanism is multifactorial including both host and microbial factors. The 
phagocyte activity of the alveolar macrophages and polymorphonuclear leukocytes 
may be overwhelmed by the rapid accumulation of capsular polysaccharides often 
seen with type 111 infections. This mechanism as well as a large antigenic load of 
capsular polysaccharide leads to reduced humoral and mechanical defences. This 
together with toxin production including leukocidin, haemolysin, pneumolysins and 
hyaluronidase may predispose to lung necrosis. 96,221 The pathology of the lung 
frequently shows significant vascular thrombosis which undoubtedly is particularly 
important in the pathogenesis of massive pulmonary gangrene. 
Numerous host factors have been implicated, however, in our patients, alcoholism and 
smoking were the only common factors, although aspiration may well have played a 
role. Both were young (aged 33 and 39 respectively) ,and the white-cell counts (5,800 
cells/ml and 12,800 cells/ml) were inappropriately normal. Massive pulmonary 
gangrene frequently occurs in patients who are at risk of aspiration - as in our two 
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patients - however anaerobic bacteria have only occasionally been cultured in this 
setting. The association of both S pneumoniae and K pneumoniae with aspiration is 
well recognised, as is the synergistic tissue necrosing effect of a combined 
aerobic/anaerobic infection. It is therefore likely that aspiration is a factor in some 
cases of massive pulmonary gangrene.221 Although successful medical management 
has been described in three cases of massive pulmonary gangrene,222 the majority 
have been treated surgically either by drainage or resection. In both our cases, 
medical therapy had already failed making surgery the only option. Surgery, in these 
circumstances has a high morbidity and mortality,223 and both patients developed a 
post-pneumonectomy empyema, a distressing, difficult problem to treat; one also had 
a wound haematoma. It is uncertain whether earlier surgical drainage would have 
modified the outcome. 
This late complication of massive pulmonary gangrene is rare and has only been seen 
in these 2 cases while over the same 9 year period 446 patients have been admitted to 
our ICU with severe community-acquired pneumonia. The successful outcome in 
these two cases where there was ongoing clinical deterioration with extension of their 
disease after 7 days of full therapy suggests that surgery should be considered in 
patients with a similar pattern of disease. 
SURGICAL DRAINAGE OF LUNG ABSCESS COMPLICATING 
COMMUNITY-ACQUIRED PNEUMONIA. 
Introduction 
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Community-acquired pneumonia may occasionally be complicated by necrosis and the 
development of an acute lung abscess. In the setting of a critically ill ventilated 
patient this may lead to soiling of areas of normal lung, as well as an ongoing 
inflammatory response from inadequately drained abscess necessitating prompt 
intervention. Two cases of acute community-acquired pneumonia complicated by 
pulmonary necrosis which was successfully managed by surgical drainage have been 
previously reported. 27 
Case 1. 
A 41 year old white male smoker and alcoholic, having had no recent binge, was 
admitted with a 2 day history of cough, fever and right sided chest pain. On 
examination he was fully conscious, pyrexial with a tachycardia, signs of a right sided 
pneumonia and stigmata of chronic liver disease. The chest radiograph showed dense 
upper lobe consolidation and patchy, ill-defined opacification of the lower lobe. A 
Gram's stain of his sputum showed pus cells and Gram positive cocci in pairs, and a 
blood culture was positive for a penicillin sensitive S. pneumoniae. Penicillin was 
commenced intravenously. The following day he became confused and hypoxaemic 
on 40% face mask oxygen, requiring intubation and intermittent positive pressure 
ventilation (IPPV). 5 days later the chest radiograph showed extension of the 
pneumonia to involve the lower zone with areas of breakdown in the mid zone. 
Because of the deterioration in his condition, with large amounts of purulent 
secretions being suctioned from the endotracheal tube and obvious cavitation of the 
pneumonia on the chest radiograph, open drainage of the lung was performed via a 
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mini thoracotomy on day 7. The pleural space was fused; about 1 cm of lung was 
incised before entering a cavity from which approximately 150 ml of watery brown 
pus was drained. A de Pezzar drain was inserted with an underwater drainage system. 
Culture of the pus was negative; histology showing acute pulmonary inflammation 
and necrosis. Following surgery his condition showed marked radiological and 
clinical improvement. 100 ml of pus drained daily from the chest drain and there was 
a marked reduction in the volume of tracheal secretions but there was a persistent air 
leak. Amikacin and metronidazole were added to his treatment. A computerised 
tomographic (CT) scan of the chest on day 16 showed consolidation of the right upper 
lobe, with breakdown and small areas of liquefaction but no pleural, or significant 
intrapulmonary collection of pus requiring further drainage.The patient and was 
weaned from the ventilator on day 19, at which stage his sputum which was still 
purulent and cultured H. influenzae. He was commenced on cotrimoxazole, his other 
antibiotics being discontinued. He was discharged home two weeks later but was 
readmitted 4 weeks thereafter with an empyema which responded well to surgical 
drainage. 
Case 2. 
A 56-year old man who had been well until the previous week, developed back pain 
with abdominal distension, following a day's swimming in the sea. Distended loops 
of bowel and linear atelectasis at the left base were demonstrated on the chest 
radiograph, and were interpreted as indicating intra-abdominal pathology. The patient 
underwent a laparotomy which was negative. Post-operatively he developed 
respiratory distress with radiographic features of a worsening pneumonia which was 
treated with cephamandole. His white cell count which was 4,700 cells/ml post-
operatively dropped to 1,300 cells/ml and his Pa02 fell to 6.2 kPa on 40% oxygen by 
face mask on the second day after surgery. Intravenous erythromycin was added and 
subsequently netilmicin, when a Klebsiella spp. was cultured from his sputum. His 
condition continued to deteriorate and he was transferred by air ambulance to our 
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ICU, intubated and hypotensive with a severe left lower lobe pneumonia. A tracheal 
aspirate on admission grew K. pneumoniae sensitive to amikacin and ceftriaxone. 
A diagnosis of pneumonia presenting with abdominal pain and ileus was made and 
therapy was changed to ceftriaxone and amikacin. The following day his chest 
radiograph was suggestive of cavitation in the left lower zone and this was confirmed 
by CT scanning. Surgical drainage of the abscess was performed after a double lumen 
endotracheal tube had been inserted to prevent spillage, as there were copious purulent 
secretions. At surgery an abscess involving the lingula with an adjacent empyema 
was found. E. coli, Pr.· mirabilis and Enterococcus spp. were cultured from the pus 
and also from a throat swab; there was no preceding history of aspiration. Following 
the thoracotomy, profuse pus was drained and the patient rapidly improved. His 
general condition improved with pyrexia, hypoxaemia and chest radiograph resolving 
and he was discharged from the ICU 10 days later. 
Discussion 
Lung abscess is recognised as a rare complication of community-acquired pneumonia, 
seen commonly in the alcoholic, and occasionally in immunocompetent patients. 
Pneumonia complicated by abscess formation has a high mortality and although many 
respond to antibiotics, surgical treatment using pneumonotomy and open drainage has 
been recommended if endobronchial drainage has failed, and where there is ongoing 
clinical evidence of toxicity, or where the abscess cavity fails to diminish in size.223-
225 Percutaneous or open drainage of lung abscess has also been recommended for 
lung abscesses in patients requiring IPPV where there is failure to wean from 
mechanical ventilatory support or where the size of the abscess cavity is greater than 4 
cm.226 In patients who require endotracheal intubation, the copious secretions from 
the abscess cavity may be difficult to control adequately by suction, and the 
concomitant use of intermittent positive pressure ventilation (IPPV) exacerbates the 
problem by causing wide dissemination of pus. Spill-over of pus to unaffected areas 
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may be temporarily prevented by the use of double lumen intubation with isolation of 
the affected lung, but suctioning through these tubes is difficult and ineffective. At 
this stage endobronchial manipulation is possibly contraindicated because of the 
critical hypoxaemia. Surgical drainage of the lung abscess provides an alternate route 
for removal of this infected material, and it can prevent further intrapulmonary spread 
and result in rapid resolution of the infection. In this setting the main reason for 
drainage is to prevent endobronchial spill of pus into the lungs. Wide bore 
percutaneous or surgical drainage is probably preferable to the use of fine bore tube 
drainage. Death from community-acquired pneumonia is usually the result of multiple 
system organ dysfunction (MODS), either due to fulminant septicaemia or the 
persistence of infection, complicated by abscess formation or empyema. In other sites 
of severe sepsis, surgical drainage and removal of the infection has been demonstrated 
to result in the resolution of MODS and survival of the patient.227 The rapid 
response and defervescence of sepsis in our two patients following surgical drainage 
suggest that this is a similar situation and that surgery may prevent the development of 
MODS and lead to more rapid recovery. The decision as to when to proceed to 
surgery is difficult, particularly in critically ill patients on ventilators where only 
antero-posterior supine or semi-erect chest radiographs, without lateral projections, 
are available, which generally do not give sufficient definition to define the extent, or 
localisation of intrapulmonary disease. The onset of cavitation is difficult to 
determine by these methods and we have utilised CT scanning to define cavitation 
more clearly, both for diagnosis and planning surgery. In the first case CT scanning 
was performed to confirm the adequacy of surgical drainage, whereas in the second, it 
was used to localise the site of cavitation and to plan surgery. CT scanning is 
extremely reliable in this situation as it can clearly differentiate between pleural and 
pulmonary disease. Cavitation and abscess formation in community-acquired 
pneumonia has been seen as a rare complication of infections both with S. 
pneumoniae and K. pneumoniae; more frequently the causative organisms are multiple 
and often include anaerobes.94,221,228 These features, combined with the higher 
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incidence in alcoholics, support the postulate that these pneumonias are probably the 
result of micro or macro aspiration of oropharyngeal flora. In this situation antibiotic 
selection should cover the primary isolate and include anaerobic cover, particularly if 
the sputum is fetid. 
We therefore suggest that in addition to the established indications for surgical 
intervention in community-acquired pneumonia complicated by a lung abscess; that is, 
failure of toxicity to settle and failure of the cavity to decrease in size, one should 
consider surgery for those with respiratory failure necessitating IPPV. These patients 
should be regarded as surgical emergencies and the abscess should be drained 
immediate! y. 
SELECTIVE DECONTAMINATION OF THE DIGESTIVE TRACT IN 
PREVENTION OF SUPERINFECTION IN COMMUNITY-ACQUIRED 
PNEUMONIA. 
Introduction 
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Selective decontamination of the digestive tract (SDD) is used to prevent the 
development of secondary infections in high risk patients within the ICu.229-231 
While controversial, it is thought to benefit primarily non-infected patients e.g. trauma 
and post-operative cases; most studies have excluded patients already infected on 
admission. 230 ,23 2,233 
Patients with primary pneumonia requiring ICU admission, usually require prolonged 
ventilation and antibiotic therapy; the mortality is reported to be in excess of 29% 1. 
Pneumonia itself has been shown to predispose to further episodes of respiratory tract 
infection, which may prolong the hospital stay234. It is therefore not too surprising 
that Sir William Osler made the following observation and stated that"Recurrence is 
more common in pneumonia than in any other acute disease" 
Thus these patients with CAP, who may be at particular risk for the development of 
secondary pulmonary infection, may benefit from prophylaxis with selective 
decontamination of the digestive tract (SDD). The efficacy of SDD has not previously 
been evaluated in patients with pneumonia requiring ICU therapy who may be 
considered to be at greater risk for the development of super infection. 
Patients and Methods 
All patients admitted to a respiratory ICU who were expected to require intubation for 
more than 2 days and ICU admission for 5 days, were randomised to receive either 
SDD (oral gel 5g: amphotericin B 2%, polymyxin E 2%, tobramycin 2% and enteral 
solution 10 ml containing amphotericin B 500 mg, polymyxin E 100 mg and 
tobramycin 80 mg) or placebo. All patients received intravenous cefotaxime, lg 8 
hourly for 72 hours. 
Inclusion criteria included: 
- Aged 16 or older 
- Duration of intubation > 48 hours 
- Duration of ICU admission > 5 days 
- Informed consent 
Exclusion criteria: 
- Allergy to investigation drugs 
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These patients with community-acquired pneumonia formed part of a larger study on 
selective decontamination which have been previously reported.231 Analysis of this 
group was decided a priori, and the disease was defined as an acute febrile illness, 
with clinical signs of consolidation and crackles, and radiological opacification, in 
patients who had not been hospitalised in the previous month. Patients were fully 
examined on entry, the admission diagnosis was defined and the severity of illness 
was assessed according to the APACHE II and organ failure.208,235 Factors 
recognised as likely to affect the development of secondary infection,236,237 such as 
the presence of diabetes mellitus or other immunocompromising diseases, the 
presence of malnutrition, alcohol abuse, the use of steroid and other 
immunosuppressive therapy, and the use of antacids or H-2 antagonists were 
documented specifically. 
Microbiological surveillance included culture of oropharynx and tracheal secretions, 
stomach aspirate, urine and rectal swabs on entry, and twice weekly, until 3 days after 
ICU discharge; these results were withheld from the clinicians to avoid unblinding. 
Clinical monitoring which included biochemical, and haematological investigation, 
and clinical and radiological examination was performed daily looking in particular 
for evidence of secondary infection. Nosocomial infection was diagnosed if signs of 
infection developed more than 48 hours after admission to the ICU. If a nosocomial 
infection was diagnosed, appropriate cultures were taken for isolation, identification 
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and sensitivity testing of the causative organisms. All central venous catheters were 
cultured on removal. The results of diagnostic were available to the clinicians. 
The following definitions of infection were used: 
Septicaemia was diagnosed as the clinical observation of all of the following with no 
obvious localising site of infection: 
a positive blood culture 
a rise or fall in temperature(> 380C or <35.5°C) 
a rise in white blood cell count(> 10 000 cells/ml), or a left shift in its morphology. 
evidence of organ dysfunction. 
Criteria for organ dysfunction were defined as follows: 
lung: Pa02 <8 kPa on 40% oxygen, or respiratory rate <5 breaths/minute or >49 
breaths/minute, or PaC02 >6 kPa, or AaD02 >46 kPa, or dependent on ventilator for 
>4 days. 
kidney: urine output <479 ml/24 hours, or <159 rnl/8 hours, or serum creatinine >300 
µmol/1, or serum urea > 20 mmol/1. 
liver: liver enzymes more than twice normal or total bilirubin > 50 mmol/1. 
central nervous system: unconscious with a Glasgow coma scale of <6 without the use 
of sedatives for more than 24 hours 
haematological: white cell count <1 000 cells/ml, or platelets 20 000 cells/ml. 
cardiovascular: mean blood pressure <49 mm Hg, or pH <7 .24. 
Nosocomial pneumonia was defined as a new infiltrate on the chest radiograph more 
than 48 hours after admission to the ICU, purulent bronchial secretions with many 
leukocytes, temperature above 380C, · _white blood cell count > 10,000 cells/ml, 
increasing or showing a left shift, substantial numbers of organisms shown by Gram 
staining of the tracheal aspirate, with a pure growth cultured from the tracheal 
aspirate, and a deterioration in gas exchange of 2 kPa or more. 
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Bronchial infection was defined by the presence of all the features of pneumonia, 
except the radiographic changes were absent. 
Urinary tract infection in patients who had been catheterised for at least 48 hours 
before collection of the specimen, was defined by the presence of local or systemic 
signs of infection, with culture of bacteria or fungi, and the presence of more than 108 
white cells per litre of urine. 
Vascular-catheter related sepsis was defined as temperature above 330c, white 
blood cell count above 10,000 cells/ml or left shift, with relief of signs on removal of 
the catheter; a positive catheter tip culture, blood culture, or the presence of local 
inflammation were not required for the diagnosis. 
No routine prophylaxis against gastrointestinal bleeding was used. Ranitidine was 
prescribed in patients with pre-existing ulcer disease or active gastrointestinal 
haemorrhage, and in those at high risk of gastrointestinal haemorrhage (from bums, 
liver failure or head injury). Sucralfate was not used for the duration of the study, 
because it is thought to bind to enteral medication and might thus have inactivated the 
drugs administered for decontamination, and also because of its own antibacterial 
properties which might have caused difficulty with the interpretation of 
results. 238,239-
Patients already receiving an antibiotic for their pneumonia on admission to the ICU 
were continued on the antibiotic if the sensitivity patterns were appropriate, or if the 
patient appeared to be responding; otherwise, if appropriate, cefotaxime lg 8 hourly 
was substituted and continued as therapy. In all cases attempts were made to avoid 
antibiotics which might interfere with the anaerobic flora. 
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RESULTS 
Forty-four patients fulfilled criteria for inclusion in this subgroup, and there were a 
further three who were not included, because their duration of stay was unexpectedly 
prolonged, but who subsequently proved suitable and were analysed separately. Eight 
patients were withdrawn as they did not meet the criteria for duration of ICU stay or 
intubation (including 6 early deaths). There was no difference in demographics or 
severity of illness scores between the SDD and placebo groups (Table 34 ). 
Table 34: Demographic Data 
SDD Placebo Withdrawn Suitable 
No of patients 12 24 8 3 
Age 43.2+-13.1 45.7+-18.3 56.9+-14.L 47+ 3.5 
Male:female 8:4 16:8 2:5 1:2 
Hospit >48 hrs # 6 13 1 3 
APACHE II* 14.6± 6.4 17.1± 5.9 27.4±13.7 15.2±6.5 
Organ failure 1.4± 0.7 1.5± 0.6 1.7± 1 1 
Shocked** 4 1 2 0 
* p = 0.25 Student's t test, **P = 0.06 Chi-square test, # Hospitalised for more than 
48 hrs before ICU admission. 
Factors such as· carcinoma, underlying diabetes which have previously been described 
as predisposing to the development of secondary infection, were equally distributed 
between the active and placebo groups. The use of invasive and therapeutic 
monitoring procedures whilst in the ICU was of equal frequency in all patients: 
haemo-dialysis in 2 SDD and 3 placebo patients; pulmonary artery catheters in 9 and 
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18 respectively; central line in 10 and 23; chest drains in 3 and 10; parenteral nutrition 
in 4 and 15. Four SDD and 9 placebo patients had tracheotomies (mean duration 16.3 
days vs. 17.2 days). 
Complications occurred infrequently in both groups (11 vs. 27). Five patients 
developed pneumothoraces related to positive pr~ssure ventilation. 
There was only one nosocomial infection in the decontaminated patients, compared 
with 10 infections in the placebo group (Table 35). 
Table 35: Types of Infections and Number of Infected Patients. 
SDD Placebo Withdrawn Suitable 
No of patients 12 24 8 3 
Infected patients* 1 8 0 1 
Total Infections 1 10 0 1 
Bronchial 1 3 0 1 
Nosoc. pneumonia 0 2 0 0 
IV catheter 0 2 0 0 
* x2 p =0.22 
The micro-organisms causing secondary infection are shown in Table 36. 
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Table 36: Aetiology of Secondary Infection 
SDD Placebo Withdrawn Suitable 
No of patients 12 24 8 3 
S. epidennidis 0 1 0 0 
Enterobacter 0 1 0 0 
Klebsiella spp 0 1 0 0 
Pseudomonas spp 0 2 0 0 
Acinetobacter spp 1 2 0 1 
Candida spp 0 1 0 0 
Other 0 1 0 0 
Morbidity and mortality were similar for both groups, although unfortunately the 
numbers are too small for meaningful comparison (Table 37). 
Table 37: Duration of Hospitalisation and Mortality 
SDD Placebo Withdrawn Suitable 
ICU stay 18±16.1 17.7±11.3 2.1± 1.2 22.7±16.9 
Hospital stay 32.3±22.3 35.4±20.4 5.9± 8.6 41±22.5 
Duration IPPV 11.1±9.7 12.8± 5.6 1.9± 1.2 19.3±16.2 
ICU deaths 0 5 6 0 
Hospital deaths 1 1 0 0 
Mortality 8.3% 25% 75% 0% 
Discussion 
There were ten infections in the placebo patients, while only one SDD patient 
developed secondary infection. There was only 1 death in the SDD group where 
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therapy was withdrawn because of hypoxic brain damage sustained following cardiac 
arrest on intubation. There were six deaths in the placebo group of which one was 
definitely related to secondary infection ( Candida septicaemia), and one possibly 
related to secondary infection. Although the groups were largely comparable four of 
the twelve patients enrolled to the SDD group were shocked on admission, compared 
with only one in the control group: this alone, although not statistically significant, 
should have predisposed to a higher mortality rate in this group, as shock has been 
shown to be a predictor of poor outcome, in both pneumonia and severe sepsis 
(Hammond,JMJ; SA Pulmonology Congress, Wilderness, 1989). Although 47 
patients with pneumonia were admitted over the study period, only 36 met criteria for 
analysis, as the others failed to meet the criteria for inclusion because of too short a 
duration of intubation or ICU stay; these included six patients who died early within 
five days from respiratory or multiple organ failure. Most studies of SDD m 
heterogeneous groups of ICU patients have shown a reduction in the rate of 
respiratory infection, however there has been little or no effect on mortality.229 In a 
study from our unit we were unable to show a significant reduction in infection 
although a number of deaths could be directly attributable to secondary infection. Our 
study differed from those studies that showed a striking reduction in infection in that 
we had a very low incidence of infection (30%) compared with infection rates of over 
50%, and also we used cefotaxime for 72 hours in the control group as well as the 
SDD group, which may have reduced early onset infections.231 These conflicting 
results have led clinicians to believe that this technique may be valuable in certain 
subgroups of patients, and previous analysis have concentrated on primarily non-
infected groups as it was thought that these may derive more benefit from SDo.230 
Although the numbers are insufficient in this study to show significant differences in 
outcome , it is very suggestive that SDD exerted a protective effect in these patients 
with severe pneumonia, and may both reduce secondary infection and even mortality, 
and it may well be that primarily infected patients may derive significant benefit from 
this technique. 
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CHAPTER14 
SEVERE COMMUNITY-ACQUIRED PNEUMOCOCCAL PNEUMONIA. 
Introduction. 
Streptococcus Pneumoniae is the most common type of micro-organism leading to 
CAP in all settings, and accounts for 8.5 to 23% of cases where the diagnosis relies on 
standard microbiological evaluation,8,9 to as many as 76% where specific 
immunological tests for pneumococcal antigen detection are added. 51 This micro-
organism is also the most frequent pathogen in other types of severe pneumonia, and 
in this study it accounted for 16% of pathogens in nosocomial pneumonia, 20% 
following aspiration, and 17 .1 % in immunocompromised patients. 
In spite of having effective antibiotics for the past 50 years this micro-organism causes 
fatal disease in as many as 15-50% of patients with community-acquired bacteraemic 
pneumonia,2,99,173,240,241 and this high mortality has apparently not been 
influenced by intensive care management.215 The majority of deaths occur within the 
first 24 hours of admission,99 and are frequently associated with underlying disease 
and old age. Infection in young adults has a mortality of 20%, whereas in patients 
aged between fifty and sixty years it is 25 to 40%, and in the over 70's, 50 to 60%.98 
In those with AIDS, the incidence is 5.5 to 17.5 times higher than in the normal 
population, and they have been shown to have a mortality of 57% compared with 18% 
in non-AIDS, aged matched patients.34 In a recent study significant differences in 
outcome between patients in Sweden and the USA of 5 and 26% respectively have 
been unexplained, other than by an increased incidence of associated disease with an 
attributable mortality in patients from the latter country. 
This chapter characterises the clinical features of severe community-acquired 
pneumococcal pneumonia leading to respiratory failure requiring ICU admission, and 
contrasts bacteraemic with non-bacteraemic disease. 
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Patients and Methods 
All patients with community-acquired pneumonia and a diagnosis of pneumococcal 
infection made on grounds of a positive blood culture, or the presence of Gram 
positive diplococci on a Gram's stain of sputum or of tracheal aspirate, or a positive 
culture of S. pneumoniae from bronchial secretions, were included in this analysis. 
Further methodology described in chapter 8 applies to this study. 
Results. 
There were 63 patients who had pneumonia caused by S. pneumoniae, representing 
32% of the total number of 196 patients with CAP, Of these 52 had S. pneumoniae as 
the sole isolate, and 11 had a second organism isolated. H. influenzae in 8, S. aureus 
1, Ps. aeruginosa 1, and a Group A Beta haemolytic streptococcus was the second 
micro-organism isolated in 1. In 34 (54%) of these patients the diagnosis of S. 
pneumoniae was made on blood culture. 
The severity of illness, clinical features associated with an adverse outcome, and 
demographics of the bacteraemic and non-bacteraemic patients are shown in table 38. 
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Table 38: Clinical features. 
Bacteraemic Non-Bacter. Total 
n= 34 29 63 
Age 45.5 +-15.88 43.79 +- 18.22 44.7 +- 16.88 
Male:Female 20:14 12:17 32:31 
Race:Black 15 7 22 
Mixed 18 22 40 
White 1 0 1 
APACHE II 18.9 +- 8.87 17.72 +- 8.6 18.35 +-8.7 
Organ Failure 1.53 +- 0.96 1.28 +- 1.16 1.41 +- 1.06 
Shock 5 4 9 
Acute Renal Failure 12 4 16 
Associated.Dis.(n=) 24 20 44 
Asthma 5 1 6 
Chronic Lung Dis. 8 11 19 
-
Diabetes 5 2 7 
The clinical features on presentation are illustrated in table 39. 
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Table 39: Clinical features of bacteraemic patients on presentation . 
Bacteraemic Non-Bacteraemic 
(n = 30) (n = 29) 
Age >60 years 5 6 
Temperature > 38.5 oc 6 3 
< 35.5 oc 2 4 
Resp. rate >30 breaths/min 14 15 
wee < 5,000 cells/ml 7 11 
5000 - 18,000 cells/ml 14 11 
> 18,000 cells/ml 8 7 
DIC 1 4 
S.albumin < 35 g/1 26 24 
Urea > 7 mmol/1 21 16 
Impaired level of consciousness 5 4 
Shock (SBP < 80 mm Hg) 3 4 
Compromising disease 24 20 
Arterial blood gas (n = 29) (n = 29) 
Pa02(mm Hg)/Fi02 * 178.2±103 206.5±151 * 
PaC01. kPa 4.55±1.33 4.67±1.09 
pH 7.35±0.29 7.37±0.12 
Base excess 7.35±0.29 -4.71±4.74 
t test * p= 0.417 
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All patients required ventilatory support; IPPV was necessary in 50 patients (79% ); 
CPAP by face mask in 9, and 4 were treated with face mask oxygen only. The 
duration and mode of ventilatory therapy is shown in Table 40. 
Table 40: Ventilatory therapy 
Bacteraemic Non- Total 
Bacteraemic. 
No of Patients 34 (54%) 29 (46%) 63 
02 only 2 2 4 
CPAP 5 4 9 
IPPV 27 23 50 
PEEP (cm H20) 7.74 +-4.09 7.91 +- 3.57 7.81 +- 3.84 
Tracheostomy 13 8 · 21 
Duration IPPV * 8.97 +-7.14 9.22 +-7.13 9.08 +-7.07 
ICU admission 11.47 +-8.98 11.03 +- 11.99 11.27 +- 10.38 
Pts.with complications** n= 14 n= 17 31 
Complications (n) 38 36 74 
Mortality(%)*** 5(15%) 8(28%) 13(21 %) 
* t test p = 0.89; ** x2 p =0.25; *** p = 0.34. 
Fifty-three of the patients received intravenous penicillin, one erythromycin, one 
amoxicillin, one cotrimoxazole, and the remaining seven a third generation 
cephalosporin. Three of the non-survivors were not given penicillin. 
Complications occurred frequently in both groups, with almost half the patients 
developing complications, many multiple complications.(see table 41) 
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Table 41: Complications occurring in the ICU. 
Complication No of Patients 
GIT Bleeding 3 
Cardiac Failure 4 
Liver Failure 2 
Renal Failure 9 
Respiratory infection 2 
Other nosocomial infection 20 
Pulmonary haemorrhage 1 
Ventilatory complications* 4 
Pneumothorax 5 
Delirium Tremens 3 
Diarrhoea 4 
Drug complications 2 
Other 16 
* Accidental extubation; blocked tube; CVA on IPPV. 
Thirteen of the sixty-three patients died; eight deaths were clinically assessed as being 
due to multiple organ failure, four to respiratory failure, and one due to brain death 
sustained after a cardiac arrest. Two deaths occurred within 24 hours of admission 
and 50% within 72 hours; the duration of admission and time of death following 
admission are shown in figure 29. 
Figure 29: Time of death following admission. 
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The duration of ventilation, ICU admission, number of complications and mortality 
are shown in table 42. 
Table 42: Duration of treatment, morbidity, and mortality 
Survivors Deaths Total 
No of Patients 50 13 63 
Duration of IPPV 9.97 +- 7.25 6.31 +- 5.88 9.1 +- 7.1 
Duration ICU stay 12.5 +- 11 6.54 +- 6.05 11.3 +- 10.4 
No of Complications 54 20 74 
Patients with Comp. 23 8 31 
Mortality (%) 13(21 %) 
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A number of clinical features are recognised to be associated with an increased 
mortality and these clinical parameters are tabulated for survivors and non-
survivors.(see table 43) 
Table 43: Clinical features that may influence outcome 
Survivors Non-survivors P= 
(n=46) (n=12) 
Age >60 years 6 5 0.078 
Temperature> 38.5 oc 8 0 ns 
< 35.5 oc 4 2 ns 
Resp. rate >30 breaths/min 23 7 0.962 
wee < 5,000 cells/ml 10 4 ns 
5,000 - 18,000 cells/ml 23 5 ns 
>18,000 cells/ml 14 1 0.207 
DIC 2 3 0.102 
S.albumin < 35 g/1 41 10 ns 
Urea > 7 mmol/1 30 7 0.768 
Impaired level of consciousness 8 2 0.761 
Shock (SBP < 80 mm Hg) 3 4 0.048 
Bacteraemia 26 5 0.454 
Compromising disease 27 7 0.886 
Arterial blood gas n=48 n=ll 
PaO?(mm Hg)/FiO? 189±104.6 201±209.3 0.859 
PaCO? kPa 4.59±1.19 4.54±1.34 0.902 
pH 7.39±0.13 7.23+0.41 0.268 
Base excess (n=18) 
-4.43±5.90 -3.15±4.45 ns 
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Discussion 
In this group of patients with severe CAP requiring ICU management, S. pneumoniae 
still remains the most common causative organism occurring in 32% of cases, despite 
an increased incidence of both S. aureus and Gram negative infections. This 
incidence may have been even higher if more sensitive immunological tests were used 
to detect the offending agent, as in 29.6% of cases the pathogens still remained 
unknown, and many of these, particularly those who had received antibiotics, may 
have been caused by S. pneumoniae. The diagnosis of pneumococcal pneumonia was 
made by blood culture in 54% of patients which may further suggest that the overall 
incidence of 32% is an under estimate as Macfarlane using antigen detection as well 
as other common techniques, found an incidence of pneumococcal pneumonia of 76% 
with only 14% positive on blood culture.51 The patient profile was in many respects 
similar to other reported studies of pneumococcal pneumonia, however the age (mean 
44.7 years) with only 11 patients over the age of 60 years tended to be younger. Other 
studies have reported mean ages of 45 to 66 years with most tending towards the older 
age group.173,242,243 The usual predominance of males was also not seen and 
pneumococcal pneumonia occurred as commonly in females. The disease was also 
more frequent in lower socio-economic groups of patients. Seventy percent of 
patients had underlying disease with COPD, asthma and diabetes being common. 
Alcoholism has been shown to be high in these patients, particularly in some 
countries, and in Sweden it occurred in 27% compared with 10% in the USA.243 The 
incidence of alcoholism was low with only four patients with a definite history 
however it was difficult to determine alcoholism accurately, and two patients neither 
of whom had a documented history of ethanol abuse, developed frank delirium 
tremens. A recent study from Halifax has also shown the increased number of 
females, but also increased alcoholism. 241 
In our study all isolates of S. pneumoniae were sensitive to penicillin, and this 
contrasts with pneumococcal pneumonia reported from Israel (55 adults and 49 
children with pneumococcal bacteraemia), of which 6 (5.8%) were penicillin resistant, 
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with 3 of these isolates occurring in adults.173 In two of our cases who died 
appropriate antibiotic therapy was delayed which further emphasises the importance 
of appropriate antibiotic therapy. 
The patients were critically ill with 79% requiring CPPV, and the AP ACHE II score 
was over 18 with most of the score being derived from deranged physiology because 
of the young age of the patients. Bacteraemia which is also considered to be an 
adverse prognostic factor was also present in 54% of cases. There were however no 
significant differences between the bacteraemic and non-bacteraemic patients in any 
clinical parameters which have been reported to be associated with an increased 
mortality and more died in the non-bacteraemic group.134,173,244 The only clinical 
feature that predicted an adverse outcome was the presence of shock. More elderly 
patients succumbed, but this did not achieve significance. 
The overall mortality was 21 % with a mortality of 15% in the well defined group of 
bacteraemic patients; other recent studies have reported mortalities of 18, 19,25.9, 
28.5 and 33% in bacteraemic patients.173,241,242,244,245 The difference in 
outcome between bacteraemic and non-bacteraemic patients didn't achieve statistical 
significance but this may be due to small numbers. If it is real, it is difficult to explain 
as the patients were similar in all clinical parameters that were measured. Previous 
antibiotic therapy and duration of symptoms prior to admission were not documented, 
and the non-bacteraemic group may have included more patients who had received 
antibiotics and failed to respond initially. 
Our mortality is however low for patients requiring ICU admission with 
pneumococcal pneumonia in whom mortalities of 62 and 76% have been previously 
reported.173,215 This suggests that modem intensive care may have a favourable 
influence on outcome in pneumococcal pneumonia. 
A recent comparison of outcome in bacteraemic pneumococcal pneumonia between 
patients from the USA and Sweden showed a significant difference in outcome of 5% 
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versus 26% (p<0.001), which was largely unexplained, other than that there were 
more American patients with underlying chronic ill health. 243 
Four of the 13 deaths occurred within 48 hours of admission and it has been suggested 
that in these patients little can be done to influence outcome.99 Whilst this may be 
correct with the use of conventional therapy, it may not apply to techniques using new 
modalities such as tumour necrosis factor, and interleukin monoclonal antagonists 
used to block the cytokine prostaglandin and other inflammatory pathways.193 This 
group of patients may in fact be the only patients who may benefit from this form of 
therapy, and the small number of these patients in contemporary cytokine blocking 
trials may be the reason for the clinical studies with these agents being inconclusive. 
As intravenous penicillin was the antibiotic used in most cases it would suggest that 
intensive care treatment which is the only additional therapeutic change will result in 
mortality of under 25%, contradicting the conclusions of other previously reported 
studies that suggest that mortality is uninfluenced by intensive care.173,215 
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CHAPTER 15 
SEVERE COMMUNITY-ACQUIRED KLEBSIELLA PNEUMONIA 
Introduction 
Klebsiella pneumoniae (Friedlander's bacillus) is an uncommon cause of community-
acquired pneumonia, particularly in the general population of the developed world. It 
causes a destructive lobar pneumonia with a high mortality and serious complications 
such as lung abscess, empyema and Gram negative septicaemia.92 Klebsiella spp. 
infections account for 1.5% of general hospital admissions with pneumonia125 yet, 
significantly, in this study, Klebsiella. spp. accounted for 8% of ICU admissions with 
community-acquired pneumonia. These patients are drawn from an outpatient 
pneumonia population with a similar incidence of Klebsiella pneumonia as is seen in 
the United States or United Kingdom.9 The incidence of Klebsiella in nosocomial 
pneumonias is much higher - approximately 12%.246,247 
These cases with community-acquired Klebsiella pneumonia represent all cases 
admitted to our ICU over a 10 year period (since computerisation of our ICU patient 
records). This enlarged data base has been used because of the rarity of this form of 
pneumonia in an attempt to draw more definitive conclusions. The first 17 cases were 
published previously and this group has now been expanded with the recent cases to 
confirm the earlier findings statistically if possible in a larger group.129 I have 
attempted to describe the clinical features of the disease, define features which may 
predict a poor outcome, and document therapeutic interventions which may help to 
improve the prognosis. 
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Patients and Methods 
All cases of community-acquired Klebsiella pneumonia treated in our ICU between 
January 1982 and December 1992. Data was obtained from our Intensive Care Unit's 
patient records and computer data collected routinely on all patients during 
hospitalisation. The severity of illness was scored using the therapeutic intervention 
scoring system in the earlier cases, and the organ failure score and AP ACHE II score 
in later admissions.208,235,248 Cases were selected on the basis of the culture of 
Klebsiella. spp in the sputum or tracheal aspirate and/or blood within 24 hours of 
admission to the ICU. Cases with a history of aspiration or possible aspiration were 
excluded. No patients had been admitted or treated in hospital in the month prior to 
admission. 
Microbiological investigations were performed usmg routine laboratory methods. 
Initial respiratory therapy with CP AP by face mask was administered if the patient 
was co-operative and had an effective cough. If patients were unable to clear 
secretions, showed deterioration in gas exchange, or had persisting hypoxaemia (Pa02 
<8.0 kPa) despite conservative therapy, nasotracheal intubation was performed and 
mechanical ventilation instituted using a Bear I or IIE, CPUl or Bennett MAI 
ventilator usually in the IMV mode. Inspired oxygen concentration and PEEP were 
adjusted to maintain a Pa02 of over 8 kPa. A tracheostomy was performed if tracheal 
toilet was difficult or if a duration of intubation of> 7 days was anticipated, provided 
the patient had no increased risk of bleeding. Our antibiotic protocol in severe 
pneumonias usually involved the initial administration of intravenous penicillin and 
an aminoglycoside with the addition of cloxacillin if staphylococcal pneumonia was 
suspected, until the nature of the underlying organism is known, when therapy is 
adjusted. In patients with contra-indications to the use of arninoglycosides, a third 
generation cephalosporin was generally substituted. Over the past 5 years when 
Klebsiella pneumonia was suspected, a third generation cephalosporin was combined 
with the arninoglycoside. Septic shock was managed using a combination of 
intravenous fluids consisting of a limited volume (500 ml) of balanced salt solution 
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initially, followed by fresh frozen plasma or stabilised human serum. Additional 
balanced salt solution was given to maintain an adequate pre-load and blood to 
maintain a haemoglobin of 12g%. Inotropic support using dopamine HCL 10 micro 
gm/kg/min and dobutamine or adrenaline in a dose sufficient to maintain a blood 
pressure of > 90 mm Hg was used. The therapeutic goal was evidence of adequate 
organ perfusion, i.e. adequate hourly urine output with no worsening in level of 
consciousness, and maintenance of acid-base status. Pulmonary artery catheters were 
used in all cases who did not achieve the therapeutic goal or in whom> 15 cm PEEP 
was used. H2 antagonists were used prophylactically to reduce gastric bleeding in all 
earlier cases and recently sucralfate in 4 cases prior to 1986. Since 1986 no routine 
prophylaxis for stress ulceration has been used. 
Nominal data was tested using the Chi squared test, normally distributed interval data 
using a simple "t" statistic, and other data using a Mann Whitney rank test. 
Results 
Thirty-two (8%) of 421 patients with community-acquired pneumonia admitted to the 
ICU over this period because of severe respiratory failure were considered to have 
Klebsiella pneumonia. These included 26 males and 6 females with a median age of 
46 years (range 19 to 65 years). There were 10 blacks, 5 whites and 17 patients of 
mixed race; 26 were of lower socio-economic class ( defined as an annual household 
income of under R8000 ($ 2000). All patients were critically ill: The mean severity 
of illness score using the Apache II system performed on 21 recent patients was 19.99 
(range 9-44), with a mean of 17.2 in survivors and 23 in non-survivors (p= 0.028; last 
16 patients only).208 Therapeutic intervention scoring system used in 14 patients 
yielded mean scores of 31.7 (range 13-60) and 28.3 and 34.3 (ns) in survivors and 
non-survivors respectively. The majority of patients all had one or more severe 
associated medical disease; alcoholism (14 patients), diabetes (6), chronic lung 
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disease (13), carcinoma (2), epilepsy (3), pancreatitis (2), cardiac disease(3), chronic 
renal disease (2), acromegaly (1), and hyperlipidaemia (1). Only two patients had no 
underlying disease. 
TABLE 44: Clinical features on admission in 32 patients. 
Survivors Non-Survivors 
(n = 13) (n = 19) 
Age >60 years 1 3 
Temperature > 38.5 oc 5 8 
< 35.5 °c 1 2 
Resp. rate >30 breaths/min 5 10 
wee < 5,000 cells/ml 8 7 
5,000 - 18,000 cells/ml 1 5 
>18,000 cells/ml 2 2 
DIC 5 9 
S.albumin < 35 g/1 12 19 
Urea > 7 mmol/1 9 9 
Impaired level of consciousness 5 12 
Shock (SBP < 80 mm Hg) * 4 16 
Compromising disease 10 16 
Arterial blood eas (n = 13) (n = 15) 
PaO?(mm Hg)/FiO? 194 190 
PaCO? kPa 3.7 3.34 
pH 7.42 7.37 
Base excess (S = 7, NS =7)** -4.43 -8.8 
* p = 0.08; ** p = 0.23 
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All patients presented with classical clinical features of severe pneumonia, the median 
duration of illness prior to presentation being 1 day (range 12 hours - 3 weeks). The 
majority of clinical features indicative of severe pneumonia present on admission 
showed no difference in incidence between survivors and non-survivors.(Table 44). 
In twenty-seven of twenty-eight patients in whom arterial blood gases were available 
prior to ventilation significant hypoxaemia was present, but there was again no 
difference between survivors and non-survivors (Table 44). Eight of ten patients who 
had an uncompensated metabolic acidosis on admission died. Most patients showed 
segmental or lobar opacification on the chest radiograph (see table 45) 
Table 45: Radiological features in Klebsiella spp. pneumonia 
Chest radioeraph Survivors Non-survivors 
No of Patients 13 14 
Lobar/Segmental pneumonia 13 13 
Bronchopneumonia 0 1 
Effusion 1 2 
ARDS 3 6 
In those with segmental opacification there was usually rapid spread to involve the 
whole lobe. The classical feature of a bulging fissure was seen infrequently. Nine 
patients who developed a rapidly spreading opacification adjacent to the initial 
changes and involving the opposite lung were considered to have developed ARDS. 
Six of these 9 patients failed to respond to treatment. 
Twenty-eight patients required ventilatory support by constant positive pressure 
ventilation (CPPV) and in 11, PEEP of more than 10 cm H20 was necessary to 
achieve adequate oxygenation. One was given CPPV only, because of severe COPD. 
Differential, asynchronous lung ventilation using two ventilators and a double lumen 
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endotracheal tube was unsuccessfully used in 3 patients, and with success in one 
patient who subsequently required a drainage procedure. One required double lumen 
intubation and independent lung ventilation for a large bronchopleural fistula and in 
the other three this was used to try and avoid spread of unilateral disease. The median 
duration of ICU admission was 8 days (Mean 9.29 days, range 12 hours to 84 days). 
There were 19 deaths, 6 of which occurred within 24 hours from septicaemia, the 
remainder occurred from 2-52 days after admission from unremitting sepsis. Fifteen 
of the 19 deaths resulted from the development of multiple organ failure. In 2 patients 
death was due to severe respiratory failure leading to inability to achieve adequate 
ventilation; one died of shock and one developed a fatal pulmonary embolism. 
Table 46: Complications on Admission or Developing During Therapy. 
No. of Patients 
Shock 20 
Coma 14 
Renal failure 15 
Hepatic failure 6 
Delirium Tremens 5 
Pneumothorax 4 
Pulmonary Super infection 10 
GIT bleeding 5 
GIT perforation 2 
Arrhythmia 5 
Other* 10 
* Ischaemic limb, anaphylaxis, CVA, venous thrombosis, pulmonary embolus, 
diarrhoea, pancytopenia, and pressure sores. 
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All but five patients developed significant complications. Barotrauma occurred in 4 
patients leading to bronchopleural fistulae. Super infection was common and 
developed in 10 patients (Table 46). 
Five of 15 patients who developed renal failure were haemodialysed of whom two 
survived. Only one patient who developed G.I.T. complications survived. 
Twenty seven patients received aminoglycosides, 21 in combination with a third 
generation cephalosporin. Four patients received a third generation cephalosporin 
only, and 1 clindamycin and cloxacillin. Only 1 of the patients receiving 
arninoglycosides without a third generation cephalosporin survived, as compared with 
9 of 21 patients receiving arninoglycosides in combination with a third generation 
cephalosporin. Delay in appropriate antibiotic therapy was common and in 2 non-
survivors there was more than 24 hours delay. 
Thirty cases had Klebsiella pneumoniae cultured from their tracheal secretions; the 
Gram stain showing numerous pus cells and Gram negative bacilli, with Klebsiella 
spp. predominating on culture. In 25 patients these came from tracheal aspirates 
performed immediately on intubation and in five from initial sputum. Most sputum 
specimens were blood stained. Blood culture was positive in 14 (44%). The 
sensitivity pattern of the early isolates is shown in Figure 30. 
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Figure 30: Initial isolates of Klebsiella species showing sensitivities by disc. 
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Discussion 
These patients with severe, community-acquired Klebsiella pneumonia presented with 
a characteristic clinical picture. This included a history of chronic disease particularly 
alcoholism and diabetes with an acute, fulminating, febrile illness characterised by 
confusion, shock, spreading lobar consolidation on chest radiograph, and copious, 
purulent, blood-stained sputum with numerous Gram negative organisms evident on 
Gram stain. Recent studies of community-acquired pneumonia have shown that there 
are no pathognomonic clinical features that can accurately predict an aetiological 
diagnosis.17 ,43, 122 Radiological changes in pneumonia are also generally an 
unreliable predictor of the causative organism.249,250 The influence of specific, 
pathogenic micro-organisms causing a more severe pneumonia has not been 
considered, nor the accuracy of the Gram's stain of tracheal secretions, or radiological 
features in this setting of severe pneumonia. The spectrum of infecting pathogens 
causing pneumonia has also not been adequately defined in patients requiring ICU 
management. Our study indicates that the incidence of Klebsiella pneumonia is as 
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high as 8%. In this clinical setting, therefore, particularly when there is copious 
sputum and significant Gram negative organisms present on the Gram's stain, 
Klebsiella pneumoniae should be considered as the most likely pathogen and 
appropriate therapy, i.e. an arninoglycoside in an adequate dose plus a third generation 
cephalosporin, should be instituted early. Patients with the above clinical features as 
well as other markers of severe pneumonia including the elderly (> 60 years), 
tachypnoea > 30 breaths/min, diastolic BP < 60 mm Hg, confusion, urea > 7 mmol/L, 
Pa02 < 8 kPa, leukocyte count < 4 ,000 or > 30,000 cells/ml and serum albumin < 35 
g/L. require urgent intervention with intensive care management.250. 
The AP ACHE II scoring system, although useful in determining the severity of 
disease in large groups of patients, is generally unreliable in predicting mortality in 
individuals when scored over the first 24 hours. In patients with respiratory failure 
from infection, a lower than expected score predicts mortality and thus respiratory 
infection has been accorded a higher risk index.188 In our patients the high mortality 
for a relatively low AP ACHE II score would confirm a higher risk index. 
Survivors had a significantly lower APACHE II score than non-survivors suggesting 
that in patients with K. pneumoniae infections the AP ACHE II score is a useful 
predictor of outcome. The presence of septicaemic shock and confusion present on 
admission also appeared to predict a less favourable outcome; complications 
including ARDS, renal failure requiring dialysis, and gastro-intestinal bleeding also 
indicated a high mortality. 
Intubation and ventilation should be instituted in any patient who is confused and 
unable to clear secretions, even if the arterial blood gases are maintained above a level 
regarded as being satisfactory. In this setting, deterioration with respiratory and 
cardiac arrest can occur rapidly, and respiratory deterioration may be halted with early, 
active, ventilatory support and effective bronchial toilet. Empiric antibiotic therapy in 
patients with this early presenting clinical picture should include appropriate Gram 
negative cover to achieve early, effective antibiotic serum levels. Previous studies 
have shown an increase in mortality if the serum arninoglycoside levels are inadequate 
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in severe Gram negative infections.212 In an earlier smaller study which forms part 
of this group, many patients had low serum aminoglycoside levels despite careful 
dosage according to nomograms using 1.5 mg/kg 8 hourly for gentamicin and 
tobramycin, and 15 mg/kg daily for arnikacin.129 Others have also found wide 
variability in arninoglycoside serum levels in critically ill patients.213 In this 
particular group of patients where the frequency of acute renal insufficiency is very 
high, therapy with arninoglycosides is even more complicated. Experimental studies 
of Klebsiella pneumonia in animal models have demonstrated the efficacy of 
continuous infusions of third generation cephalosporins in controlling Klebsiella 
pneumoniae.251 In immunocompromised patients, a combination of arninoglycosides 
and a third generation cephalosporin has been shown to be more effective than single 
agent therapy.252 We have more recently adopted an antibiotic regimen for 
Klebsiella spp. infection, combining aminoglycosides with a third generation 
cephalosporin in an attempt to achieve maximum, effective antibiotic therapy and our 
early clinical results suggest that this may be a more effective antibiotic regimen in 
these severely compromised patients who have an exceptionally high mortality. This 
approach has recently been supported in a study of 230 patients with Klebsiella 
pneumoniae infections that were found to respond better to combination than 
monotherapy ,17 6 I would recommend with the foregoing information that 
combination antibiotic therapy is mandatory for severe community-acquired 
Klebsiella pneumonia. 
Mechanical ventilatory manoeuvres used in an attempt to decrease the spread of a 
disease such as independent lung ventilation and postural drainage, appear to have 
little effect on the spread of the disease. However, they do positively influence the gas 
exchange in critically hypoxaemic patients, and may help to buy time for therapy to 
become effective, and thus should be attempted. The most important aspect of 
management however, is the early recognition of this potentially fatal pneumonia, 
which will permit early effective antibiotic treatment, and ventilatory support. 
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CHAPTER16 
CIDCKENPOX PNEUMONIA 
Introduction 
Chickenpox (varicella) usually a mild disease of childhood, may cause a severe 
pneumonia in adults. The true incidence of pneumonia complicating chickenpox in 
adults is unknown, however in a report of 114 patients from a military institution with 
chickenpox infection, who all underwent radiological investigation, the incidence of 
abnormality suggesting pneumonia on the chest radiograph was 16.3%.253 There 
have also been reports of small series of varicella pneumonia in adult patients from 
Spain (13 cases over 10 years) and Hungary where 13 of 93 adult patients with 
varicella requiring hospital admission had pneumonia and 34% of cases in a series of 
253 hospitalised adults in the USA.254-256 
V aricella pneumonia has a reported mortality of between 10 to 20% in the general 
population; in pregnancy it may be as high as 41 %, although recent studies report a 
mortality of only 10 and 11 %, respectively, for non-pregnant and pregnant 
patients.253,257 ,258 
Anti-viral agents (particularly acyclovir) are reported to have little influence on 
mortality in severe varicella pneumonia in adults, however this is based largely on 
anecdotal reports and has not been adequately evaluated.257 We have shown in one 
of the earliest cases treated with acyclovir, that the virus can be cleared from the 
vesicles within 24 hours, and that cropping of vesicles ceases almost immediately on 
commencing acyclovir.259 In a recent report of 13 cases of varicella pneumonia, 
acyclovir was thought to be of value in cases with hypoxaemia, and a current review 
of its use in pregnancy suggests a reduced mortality.254,260 A suggested reason for 
lack of efficacy in some reports is the possible delay in treatment, or the development 
of secondary bacterial infection. 257 
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This descriptive study reports the clinical presentation and management of 15 cases of 
varicella pneumonia with respiratory failure admitted to our respiratory intensive care 
unit over a period of 10 years from 1984 to 1993. Because of the rarity of this disease 
and small numbers a longer study period was used. 
Patients and Methods 
These 15 cases with a clinical diagnosis of varicella, and radiological and clinical 
features of pneumonia, represent 4% of patients with community-acquired pneumonia 
who were treated in the ICU over this time period. All patients were in respiratory 
failure with hypoxaemia and required ventilatory support either with face mask 
oxygen, continuous positive airway pressure (CPAP) by face mask or intermittent 
positive pressure ventilation with PEEP (CPPV). Indication for mask CPAP was 
persisting hypoxaemia (Pa02 <8 kPa), despite 40% oxygen by mask, adequate 
alveolar ventilation (PaC02 <5.5 kPa), with an adequate cough, in a fully co-operative 
patient who was capable of protecting the airway. Failure to meet the above criteria 
for adequate respiratory function despite CP AP, was an indication for immediate 
intubation and CPPV. A free-flow design CPAP apparatus with an oxygen blender 
and heated humidification was used for CPAP. (Cape CPAP system.), and patients 
requiring CPPV were ventilated using constant volume ventilators (Bear 2 or 2e ) with 
a heated humidifier (Fisher-Paykel). 
Patients were fed enterally as soon as possible, with a normal diet or by enteral tube 
feeds with the majority receiving 1000 to 1,500 kcals /day. No prophylaxis was used 
for stress ulceration. 
Continuous ECG and oxygen saturation was monitored and routine two hourly 
recording of pulse, respiratory rate, blood pressure, temperature was done by nursing 
personnel. 
Patient demographic data were recorded and the severity of illness was calculated 
using the AP ACHE II scoring system with the worst physiological parameters in the 
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first 24 hours following admission being used. 208 All associated diseases and 
compromising factors present on admission were recorded. The duration of 
ventilation, indications for different ventilatory modalities, and complications were 
documented. A special note of all procedures and their complications, and all other 
complications were recorded. Drug therapy was also documented. 
All information was collected during the patients stay in the ICU by the investigator or 
deputy and stored on a data base programme (D Base-IV, Ashton-Tate, Mountain 
View, Calif.), designed for this ICU information. Analysis was performed using the 
statistical programme "Statcalc" of Epi-Info (Version 5) (U.S.Department of Health 
and Human Sciences/Public Health Service/Centre for Disease Control USA). 
Numerical data is reported as mean and standard deviation. Comparison between data 
was done by Students t for nominal data, and Chi square testing for categorical 
variables where appropriate. 
Results 
Nine of the fifteen patients were young females, only one of whom was pregnant, and 
the remainder had no underlying disease, but had had direct exposure to chickenpox. 
The two elderly male patients also had close direct exposure to grandchildren who had 
chickenpox and only one patient, fl 16 year old boy, had a major 
immunocompromising disease (Hodgkin's disease). No patients were suspected of 
having HIV infection and serological investigation was not performed. The average 
age was 27.3 ± 12.12 years, and the duration of ICU admission was 6.07 ± 1.91 days. 
The demographics and severity of illness, ventilatory therapy, and duration of ICU 
admission are shown in table 47. 
206 
Table 47: Demographic features, severity of illness and ventilatory therapy 
Patient Age Sex Compromising APACHE II Vent.Rx ICU Days 
factors 
1 30 F pregnant(32/52) 3 CPAP 7 
2 25 F - 5 Mask 4 
3 22 F - 1 CPAP 3 
4 27 M - 5 CPAP 5 
5 24 F - 12 CPAP 9 
6 18 F - 4 CPAP 4 
7 55 M - 15 CPPV 8 
8 16 M Hodgkin's - Mask 6 
+splenectomy 
9 21 M - - Mask 6 
10 24 M - - CPPV 7 
11 29 F - - CPPV 8 
12 18 F - 12 CPAP 5 
13 24 F - 13 CPAP 8 
14 20 F - 9 CPAP 4 
15 56 M COAD - CPPV 23 
The diagnosis was clinically obvious in all patients with a history of exposure, a 
febrile illness (m.ean temperature 38.5 oc ± 0.96), and a typical vesicular rash, which 
usually involved the oropharyngeal and buccal mucosa! surfaces. The patients were 
all sick and toxic with marked respiratory distress and hypoxaemia on admission. The 
mean respiratory rate was 37.7 ± 9.44 breaths /minute and the mean ratio of Pa02 mm 
Hg to Fi02 was 216 ± 99.2. All patients had a typical diffuse nodular infiltrate on the 
chest radiograph, however in some, in addition to the interstitial infiltrate, areas of 
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confluent opacification were also present. In three cases the diagnosis was confirmed 
with serology. The presenting clinical features are shown in table 48. 
Table 48: Presenting clinical features in patients with chickenpox pneumonia. 
Patient Temp. oc Resp.Rate PaO,/FiO,. WCC* Pits* Onset** 
1 38.2 38 218 12,200 155,000 5 
2 37.1 40 184 8,000 239,000 5 
3 38.8 34 300 5,100 101,000 3 
4 38 40 286 9,660 144,000 4 
5 40 42 250 2,640 120,000 4 
6 38.3 44 203 8,180 62,000 4 
7 37.8 28 126 6,300 58,000 6 
8 38.5 32 178 4,800 381,000 4 
9 40 30 196 9,510 78,000 14 
10 38.2 60 139 7,700 60,000 5 
11 38.1 32 203 9,700 79,000 6 
12 39 54 167 16,700 193,000 2 
13 39.8 40 481 10,100 127,000 4 
14 37.8 40 180 13,000 207,000 11 
15 37.9 40 137 - - 7 
* cells/ml; ** Time of onset to admission (days). 
The serum urea, creatinine and bilirubin were normal in all cases; mean serum 
albumin 34.1 ± 3.4 mmol/1; the mean serum Na+ was 132.2 ± 2.91 mmol/1, and the 
liver enzymes were all elevated with a mean ALT of 49.7 ± 27 units/I, AST 67.7 +- 42 
units/I and LDH 811 ± 231 units/I. 
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All patients were treated immediately on diagnosis with intravenous acyclovir 250 to 
500 mg 8 hourly for 2 to 3 days, then orally for a total of 5 days. Two patients were 
admitted with recognised bacterial super infection: one patient had a bronchial 
infection with H. influenzae considered significant on Gram's stain and culture of 
tracheal aspirate, and the other, the patient with Hodgkin's disease with an extensive 
bronchopneumonia with H. influenzae on Gram's stain and culture of sputum. Only 
those patients who were thought to have a bacterial infection using both clinical and 
bacteriological criteria, were given broad spectrum antimicrobial therapy (including 
anti-staphylococcal agents). 
Four patients including the two elderly patients required intubation and CPPV. Two 
of these patients were considered to have secondary bacterial infection and required 
CPPV 24 hours after admission after failing to respond to CP AP. The one elderly 
patient who failed to respond to initial CP AP therapy and required CPPV developed 
early onset nosocomial pneumonia. The other patients all responded well to 
ventilatory support with CPAP by face mask (8 patients), and 3 patients face mask 
oxygen only; this improved oxygenation in all cases. It was however necessary to 
maintain oxygen therapy at all times, particularly at meal times, when nasal prong 
oxygen therapy was given. The patients were monitored continuously using pulse 
oximetry, and in all patients temporary discontinuation of oxygen at the peak of illness 
led to desaturation. The average duration of CPAP was 3.25 ± 2.19 days and CPPV 
7.8 ± 7.04) days. One patient on CPAP developed significant atelectasis that 
responded to fibreoptic bronchoscopy and chest physiotherapy, and one patient on 
CPPV developed secondary lower respiratory tract infection. One patient was 
complicated by axillary vein thrombosis which responded to heparinisation. All 
patients survived. 
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Discussion 
In our community chickenpox pneumonia most commonly affects young females with 
young families, probably because of the likelihood of exposure. They present with a 
high fever, ill and toxic, dry cough, marked tachypnoea, and are very hypoxaemic; 
provided that secondary bacterial infection is prevented, recovery should occur within 
a few days. The severe hypoxaemia responds well to CP AP by face mask and this 
therapy is ideal as it avoids intubation with its attendant increased risk of infection. 
Although varicella pneumonia is said to have a high mortality there were no deaths, 
and it is of particular importance that severity of the pulmonary defect is recognised, 
and appropriate early ventilatory support with PEEP, and the management protocol 
described above is used.259,261 The degree of hypoxaemia is often difficult to detect 
clinically, and blood gas measurement or pulse oximetry are essential to diagnose the 
defect, and if oxygen therapy is indicated it should not be discontinued without 
ensuring that oxygenation is adequate. 
The use of acyclovir for varicella remains controversial. In two large prospective 
trials in children aged 2 to 18 years who were given oral acyclovir (20 mg/kg to a 
maximum of 800 mg 6 hourly ) starting within 24 hours of rash onset, the duration of 
disease was reduced by a median of 1 to 2 days. 262,263 This is a disease which 
usually only lasts 7 days and is seldom complicated in children, and this coupled with 
the fact that acyclovir is expensive and unlikely to influence the transmission of 
varicella, has brought about the recommendations that acyclovir should not be used 
routinely in uncomplicated varicella. 264 Serious complications of varicella are 
however so rare that these controlled trials would have insufficient power to detect 
any effect on the incidence of these complications. There is a place for acyclovir 
therapy for immunocompromised individuals and adults where varicella is a much 
more severe disease, with an increased likelihood of pneumonia. A recent review of 
19 patients (8 of whom were pregnant), reported a mortality of 38%; acyclovir was 
thought not to influence outcome however in these patients as it was often given late, 
and death was frequently associated with secondary bacterial infection.(van Eeden, 
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South African Pulmonology Society Congress, Abstract, 1991) The lack of efficacy 
was thought possibly to be due to a delay in therapy, however in the group of fifteen 
patients reported in this analysis with no deaths, the average time of onset of illness to 
the administration of acyclovir therapy was as long as 6 days. Although a number of 
other uncontrolled studies have also suggested that acyclovir has no effect on 
mortality257, a recent report suggests that it may be of value in adult patients with 
respiratory symptoms and hypoxaemia.254 Pregnancy requires special consideration 
as it is thought to increase the risk of varicella pneumonia 20 fold, as well as 
increasing the associated mortality to both the infant and mother. Previous studies 
have reported mortalities of as high as 45%, however a recent review of over 21 cases 
reported in the English literature where acyclovir was used in pregnancy, found a 
mortality of only 14%, and reports in other languages would support this reduced 
mortality since the introduction of acyclovir. 260 Reviews of small series of patients 
in whom acyclovir has been used suggest that the mortality should not be much 
greater than 10% even if pregnant patients are considered. 257,258 
Varicella zoster is exquisitely sensitive to acyclovir and rapid cessation of cropping of 
vesicles is usually seen shortly after starting this agent. Following our experience in 
patients in respiratory failure, we would strongly recommend the use of acyclovir as it 
will hasten resolution and shorten the time that ventilatory support is 
necessary.259,265 The recommended dose of acyclovir is 7.5 to 10 mg/kg 8 hourly 
intravenously or 800 mg 6 hourly orally which will give serum trough levels above the 
ID50 of 1.12 micro gm/m1.265,266 The use of acyclovir in pregnancy appears safe 
during the latter trimesters of pregnancy and no foetal abnormalities have been seen in 
77 cases where acyclovir was used in the first trimester.260 Varicella infection in the 
first trimester may itself increase the incidence of foetal abnormalities, and 
embryopathy has been shown to occur in 2.2% of cases. Prophylactic varicella hyper 
immune globulin should be considered in individuals who have not had the disease 
and who have been exposed, or varicella vaccine may reduce this risk in unexposed 
individuals when given before pregnancy.264 
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The use and efficacy of CP AP by face mask for ventilatory support in varicella 
pneumonia has been recommended in a number of case reports267, and we would 
endorse this foflI,l of ventilatory support as it significantly reduces the risk of 
secondary respiratory infection. Although this has not been confirmed in patients with 
pneumonia where it is usually suitable for only 5% of cases requiring respiratory 
support,268 it has been found useful in a small number of cases when the patients fall 
short of the requirement for intubation and CPPV. 268 Mask CP AP has however been 
clearly shown to reduce complications and infection in other causes of respiratory 
failure particularly when secondary to chest trauma. 218 
This study suggests that the early administration of acyclovir, coupled with 
recognition of the severe hypoxaemia that results from varicella pneumonia, which 
can be reversed with PEEP and particularly CPAP by mask, should reduce the 
mortality of severe varicella pneumonia to single figures. 
212 
CHAPTER 17 
STAPHYLOCOCCAL PNEUMONIA. 
Introduction 
S. aureus is an uncommon cause of CAP with an incidence of 1.5% to 4 % in 
emergency room or community based studies.9,17,52,125 There is however a 
suggestion that this disease is becoming more common not only in hospital acquired, 
but also in community-acquired infections.104 When more severe disease is 
considered, however, the incidence is considerably higher with an incidence of 3 to 
9%,32,119 and in a previous report we noted an increased mortality of 50%.l The 
diagnosis of staphylococcal pneumonia from the community is usually easy both on 
clinical, microbiological, and radiological grounds. I 02 The disease may either be 
haematogenous in origin, with typical lobular opacification on the chest radiograph, 
often with seeding and other sites of infection, and occurring more commonly in third 
world settings in previously fit young patients; or of an aerogenous aetiology which is 
clinically less distinctive. 68,102 This latter form is commonly seen during influenza 
epidemics where it is recognised to have a high mortality.105 The microbiological 
diagnosis is usually not difficult, with numerous Gram positive cocci in clusters 
present on the Gram's stain of sputum, and a blood culture which is often 
positi ve.102, 104 
This type of pneumonia is therefore of particular interest both from our geographical 
setting where a higher prevalence of haematogenous disease may occur, and also 
because of the severity of the pneumonia in our ICU patient population. 
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Patients and Methods. 
This is a sub-group analysis of the major study population and the same diagnostic 
and therapeutic approach, and data collection described in chapter 8 was applied. The 
definition of a haematogenous infection was a distinctive lobular pattern on the chest 
radiograph, or a patient who had other sites of infection in addition to the pneumonia. 
Any other staphylococcal pneumonia was considered aerogenous. 
Results. 
Seventeen of the 196 patients with CAP had pneumonia caused by S. aureus. In two, 
there were dual infections with S. pneumoniae in one, and Group A Beta haemolytic 
streptococcus in the other. Seven were considered to have haematogenous infection 
and ten aerogenous infection. No patient had the disease clearly associated with 
influenzae, however one patient had severe asthma, another mild asthma, two COPD, 
one diabetes, and one developed pneumonia one week after a minor stab in the neck. 
The patients were aged from 13 to 75 with a median age of 37 years ( mean 37.1 ± 
20.93). There were 2 white, 4 black and 11 of mixed racial origin, and 14 male and 3 
female. 
The mean APACHE II score was 14.4 ± 6.21; organ failure score 1.29 ± 0.85. The 
clinical features are shown in table 49. 
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Table 49: The clinical features on admission. 
Pt. Age APACHE Aet.* Resp. PaO:z!Fi02 X-ray Outcome 
II Rate 
JC 64 18 Aerog. - 262.5 Inters.** Surv. 
RA 39 18 Haem. 24 264.4 Lobular Surv. 
GD 20 12 Haem. 50 330 Lobular Surv. 
AZ 42 9 Aerog. 40 137.5 Lobar Surv. 
TJ 14 7 Haem. 15 315 Lobular Surv. 
PX 18 15 Haem. 46 118.8 Lobular Surv. 
MN 16 11 Haem. 50 163.1 Lobar Surv. 
JK 54 11 Aerog. 14 431.3 - Surv. 
JD 13 8 Haem. 16 300 Lobular Sure. 
EI 36 18 Aerog. 40 240 Segmental Surv. 
KM 22 11 Aerog. 46 366 Broncho. Surv. 
CH 75 22 Aerog. 30 191.3 Segmental Died 
DP 26 15 Aerog. 48 127.5 - Died 
NZ 20 18 Haem. 14 113.1 Lobular Died 
PT 72 32 Aerog. 30 313.6 Broncho. Died 
JS 39 17 Aerog. 34 257.1 Broncho. Died 
JZ 49 10 Aerog. 20(V) 110.6 - Died 
* aetiology - Haem.= haematogenous; Aerog. = aerogenous or endogenous. 
**Interstitial 
A number of clinical features are thought to predict a poor outcome and these are 
shown in the following table 50. 
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Table 50: Clinical predictors of a poor outcome. 
Survivors Deaths o= 
(n = 11) (n= 6) 
Age >60 years 1 2 ns 
APACHE II Mean+- S.D. 11.8 ± 3.71 19 ±7.48 0.118 
Temperature > 38.50C 1 3 ns 
< 35.5°c 1 1 ns 
Resp. rate >30 breaths/min 6 3 ns 
wee < 5,000 cells/ml 2 2 ns 
5,000 - 18,000 cells /ml 5 1 ns 
>18,000 cells/ml 3 2 ns 
DIC 1 1 ns 
S.albumin < 35 g/1 6 4/4 ns 
Urea > 7 mmol/1 4 5 0.178 
Creatinine.micro mol/1 +- S.D. 130.7±106 446.2±358 0.104 
Impaired level of consciousness 0 2 ns 
Shock (SBP < 80 mm Hg) 0 4 0.017 
Compromising disease 3 3 ns 
Bacteraemia 6 3 ns 
Arterial blood eas 
PaO?(mm Hg)/FiO? 260.1 185.5 0.11 
PaCO? 4.99 4.05 0.41 
pH 7.39 7.38 0.86 
Base excess -3.39 -6 0.094 
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The diagnosis was made in 9 cases by blood culture, 3 of whom also had a positive 
Gram's stain of the sputum and 4 another site of infection. In addition there were 8 
patients with the diagnosis made on sputum or tracheal aspirate only; 2 patients had a 
positive pleural culture and in 4 a distant abscess cultured S. aureus as well. One 
patient with haematogenous infection (following the minor stab neck), had both S. 
aureus and Group A Beta haemolytic streptococcus on blood culture. 
All isolates of S. aureus were sensitive to cloxacillin. 
The chest radiographs showed a variety of abnormalities particularly in aerogenous 
infection where 1 patient had lobar consolidation, 2 segmental, 1 interstitial, and 3 
broncho-pneumonic changes; in the haematogenous group 5 had the typical lobular 
opacification associated with haematogenous origin and 1 had lobar changes. 
The clinical characteristics of patients with haematogenous infections are contrasted 
with those of aerogenous origin in table 51. 
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Table 51: Haematogenous vs. aerogenous staphylococcal pneumonia. 
Haematogenous A erogenous 
No of Patients 7 10 
Age* 20 ± 8.81 49.1 ± 18.44 
APAeHEII 11.57 ± 3.87 16.3 ± 6.96 
Male:female 5:2 9:1 
Temperature oe 37.73±0.59 37.63±1.47 
Resp. rate 28.6±15.16 33.6±11.4 
PaOJ/FiO? 229 244 
wee cells/ml 8,529±5,190 36,313±63,196 
Platelets cells/ml 160,000±123,000 242,000±129,000 
Renal failure 5 4 
Urea mmol/1 27.03±31.6 14.18±14.7 
ereatinine micro mol/1 183.7±154.2 282±325.9 
Shock 2 3 
Duration (days) 20 ± 6.83 11.2 ± 8.69 
IPPV (n) 6 10 
IPPV (days) 15.57 ± 7.91 8.8 ± 7.05 
Mortality** 1 (14.3%) 5 (50%) 
* p = 0.0014, ** p = 0.32 
Therapy 
Sixteen patients required intubation and IPPV, whereas one patient was treated with 
ePAP by face mask. The duration of ventilation is shown in table 51. Five patients 
with acute renal failure required haemodialysis, and of these two survived. Seven 
patients required chest drains to be inserted, five for barotrauma developing during 
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IPPV, and two for drainage of empyemata. All but 3 patients received cloxacillin with 
the majority receiving a combination of cloxacillin and an aminoglycoside (2 
patients), cloxacillin and fusidic acid (2 patients), cloxacillin and fusidic acid and 
vancomycin (1), cloxacillin and vancomycin (1), cloxacillin and clindamycin (1), 
clindamycin and vancomycin (1), cloxacillin, clindamycin and amikacin (1), 
cloxacillin, clindamycin, fucidic acid and vancomycin (1), cloxacillin and cefotaxime 
(1), vancomycin (1), and cloxacillin only (2), penicillin and amikacin (1). Three of the 
deaths occurred in patients receiving multiple anti-staphylococcal agents whereas in 
two deaths, one which occurred within hours after admission to hospital, inappropriate 
antibiotics were used. 
Complications 
Seven patients had an uncomplicated course, but m the remainder, numerous 
complications occurred.(see table 52) 
Table 52: Complications in staphylococcal pneumonia 
Complication No of Patients 
Gastro-intestinal Bleeding 3 
Pneumothorax 5 
Pulmonary Bleeding 1 
Tracheal Bleed 1 
Blocked ETT 1 
Accidental extubation 1 
Nosocomial Infection 7 
Other 7 
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Mortality 
Two patients died within a short time of being admitted and were considered to have 
died from overwhelming septicaemia, and the remaining deaths occurred after 13 to 
22 days of admission and were considered to have multiple organ failure. Only one 
death occurred in the 7 patients considered to have haematogenous infection, whereas 
there were 5 deaths in the patients considered to have aerogenous infection. 
Discussion 
This study confirms the high mortality in severe community-acquired staphylococcal 
pneumonia with a mortality of 35.7% compared to the overall mortality in this study 
of 25.5%. This is lower than previously reported, both by us, and in other 
studies.I, 108 The differences in the possible mechanisms of aetiology have not 
previously been reported as a separate disease entity, however in this study there are 
substantial differences in the clinical presentation with a younger age group and 
classical lobular radiological changes being typical of the patients with 
haematogenous aetiology. Many of these patients also had deep seated staphylococcal 
abscesses and only one of seven patients died. The group with aerogenous infection 
had no distinguishing clinical or radiological features and 5 of 10 patients died. This 
high mortality with staphylococcal pneumonia has previously been noted particularly 
when associated with influenza. Infection with influenzae causes an environment 
which is particularly conducive to multiplication of S. aureus and may in part account 
for the increased mortality, however in our patients there was no apparent association 
with influenza, and the mortality remained particularly high in the aerogenous group. 
All isolates were cloxacillin sensitive and the majority of patients received cloxacillin 
and an arninoglycoside and surgical drainage of localised abscesses either soft tissue, 
osteitis, pleural or arthritis was performed as early as possible and repeated if no 
resolution occurred. 
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CHAPTER 18 
CONCLUSION 
Severe pneumonia requiring ICU admission, particularly when ventilatory support is 
necessary, is one of the major clinical challenges for the intensivist. We have shown 
that the mortality associated with severe pneumonia is high, but it is considerably 
lower than previous studies, and some recent some studies where the patients severity 
of illness scores have been similar to our population.32,119,215,269 A mortality 
similar to that found in this study has also been reported in some recent studies, and 
this suggests that the mortality can be reduced with modem intensive care. Knaus 
suggests that differences in mortality between intensive care units may be related to a 
well orchestrated team approach using proven therapeutic protocols with full time 
medical direction and our results add support to this suggestion.208 The management 
protoc9ls which have evolved over the past 20 years in our ICU, including antibiotic 
therapy, diagnostic procedures, and ventilatory techniques have been well justified by 
the satisfactory outcome of these patients with severe pneumonia reported in this 
study. CAP nevertheless, still has a high mortality and deaths may be divided into 
those occurring early from severe sepsis with cardiac and respiratory failure, or those 
that occur late where complications of therapy, nosocomial infection, and multiple 
organ failure are the main contributors. The approach to therapy used in our ICU 
which included early supportive therapy with ventilation, fluid and inotrope therapy, 
and optimal antibiotic therapy with an appropriate spectrum of activity plus adequate 
serum levels, may also have contributed to this favourable outcome. Prevention of 
secondary infection with meticulous aseptic techniques as well as other prophylactic 
techniques such as SDD to prevent colonisation, may also play a role particularly in 
preventing later deaths. The introduction of new immuno-therapy particularly 
monoclonal antagonists of the inflammatory pathways may also influence early 
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deaths, as well as later organ failure. These new modalities will have to be tested in 
carefully selected patient populations with a known mortality, with well defined 
criteria for entry into studies to avoid equivocal results. It patients with pneumonia it 
will be necessary to control for factors such as co-morbid diseases, delay in therapy, 
appropriateness of therapy, type of micro-organism and the severity of illness; all of 
which is extremely difficult if not impossible. 
While the classification used in this thesis has proved useful in defining the incidence 
of aetiological agents of the different pneumonias, their therapeutic response and 
outcome, certain inadequacies with this classification have become apparent. The 
most important deficiency is found with the patient who is admitted with a co-morbid 
disease which will inevitably result in a pneumonia, often within 48 hours of 
admission, and in whom the underlying disease and not the pneumonia is the main 
factor which determines the final outcome. These patients fall by definition into the 
CAP group, but in terms of outcome, empirical antibiotic and other therapy behave 
differently, and would probably be better classified separately. This group should be 
considered as separate subgroups of CAP, with the precipitating disease specified e.g. 
muscular weakness (Guillain Barre' syndrome, myasthenia gravis etc.). In this study 
some of these patients particularly those young patients who died, death was a result 
of the co-morbid disease (chapter 11). In others with similar co-morbidity the 
pneumonia itself was mild and the patient responded rapidly once adequate respiratory 
support was instituted making the association with co-morbid disease an even greater 
confounding factor. 
The previously reported high incidence of both Gram negative and staphylococcal 
infections has been confirmed, and although the mortality for these infections is 
almost double that of the other pneumonias, it is not statistically significant because of 
small numbers. S. pneumoniae nevertheless still remains the most common pathogen 
in patients with severe pneumonia. Most patients with L. pneumophila treated in 
hospital during this period required ICU admission , however there were no deaths in 
this group given appropriate therapy. Mycoplasma and other atypical pneumonias 
222 
were seldom seen and also tend to produce a mild pneumonia. It is however 
conceivable that the incidence of M pneumoniae, Clamydia pneumoniae and 
Legionella spp: infections were under diagnosed as serology was not done routinely 
but only when clinically indicated. 
The standard diagnostic approach used proved moderately successful in detecting 72% 
of pathogens with a 30% positive yield on blood culture. The value of the Gram's 
stain of a well collected sputum specimen, particularly a tracheal aspirate obtained 
soon after intubation, especially where a single organism predominated in large 
numbers was shown to be particularly useful. The early Gram's stain of appropriate 
bronchial secretions proved to be of particular value in detecting patients with 
Klebsiella and staphylococcal pneumonia. The sensitivity of the Gram's stain of 
' tracheal aspirate or sputum in 31 patients with a positive blood culture had a 
sensitivity of 74% and specificity of 100% , and the culture a sensitivity of 68% and 
specificity of 91 % (chapter 12) in identifying most Klebsiella spp. and S. aureus 
infections, and there were few false positives or false negatives. The sputum was also 
valuable in detecting pneumococcal infections where the Gram's stain findings were 
often confirmed by the blood culture. 
Specimens obtained by fibreoptic bronchoscopy with a PSB seldom contributed to a 
positive diagnosis, although this may be because the specimen was usually taken after 
antibiotics had already been given. Similar findings have been reported by other 
authors, some of whom have suggested that a negative finding is useful, but the value 
of a negative procedure is still open to debate. 
When all clinical parameters were considered there was no delay in diagnosing any 
cases of K Pneumoniae or S aureus infections.(chapter 15,16) Individual clinical 
features including the chest radio graph were poor predictors of aetiology. Most 
patients with haematogenous S aureus and Chickenpox pneumonias were however 
identified using the chest radiograph. The specificity was however low. 
A number of previously accepted beliefs regarding pneumonia, particularly in relation 
to the determination of outcome have been shown to be of little use in patients with 
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severe pneumonia requiring ICU care. Severity of illness scoring systems including 
the AP ACHE II, organ failure and lung injury scoring systems all accurately predicted 
mortality in these patients as a group, and there was a significant difference in the 
scores between survivors and non-survivors. As previously shown, a lower score in 
pneumonia predicted a higher mortality than for other diseases The prediction for 
individuals with the AP ACHE II was unreliable and no level could accurately predict 
death. 
The organ failure score was found to be a more reliable predictor of outcome in 
individuals: all patients with 4 or more organ failure on day 1 died, 11 of 19 (58%) 
with 3 organ failure, 13 of 36 (36%) patients with 2 organ failure, and only 18 of 101 
patients with 1 organ failure on day 1 died; however on subsequent days less than 4 
organ failure was not predictive of individual outcome, as even patients with 3 organ 
failure on day 3, eight of 19 patients (42%) survived (unfortunately the numbers of 
patients with higher organ failure scores were too small for adequate evaluation). The 
acute lung injury score proved no better than the AP ACHE II score for individual 
prediction. 
The rules suggested by the BTS and other studies that proved valuable in hospital 
based populations of pneumonia, failed to perform in this selected group, all of whom 
had severe pneumonia. Rule 1 had a positive predictive value of only 42% with a 
sensitivity of 65% and specificity of 70%. Whilst age of more than 60 years was a 
significant predictor of mortality, a number of young patients died. In these patients 
death was often due to co-morbid disease rather than the pneumonia itself. 
The presence of septic shock was the most significant predictor of an adverse 
outcome, however this clinical feature on its own predicted less than 50% of deaths. 
Other clinical features that were significantly different between survivors and non-
survivors included a low serum albumin, WCC, a DIC and an elevated inorganic 
phosphate, ALT and urea. Only one of the 6 patients with very high white cell count 
(> 40,000 cells/ml) died, whereas 46% of 39 patients with a count of < 4,000 cells/ml 
died (X2 p = 0.225). When the Bonferroni correction for multiple comparisons was 
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applied only shock retained its predictive value. The serum albumin was significantly 
lower in non-survivors than in survivors, but even in survivors the mean level was 
only 28.6 g/1 illustrating the difference between the local population and more 
developed populations. 
There are a number of other important factors that related to death in the individual 
patients, the most remediable of these being the incorrect selection and use of 
antibiotics. We found that in some cases inappropriate antibiotics were initially 
selected, in others inadequate doses were administered, and in a number of cases a 
delay in antibiotic administration occurred. A number of patients presented after days 
of delay, most without having received any treatment, and this almost certainly 
contributed to death in some instances. This reflects the poor community-based 
medical facilities provided, and the lack of health education in our patient population. 
Although some of these factors have been shown to be associated with deaths in this 
thesis , they have not yet been used in any scoring systems. In order to accurately 
predict the outcome in pneumonia, these factors will need to be incorporated into 
future scoring systems. (This statement is now dated as Leroy has reported at the 
International Congress of Antimicrobials and Chemotherapy in 1984 and 1985 in two 
abstracts. The first defining similar prognostic factors and weighting them according 
to their statistical values and showing some value in a retrospective cohort, and the 
second applying this system to a prospective group and showing rather disappointing 
results. This particular aspect of this thesis has now been updated with additional 
patients and an updated discussion and is included as appendix 5.) 
The antibiotic policy adopted during this study using penicillin and an 
arninoglycoside, usually arnikacin, with the addition of cloxacillin, a third generation 
cephalosporin, or erythromycin in special circumstances, would seem to be 
appropriate, as the outcome for all groups was as low or lower than any previous 
mortality figures reported in the literature. Low serum levels of arninoglycoside were 
not infrequent, serving to emphasise the need to give appropriate, often larger than 
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usual doses of antibiotic, because of the increased volume of distribution in this group 
of critically ill patients. 
The efficacy of the use of early intubation and the ventilatory techniques employed 
were confirmed by the infrequency of both of ventilatory complications and of death 
due to irreversible hypoxaemia. Following on from this, I would recommend that 
intubation should be expedited in any patient who is confused, shocked, unable to 
clear secretions, exhausted or who has unresponsive hypoxaemia. 
The need for a multidisciplinary approach was highlighted by the low mortality in 
those patients who required dialysis, and also the overall low mortality of only 
24.5%. 
The cause of death was usually early shock, or more commonly multiple organ failure 
after many days of ICU support suggesting that in order to achieve any further 
reduction in mortality attention will need to be directed at these two areas. The 
reversal of early shock may be improved by early diagnosis with optimal antibiotic 
support, and this is the area where the newer methods of immunomodulating the 
inflammatory cascade may have an important role to play; while the prevention of 
progressive multiple organ failure may be achieved by providing a high degree of 
support and preventing secondary complications Any innovation however, should 
only be incorporated into common practice once it has undergone rigorous and critical 
evaluation. 
Implicit to the successful achievement of all of the above, is the need for a highly 
trained and motivated critical care team, drawing on the support of ancillary services 
and efficiently utilising the ever-increasing armamentarium at their disposal. 
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Summary of Important Findings 
1. Classification should include: CAP with subgroups according to co-morbid 
disease, aspiration pneumonia, nosocomial pneumonia with V AP as well as time of 
onset, and pneumonia in immunocompromised patients. The severity of pneumonia 
should also be considered e.g. severe CAP vs. mild CAP. 
2. Aetiology differs in severe CAP 
Gram negative, S. aureus and L. pneumophila increased 
M. pneumoniae, C. pneumoniae uncommon. 
3. Prediction of outcome 
Group mortality predicted well by AP ACHE II and Organ failure scores. 
Organ failure score best individual predictor 
Modified BTS rules perform poorly. 
Lung injury score is a poor predictor 
4. Therapeutic approach works well 
Early intubation 
Conventional ventilation 
CP AP when tolerated 
5. Antibiotic protocol appropriate and cheap. 
6. Mortality in bacteraemic pneumococcal pneumonia is not increased. 
7. Acyclovir and CP AP for V aricella pneumonia. 
8. Staphylococcal pneumonia has 2 distinctive types depending on pathogenesis 
9. ICU care reduces mortality in severe pneumonia. 
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SURGICAL DETAILS 
Type of Surgery 
1 . General - niajor vascular 
2. - bowel resection - small 
3. - bowel resection - large 
3 
4. - gastrectomy /gastric surgery /vagotomy etc. 
5. - cholecystectomy 
6. - hepatectomy 
7. - pancreatectomy 
8. - hernia repair 
9. -varices 
10. - oesophagectorny 
11 . - laparotomy 
12. Thoracic - lobectorny 
13. - pneumonectorny 21. Neurosurgica
l 
14. - decortication 22. ENT 
15. - bullectomy 23. Ophthamo
logy 
16. - open lung biopsy 24. Gynaecology
 
17. · • . other (specify) 25. Obstetric 
18. Cardiac 26. Other surg
ery (specify) 
19. Urological 27. Erriergency surge
ry 
20. Orthopaedic 28. Elective surgery 
NO. OF ORGANS FAILED (Day 1) 
NO. OF ORGANS FAILED (Day 2) 
NO. OF ORGANS FAILED (Day 3) 
NO. OF ORGANS FAILED (Day 4) 
NO. OF ORGANS FAILED (Day 5) 
DEFINITION OF ORGAN FAILURE (only 1 criteria in each system necessary) 
Renal 
CVS 
1. 
2. 
3. 
1. 
2. 
3. 
4. 
Haematological 1. 
2. 
3. 
Respiratory 
Neurologic 
1. 
2. 
3. 
4. 
1. 
Urine outputs. 479 ml/24 hours or~ 159 ml/8 hours 
S.creatinine > 300 mm/I 
S.urea > 20 mmol/1 
MBP ~49mmHg 
HR..$. 54/min 
VF or VT 
pH..$. 7.24 PC02 s. 6 
wee < 1000 mm3 
Platelets < 20000 rnm3 
HCT ~20% 
RR~ 5/min or.?.. 49/mln 
PaC02 .?.. 6 kPa 
AaJK)2.?.. 46 kPa (F102 - Pa02 - PaC02) 
Dependent on ventilator for.?.. 4 days 
Unconscious GCS s. 6 (no sedatives for 24 hours) 
D 
BACTERIOLOGY 
INFECTIONS PRESENT ON ADMISSION 
(how diagnosis is made) 
01 . Sputum 
02. Tracheal aspirate 
03. Bronchoscopy 
04. Blood culture 
05. Serology 
06. Wound swab 
07. Aspirate - pleural 
08. - peritoneal · 
09. Transtracheal aspirate 
10. CSF 
11. 
12. 
13. 
Tissue biopsy 
Lung biopsy 
Cther (specify) 
Bacteriological diagnosis 
01. s·treptococcus pneumoniae 
02. Staphylococcus aureus 
03. Staph.epidermidis 
04. H.lnfluenzae 
05. E.Coli 
06. Klebsiella sp. 
07. Serratia sp. 
08. Proteus sp. 
09. Pseudomonas sp. 
10. Acinetobacter sp. 
11 . Anaerobes (specify) 
12. TB 
13. Mycoplasma 
14. Legionella 
15. Viruses 
16. Alckensia 
17. Malaria 
18. Candida 
19. Aspergmus 
20. Strep milleri 
21 . Other strep 
22. Enterobacter 
23. Enterococcus 
24. Unknown 
25. Other organism 
26. Branhamella catarrhalis 
27. Neisseria meningitidls 
28. Pneumocystic carinii 
4-
14. 
15. 
Community acquired D 
Noaocomlal 
Admission Infection Only 
Secondary "Significant" 
organism Isolated in ICU 
(le required Rx) 
B 
SPEC..\L INVESTIGATION 
01 . FOB 
02. Brushings 
03. Trans Bronchial Biopsy 
04. Open Lung Biopsy 
05 . Echo cardiography 
06. Lung scan 
07. MUGA 
08. CAT 
09. (Ultra sound) ABO 
10. Angiography 
11 . Cardiac catheterization (fluroscopy) 
12. I.cranial pressure monitoring 
13. Intra-arterial pressure monitoring 
1 '1 . Bone marrow 
1~ . Liver biop·sy 
16. Renal biopsy 
17. Lumbar puncture 
18. Gallium scan 
19. Indium oxide scan 
20. Cardiac biopsy 
21 . Bone scan 
22. Other (specify) 
S.G. Catheter Yes 1 
Route: 11 . J .V. P. (R) 
Nao 
12. J .V.P. (L) 
s 
14. Subclavlan (R) 15. Peripheral arm 
COMPLICATIONS OF THE SWAN GANZ CATHETER 
21 . Multiple stabs at vein ( > 3) unilateral 
22. Bilateral attempts 
23. Failed attempt 
24. Arterial puncture 
25. Pneumothorax 
26. Arrhythmias (required treatment) 
27. Failed placement 
equipment 
28. balloon 
29. transducers 
30. C. 0. computer /thermistor 
31. Ruptured pulmonary artery /haemoptysis 
32. Knot in catheter 
33. Catheter embolism 
34. Pulmonary infarction 
35. Inability to wedge 
36. Other (specify) 
D 
13. Subclavian (L) ITJ 
16.Leg 
VENTILA TORY THERAPY (rick) 
CONSERVATIVE 
CPAP - Mask 
-Tube 
ETI 
IPPV without PEE 
IPPV with P!:!:? 
::.. 15 ems 
Tracheostcmy 
Mlnitrac 
HFPPV 
(ONLY) (Only if not ventllated) 
(q.,ty if not ventllated) 
(C,ily If not ventilated) 
p 
Double lumen iub 
lndep lung vent. 
e 
DURATION IN DAYS 
rn 
Tracheostcmy 
CPAP 
IPPV 
Maximum PEEP {CMS) 
INDICATION FO 
INDICATION FO 
RETT 
R TRACHEOSTOMY 
1. Chstructed airway 
2. Secrntion retention 
3. Respiratory fallure 
4. Other (specify) 
5. Prc!onged Intubation 
6. To assist weaning 
7. Eiec:ive ventilation 
OTHER THERAPY (rick) 
1. 
2. 
3. 
4. 
5. 
6. 
7. 
8. 
9 . 
10. 
Dialysis PD 
Dialysis Haemo 
Dialy~ls PD i· Haemo 
Haemoperfusion . 
Enteral feeding 
IV nutrition 
Epidural lumbar 
Epidural thoracic 
Plasmapharesls 
Difibrillatlon (planned) 
.---
,___ 
,.._ 
PROCEDURES 
1. Peripheral IV 
2. Central IV lnternul jugular 
3. Central IV subclavian 
4. Central IV peripheral vein 
5. Arterial line 
6. Resuscitation {successfu'I) 
7. Chest drain 
8. Other 
ANTIBIOTICS 
01 
02 
03 
04 
05 
06 
07 
08 
09 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
Penicillin 
Gentamicin 
Tobramycin 
Cephamandole 
Cefotaxime 
Cloxacillin 
Fucidin 
Erythromycin 
Clindamycin 
Chloromycetin 
Amoxll/ Amplcillin 
T etracycllne 
Cotrlmoxazole 
Piperacillln 
Amikacin 
Anti TB Therapy 
· Rifampicin (not for TB) 
Steptomycin (not for TB) 
Amphotericin B 
5 Flucytosine 
Other (specify) 
Ceftriaxone 
23 Netilmlcin 
24 Metronidazole 
CARDIAC INOTROPES 
25 Adrenaline 
26 Dopamine 
?7 Dobutamine 
28 lsuprel 
?9 Glucagon 
30 Heparin 
31 Streptokinase 
SEDATIVES 
32 Benzodiazepines 
33 Midazolam 
34 Pentothal 
35 Heminevrin 
36 Barbiturates 
37 Epanutin 
38 Rivatrol 
39 Human tetanus 
immunoglobulin 
40 Etomine 
DIURETICS 
41 Furosemide 
42 Thiazides 
43 Other diuretics 
1 
DRUGS 
MUSCLE RELAXANTS 
54 Scoline 
55 Non-depolarisors 
EPIDURAL 
56 LA 
57 Opiates 
58 Both 
RESPIRATORY 
59 Amlnophylllne 
60 B-2 agonists inhalation 
61 8 -2 agonists IV 
62 lprntroplum bromide 
VASODILA TORS/ 
ANTIHYPERTENSIVES 
63 SNP 
64 TNT 
65 MgS04 
66 Minipress 
67 Hydralazine 
OTHER DRUGS 
68· Antacids 
69 Cimetldlne 
70 Insulin 
71 Oral antidiabetics 
72 Steroids 
73 lmmunosuprossants 
7 4 Chollnestoraso 
Inhibitors 
75 2 PAM or toxogonin 
76 Amphoterlcln bladder 
wash 
77 Other drugs 
78 Ranitidlne 
NEW DRUGS 
79 lmipenem 
80 Ceftazadime 
81 Perfloxacln 
82 ACE inhibitors 
83 Urokinase 
84 
85 
86 Anexate 
87 
ANALGESICS 
88 Morphine 
89 Fentanyl 
90 Other opiates 
91 Non-steroidals 
92 
..,._ __  
COMPLICATIONS (Developed in ICU) 
01 G.l.T. Bleed 
02 Hepatic failure 
03 Cardiac failure 
04 Renal failure (without dialysis) 
05 Renal failure (peritoneal) 
06 Renal failure (haemo) 
07 Renal failure (both) 
013 Pulmonary infection 
Ofl Pulmonary embolism 
1 o Pulmonary haemoptysis 
COMPLICATIONS OF VENTILATION 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
OTHER 
22 
?3 
24 
2c; 
2fi 
27 
28 
29 
30 
31 
32 
33 
Blocked endotracheal tube 
Accidental disconnection 
Ruptured cuff 
Ventilator failure 
Accidental extubation 
Tracheal perforation/dilation 
1'.0.F. 
Tracheal bleed 
Pneumothorax/BPF 
CVAonCPPV 
Atelectasis 
Septicaemia 
U.T.I. 
Endocardltls 
Infection with a second organism (Suparinfcction on antibiotics) 
Other infection 
DIC 
Diarrhoea 
Arrhythmias 
DTs 
Any other complication (specify) 
Diarrhoea due to enteral feeds 
DVT 
COMPLICATIONS OF IV LINES 
34 Complication of IV lines 
35 Phlebitls 
36 Septicaemia 
37 Other (specify) 
38 Thrombosis 
39 
COMPLICATIONS OF DRUGS 
40 Complication of drugs (specify drug) 
41 Anaphylaxis 
42 Allergy 
43 Skin reaction 
44 Diarrhoea 
45 Renal failure 
46 Other (specify) 
CAUSE OF DEATH 
01 Does not apply (patient survived) 
(One only) 
02 Arrhythmia (primary) 
03 Brain damage following arrest 
04 Head injury /stroke 
05 Complication of procedure 
06 Dissecting aneurysm 
07 Drug induced death 
08 Hepatic failure 
09 Respiratory failure 
10 Renal failure 
11 Shock (cardlogenlc) andi or CCF 
12 Hypovolaemla 
13 Septicaemia 
14 Pulmonary embolus 
15 Mechanical failure 
16 Multiple organ failure 
17 Surgical death 
18 Active treatment 
discontinued/specify reason 
19 Brain death - specify 
20 Other - specify 
Autopsy: 1. Yes 
2. No D . 
If no, must specify why not 
B 
l , ADMISSION DIAGNOSTIC CATIOORY D Po•t eMraency •ura•l"Y Y / N 
rroa the 11ata below, indicate the 2!1! primary adm1es1on dia1noais that 
noc•~•itatod ICU adMiaeion. 
?. NON OPERATIVE 
Respiratory failure from 
l. Aath•/ allerg;r. 
• 2. COPD 
3. ARDS 
4. Aapiration/poieon/toxlc 
5. Pulaonary Nbolue 
6. Reapiratory infection 
7. Reepiratory neopl-
8. Poat reapiratory arr-eat (only) 
cardlovucular failure t'l"OII 
9. ten,ertenaion 
10. __,tha. disturbance 
11. conaesti ve heart failure 
12. ffa~lc ~1•1• 
13. CoroMry ... telT dia .... 
14. Sepal.a 
15. Poat cardiac .,.....t (only) 
us. Cllrdlopnlc alloclc 
17. Dleaectin&......,.. 
t......: 
18. Nultlple traulla 
11. NN4 trauaa 
-,.01a,1c : 
20 ... , ..... dlaorder 
21. 11111/.., .. 
22. Drlrc OD 
23. Diabetic S.toecldoala 
24. QI bleedina 
It not in the abcwe epec1f'ic 
aroupe, then which orpn 
ay•t• wu the principal 
reaaon for adaiaaion? 
25. Metabolic/renal 
26. Reap1ratory 
'rJ. Neul"olOliC 
28. CVS 
29. GIT 
3. InJUl'J Severity Boore (I88) 
POSTOPERATIVE 
30. Multiple trauma 
31. Chronic CVS disease 
32. Peripheral vascular surgery 
33. Heart valve auraery 
34. Cranlotolly tor neoplas11 
35. Renal suraery for neoplu111 
36. Renal transplant 
37. Head trauaa 
38. · Thoracic surgery for neoplaam 
39. Cran1otolly tor ICH/IDH/SAH 
40. Lalllnec~/cord •uraery 
41. Hae110rmaalc shock 
G. 01 bloedin& 
43. OI auraery for neoplu• 
44. Reap1ratorr failure poet aurgc:ry 
45. GI pert'orat1on/otaetruct1on 
u· Npe·te or poetarreat, uae 
COl"l'Npondina non-operative 
cat.corr. 
It not in the above apecltic aroupe, 
then which orpn ayatea - tl\e prl nclpal 
reMon tor adlllN:lon? 
•· Neurologlc 
47. CVS 
•· ... plrator, . 
41. GIT 
50 ... tabolic/renal 
rn 
IN
JU
R
Y
 SEV
ERITY
 
SCORE 
~
everity category 1 
-
minor 
G
eneral 
:A
ches 
all 
o
v
e
r. 
H
inor laceration•,contusion,abrasions(first 
aid, 
sim
ple 
closure) 
~11 
first 
o
r 
sm
nll 
se
c
o
nd 
o
r 
sm
all 
third dcqreo burns. 
tlt~d 
and 
n
e
ck 
,c
e
r
ebral injury 
w
ith headacho, dizzyness but 
n
o
 loss 
of 
c
o
n
sciousness 
W
hiplash 
c
o
m
plaint 
w
ith 
n
o
 
a
n
atom
ical 
o
r 
radiological 
e
vidence 
A
brasions 
and 
c
o
n
tu
sions 
of 
o
c
c
ular 
apparatus (lid-, 
c
o
njunctival-
' 
c
o
rn
e
al-, 
u
v
e
al-
injuries.) 
V
itreous 
o
r 
r
e
tin
al haem
orrhage, 
F
racture 
and /o
r dislocation 
of to
o
th 
~
~
 
:H
uscle 
a
che 
o
r 
chest 
w
all 
stiffn
ess 
A
bdornlnal 
1H
uscle 
a
che,m
inor 
abrasions 
e
tc
. 
tx
trem
ltl11 
:M
inor
·
 aprains,fracture 
a
nd/or dislocation 
of d
ig
its. 
s
e
v
e
rity categorv a 
-
m
oderate 
~
~
n
vt§l 
:E
xtensive 
c
o
n
tu
sions, 
abrasions, 
large lacerations, 
a
v
u
laion
s(less than 7
,5
 
c
•
 
w
ide) 
10-
20\ body 
s
u
rface 
se
c
o
nd 
o
r third degree burns, 
Ucad 
and 
n
eck 
:C
erebral injury 
w
ith 
o
r 
w
ithoout 
skull fracture, 
less 
than 15 
m
inutes 
u
n
c
o
n
s
ciousness, 
n
o
 post trau
m
atic 
a
m
n
e
sia, 
·
 
U
ndisplaced 
skull 
o
r facial bone fractures 
o
r 
co
m
pound fracture 
of 
n
o
se
. 
~ 
L
acerations 
of the 
eye 
a
nd 
appendages; 
R
etinal detachm
ent. 
D
isfiguring lacerations. 
W
hiplash 
-
•e
v
e
r
e
 
c
o
m
plaint 
w
ith 
a
n
ato
m
ical 
o
r 
radiological 
e
vidence. 
~
 
:Sim
ple 
rib 
o
r 
ste
rn
al fractures 
~lajor 
c
o
n
tu
sion 
of 
chest
•
 w
all 
w
ithout haem
othorax 
o
r pneu111othorax 
o
r 
re
spiratory 
em
barasam
ent. 
A
bdom
inal 
1H
ajor 
c
o
n
tu
sion 
of 
abdom
inal 
w
all. 
Extrem
ities 
and/or pelvic girdle 
:co
m
pound fractures 
of d
ig
its. 
U
ndisplaced long bone 
o
r pelvic fracture 
H
ajor 
sprain• 
of 
m
ajor joints. 
Severity category 5 
-
critical ( 1uryival 
u
ncertain) 
G
eneral 
:o
v
e
r 501 body 
e
u
rface 
a
e
c
o
nd 
o
r third degree burns. 
H
ead 
and neck 
I 
c
e
rebral injury 
w
ith 
o
r 
w
ithout 
skull fracture 
w
ith 
u
n
c
o
n
sciousness 
of 
a
o
re
 than 24 hours, post trau
m
atic 
a
m
n
e
•ia 
a
o
r
e
 
than 12 hour•
·,
 
intracranial haem
orrhage. Signs 
of increased 
intracranial pressure(decreasing 
sta
te
 
of 
c
o
n
s
ciousness, bradycardia 
u
nder 60, 
,progreasive 
rise in blood pressure 
o
r progre•alve pupil 
inequality) 
c
e
rvical 
•pine injury 
w
ith quadraplegia, 
H
ajor 
alrvay 
obatruction. 
the.l..t !C
heat lnjurls• 
w
ith 
a
ajor 
r
•
•piratory 
e
abaraasaent(laceration 
of trachea, haeaom
edlaatlnua 
etc) 
A
ortic laceration, 
H
yocardlal 
rupture 
o
r 
c
o
n
tu
sion 
w
ith 
circulatory 
e
m
barassaent, 
~
m
ln
ll 
,R
upture, 
a
v
ulalon 
o
r 
se
v
e
r
e
 laceration 
of in
tra 
abdoalnal 
v
e
s
s
el• 
o
r 
o
rgan•, 
e
x
c
ept kidney•, 
spleen, 
u
r
e
te
r. 
E
xtreaitie• 1H
ultiple 
open lim
b fractures. 
Sevw
tv 
cfteaorY
?::;-
-
-pvp:(VDJg& 
6 +
-L
Y
 
X
llt::X
:-:x:xz 
G
eneral 
:E
xtensive 
c
o
n
tu
sions., 
abrasions, 
large lacerations involving 
m
o
re 
than 2 
e
x
trem
ities, 
o
r large 
a
v
ulelons(greater than 
,
,5
 
c
a
 
w
ide) 
20-301
.
 body 
s
u
rface 
se
c
o
nd 
o
r third degree burns, 
Head 
and 
neck 
:c
e
rebral injury 
w
ith 
o
r 
w
ithout 
skull fracture 
w
ith 
u
n
c
o
n
sciousness lasting 
a
o
r
e
 than 15 
aln
u
tes, 
w
ithout 
s
v
e
re
 
n
e
u
rological 
sign
s, 
B
rief post trau
m
atic 
a
a
n
e
sla(less than 
3 hours)
.
 
D
isplaced 
closed 
akull fracture 
w
ithout 
u
n
c
o
n
s
ciousness 
o
r 
o
ther 
slg~s 
of intracranlal injury, 
Loss 
of 
eye 
o
r 
a
v
ul•ion 
of 
optic 
n
e
rv
e
. 
D
isplaced facial bone fractures 
o
r those 
w
ith 
a
n
tral 
o
r 
o
rbital 
involvem
ent. 
C
ervical 
spine fractures 
w
ithout 
c
o
rd dam
age. 
tbl.l.t 1H
ultiple 
rib
 fractures 
w
ithout 
re
spiratory 
e
m
barassm
ent. 
H
aem
othorax 
o
r pneum
othorax. 
R
upture 
of diaphragm
, 
LUng 
c
o
n
tu
sion. 
Abdom
inal 
:c
o
n
tu
sion of 
abdom
inal 
o
rgan•, 
E
xtraperitoneal bladder 
rupture, 
R
etroperltoneal haem
orrhage, 
A
vulsion 
of 
u
r
e
te
r. 
L
aceration 
of 
u
re
thra, 
T
horacic 
o
r luabar 
•pine fractures, 
w
ithout 
n
e
u
rological 
involvem
ent. 
Extrem
ities 
a
nd/or pelvic girdle 1D
isplaced 
sim
ple long bone fractures 
a
nd/ 
o
r 
m
ultiple hand 
a
nd foot fractures, 
Single 
open long bone fractures. 
P
elvic fractures 
w
ith displacem
ent. 
D
islocation 
of 
m
ajor joint, 
M
ultiple 
a
m
putations 
of d
ig
its. 
L
acerations 
of the 
a
ajor 
n
e
rv
e
s
 
o
r 
v
e
s
s
els 
of 
e
x
tre
m
ities. 
seyeritv category 1 
-
11x1r1c1ir1 thteatening,surviva1 
probable) 
General 
1severe laceration
 
a
nd/or 
a
v
ulaions 
w
ith dangerous 
haeaorrhage, 
30-501 body 
•u
rface 
se
c
o
nd 
o
r third degree burns 
Head 
and 
neck 
1cerebral injury 
w
ith 
o
r w
ithout 
skull fracture, 
w
ith 
u
n
c
o
n
sciousness 
of a
o
re
 than fifteen 
m
lnutes,w
lth definite 
abnorm
al 
n
e
u
rological 
signs. 
P
ost tra
u
•a
tlc 
a
a
n
e
sia 
of 3-12 hours. 
Co111pound 
skull fracture 
~
 
ropen 
chest 
w
o
u
nds, 
flail 
chest, pneum
om
edlastinum
,m
yocardlal 
c
o
n
tu
sion 
w
ithout 
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APACHE II Data Form. 
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APPEND1X3 
Pneumonia : Predictors of Severity 
Folder Number 
--------
Name __________ _ 
Age __ _ 
Survived <Y> 
Duration ICU ___ . (days) 
Duration Symptoms . (days) 
Chronic Health <Y> Specify ____________ _ 
APACHEll __ 
Confused <Y> 
Temp. __ oc 
Resp. Rate __ _ 
Shock<Y> 
wee __ _ ({Polys} __ % {lymphos} __ % {Eosinophils} __ %) 
Platelets . Cells/ml 
DIC <Y> (Platelets< 80000/mm3, PTT prolonged, D-dimer +ve.) 
Microbiology { Organism 1 } ______ _ 
{ Organism 2 } _____ _ 
{ Organism 3 } ______ _ 
High Risk Organism <Y> 
1 Sputum (Mucoid,Purulent,Bloody) 
2Sputum -~--(Minimal,Copious) 
Bacteraernia (S. pneumoniae,Staph.Aureus etc) 
Biochernistry{Na+} 
{K+} : __ 
{P04} 
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{Mg++} 
{Urea}: __ _ 
{Cr-} : __ 
{ALT}: __ 
{AST}: __ 
{LDH} : __ 
{ Alk Phos} : __ 
{ CBilirubin} : __ _ 
{ TBilirubin} : __ _ 
{ALB}: __ 
{Total Pr-}: __ _ 
Blood gas D 1 { Pa02} : __ 
{PC02}: __ 
{PH}: __ 
{Base+}: __ 
{Base-}: __ _ 
Day2: Day3: 
Day2: Day3: 
Day2: Day3: 
Day2: Day3: 
Day2: Day3: 
Day2: Day3: 
Day2: Day3: 
{Fi02}: __ 
{Pa02/Fi02} : __ 
{PEEP}: __ Day2 : __ Day3: __ 
{XRAY Quadrants}(l-4): __ Day2 : Day3: __ _ 
{Lung Injury Score}: __ _ Day2 : Day3: __ 
Xray 1 _____ (Lobar/segmental;Lobular;Broncho;Interstitial) 
Xray2 (lmproved,same,worse on day 2) 
Xray3 (lmproved,same,worse on day 3) 
ARDS <Y> 
Effusion <Y> 
Bilateral <Y> 
Xray diagnosis ________ (S pneumoniae, S. aureus, 
H.influenzae, K pneumoniae, Atypical). 
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Lung Injury Score. 
1. Chest Xray Score 
Component Value Score 
No alveolar consolidation (0) 0 
Alveolar consolidation (1 quadrant) 1 
Alveolar consolidation (2 quadrant) 2 
Alveolar consolidation (3 quadrant) 3 
Alveolar consolidation (4 quadrant) 4 
2. Hypoxaemia Score 
Pa02/FiQ2 >300 0 
Pa02/Fi02 225-299 0 
Pa02/FiQ2 175-224 0 
Pao2/Fio2 100-174 0 
PaQ2/Fi02 <100 0 
3. PEEP Score 
PEEP <= 5 cmH20 0 
PEEP 6-8 cmH20 0 
PEEP 9-11 cm H20 0 
PEEP 12-14 cm H20 0 
PEEP >= 15 cmH20 0 
4. Compliance Score(when available) 
Compliance >= 80 ml/cm H20 0 
Compliance 60-79 ml/cm H20 0 
Compliance 40-59 ml/cm H20 0 
Compliance 20-39 ml/cm H20 0 
Compliance <20 ml/cm H20 0 
Score = aggregate sum / number of components used. 
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Prognosis of Severe Community-Acquired Pneumonia 
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intensive care. 
Abstract: 
Study Objective: To determine the predictive value of clinical prognostic factors and 
scoring systems in severe community acquired pneumonia. 
Design: Prospective non-concurrent clinical study. 
Setting: Medical intensive care unit in a 1200 bed university hospital. 
Patients: 237 consecutive patients admitted from January 1987 through December 
1993. Immunocompromised patients, those with a history of aspiration or with 
pulmonary tuberculosis were excluded. 
2 
Measurements and Results: 82% required mechanical ventilation; the mean age was 
45.2 years and 59% were male. The duration of ICU stay was 11.45 ± 11 days and the 
overall mortality was 24.8%. 
All severity of illness scoring systems were highly predictive of outcome: organ 
failure (p<0.0001), APACHE II (p<0.0001), lung injury (p=0.0007). However, in the 
individual patient their predictive value , and the prognostic score of the British 
Thoracic Society and of Fine were poor. Organ failure performed best for the 
individual patient ( >2 organs: overall accuracy 80%, sensitivity 37%, specificity 
94% ). Individually significant parameters included age (p=0.041 ), shock (Systolic 
blood pressure <=80 mm Hg (p<0.001), WCC <4000 cells/ml (p=0.036), platelets< 
80,000 cells/ml (p=0.003), > 2 lobe involvement on chest radiograph (p=0.035), 
ARDS (p=0.0001)-, urea (p=0.004), inorganic phosphate (p=0.004), conjugated 
bilirubin (p=0.041), albumin (p=0.027) and co-morbid disease (p=0.026). 
Etiological microorganisms with percentage incidence and odds of death were: S. 
pneumoniae (23.2%, odds 0.6 ), S. aureus (8.4%, odds 2.17), K. pneumoniae (8%, 
odds 1.86), H. influenzae (5.9%, odds 0.49), other Gram negatives (3%, odds 1.21), 
mixed infection ( 11 %, odds 1.39), unknown (28.3%, odds 1.16). 
Conclusions: Conventional ICU scoring systems accurately predict the severity of 
disease in severe community acquired pneumonia, however their sensitivity and 
specificity for the individual patient are poor. 
3 
Introduction 
Community-acquired pneumonia requiring intensive care admission has been shown 
in recent, well-designed, prospective studies to demonstrate differences in aetiology 
and clinical features from less severe disease.1-4 While S. pneumoniae remains the 
most common pathogen, the increased incidence of Gram negative and staphylococcal 
infections and relative paucity of Mycoplasma and Chlamydia pneumonia have 
become evident in most studies. 2-4 The mortality of these severe cases is high, 
ranging between 24% to over 50%; with the cause of this higher mortality not being 
evident from the descriptions of the clinical features or severity of illness of the 
different cohorts. 2,4-6 
There are still discrepancies in the definitions and classification of community-
acquired pneumonia which make comparisons difficult, as the criteria for inclusion 
affect the interpretation of both the incidence and outcome of differing etiologies . 3 
Older studies have for example, in some instances, selected only lobar pneumonia, or 
included aspiration pneumonia and pneumonia in immunocompromised patients, 
while others have included infections caused by Mycobacterium tuberculosis. 6-9 
The ability to predict accurately the outcome for an individual with severe 
community-acquired pneumonia requiring intensive care unit (ICU) admission has, 
thus far, eluded severity of illness scoring systems. 6, 10-13 At least part of the reason 
for the ongoing difficulty in assessing the likelihood of death in severe pneumonia is 
that adverse prognostic factors have not been evaluated in sufficient numbers of 
patients with severe pneumonia requiring admission to the ICU. 
A number of outpatient and hospital-based studies have developed and validated 
various rules to determine prognosis based on predictive clinical parameters found to 
be significant on multivariate analysis. These rules have proved useful in groups of 
patients where the likelihood of an adverse outcome is low .14-18 Other studies have 
identified clinical criteria that can accurately determine low risk patients who can be 
successfully treated as outpatients.19-21 
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The ability to define the severity of disease is essential to make therapeutic decisions 
regarding the choice of empirical antibiotics, and the need for hospitalisation or ICU 
admission. While outcome prediction in severe pneumonia is not as crucial, it is 
useful to allow clinicians to communicate accurate information to the patients and 
their families, to determine the most cost effective management strategies, and to 
evaluate current or new therapies. 
We report here a prospective clinical audit designed to assess whether the aetiology, 
clinical features, and the use of general ICU scoring systems were able to assist in the 
prediction of outcomes of consecutive patients with severe community acquired 
pneumonia admitted to our respiratory ICU over a 7 year period. We have also 
attempted to define more accurately possible significant adverse prognostic features, 
and to assess the specificity and sensitivity of several newer methods of predicting 
outcome in severe pneumonia which have been published subsequent to the initiation 
of this audit.14,15,17,20 
Patients and Methods 
Two hundred and thirty-seven adult patients with a diagnosis of community-acquired 
pneumonia presenting to our respiratory ICU between January 1987 and December 
1993 were included in this analysis. Criteria for the diagnosis included a clinical 
history of an infective illness suggestive of pneumonia; pyrexia or hypothermia; 
clinical signs of lung consolidation including crackles or bronchial breathing; an 
elevated white · cell count or a left shift in the morphology of the neutrophils, and 
evidence of an infiltrate on the chest radiograph. Patients with a history of aspiration, 
those severely immunocompromised by disease or drugs ( e.g. haematological 
malignancy or AIDS, transplant patients or cancer chemotherapy) were excluded. All 
patients with pulmonary (88 patients), or disseminated tuberculosis (28 patients) were 
excluded from this analysis, except for two patients in whom other micro-organisms 
were also present on blood culture. 
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There were no strict entry criteria for ICU admission, and all patients who were 
considered likely to benefit from ICU care on the basis of clinical judgement were 
admitted; specifically old age and clinical features suggestive of a poor outcome were 
not exclusion criteria. 
Initial antibiotic therapy usually consisted of penicillin and an arninoglycoside until 
culture results were available. A third generation cephalosporin was substituted in the 
elderly and in renal failure; in cases of suspected staphylococcal infection cloxacillin 
was added, and where a Gram negative aetiology was suspected combination Gram 
negative cover was provided. 
The majority (81 % ) of patients needed intubation and mechanical ventilation, 
however a few were able to be treated with continuous positive airway pressure 
(CPAP) by face mask or by oxygen alone. The inability to maintain adequate 
respiratory function and any evidence of septic shock (systolic blood pressure <90 mm 
Hg despite adequate volume replacement), were used as independent indicators of the 
need for immediate intubation. No routine stress ulcer prophylaxis was used. 
The causative organisms were determined using microscopic and culture evaluation of 
acceptable sputum specimens ( <5 squamous epithelial cells/LPF and >25 
leucocytes/LPF), tracheal aspirates taken immediately after intubation, and routine 
blood cultures in all cases; serological and protected specimens were taken in patients 
where no diagnosis was evident or when clinically indicated. Immunofluorescent 
staining for Legionella spp was more recently performed on the protected brush 
specimens. The pneumonia was attributed to the microorganism if it was present on 
blood culture, present in significant numbers on microscopy and in culture, or if the 
antibody titre showed a fourfold rise over time, or was very high on initial serological 
testing. 
Patient demographics and all associated diseases present on admission were recorded. 
The severity of illness was calculated using the AP ACHE II scoring system with the 
worst physiological parameters in the first 24 hours being used .10 The organ failure 
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score was assessed daily for the first 5 days following admission using the following 
criteria for defining organ failure : 
Respiratory:-
Renal -
CVS-
Respiratory rate <6 breaths/minute or >49 /minute or 
PaC02 >5.9 kPa or 
AaD02 >46 kPa (Fi02 - Pa02 - PaC02) or 
Dependent on ventilator for >3 days. 
Urine output <480 ml/24 hours or <160 ml/12 hr or 
Serum creatinine > 300 µmol/1 or 
Serum urea > 20 mmol/1. 
Mean blood pressure <50 mm Hg or 
Heart rate <55 beats/minute or 
pH <.7 .25 with PaC02 <6 kPa. 
Haematological -
wee <1000 /ml or 
Platelets <20,000 /ml or 
Haematocrit <21 % 
Neurologic 
Unconcious with a Glasgow Coma Score <7 (no sedatives for 24 hr) 
The lung injury score excluding compliance was retrospectively applied to these 
patients.13 A score of O to 4 was given for the extent of radiological involvement of 
the lung, Pa02/Fi02 ratio, compliance and PEEP, with the total being divided by the 
number of parameters scored. 
Additional clinical parameters which could possibly predict a poor outcome (age, 
confusion, tachypnoea, renal function, serum chemistry and haematology, as well as 3 
parameters of the lung injury score (Pa02/Fi02 ratio, chest radiograph, and PEEP 
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level) were carefully documented on admission. The chest radiographs were 
subsequently recalled and read by a pulmonologist who was blinded to the causative 
organism and outcome, and the pneumonia was classified as lobar or segmental, 
bronchopneumonia, interstitial or lobular, and the presence of radiological changes 
compatible with ARDS ocurring over the first 3 days of admission were noted. 
The scoring systems for pneumonia proposed by the British Thoracic Society 14 and 
Fine et al 15 were retrospectively calculated from these clinical parameters. 
All data were collected by junior medical staff during the patients stay in the ICU and 
recorded on a prescribed form which was reviewed weekly to ensure the accuracy of 
the data (by the author or a deputy when not available). Data was stored on a DBase 4 
programme specifically designed for this ICU information. 
Numerical data is reported as mean and standard deviation. Comparison between data 
was done by Student's t for continuous variables, Chi square testing (with Yates or 
Fishers exact correction if indicated), relative risk and odds ratio for categorical 
variables using Epi-Info Version 6 and Epistat statistical packages.22 
Results 
Clinical features 
During the seven year study period 237 patients were admitted with community-
acquired pneumonia: 82 were black, 20 white and 135 of mixed race, there were 141 
males and 96 females, with a mean age of 45.2 years (median 46 range 13-84 , S.D. 
17 .07). All patients were in respiratory failure: 17 required 02 by facemask, 27 
received CPAP via face mask ,and 193 IPPV of whom 172 were ventilated with 
PEEP. Tracheostomy was performed in 70 patients while the remainder were treated 
by nasotracheaj or orotracheal intubation. 59 patients died in the ICU (24.8% 
mortality, 30.6% for those requiring IPPV), with the mean time to death being 7.62 
days (range <1 - 35 days) following admission. The mean duration of ICU admission 
was 11.45 ±11.01 days. 
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The patient demographics, co-morbid disease, and clinical features on presentation 
and haematology, are shown in tables 1 and 2 for survivors and non-survivors. 
Bacteraemia was present in 69 patients (29 .1 % ) with 18 (26%) deaths compared with 
41 (24%) deaths in 168 non-bacteraemic patients (p = 0.9) 
The relationship between age and mortality and the odds ratio for death in the 
different age groups are shown in figure 1. Twenty-eight patients were over 65 years 
of age of whom 12 died (p = 0.019) and of 82 over the age of 55, 24 died (p = 0.257). 
Sixty patients were 30 years of age or younger of whom 9 (15%) died, and this, 
compared with 50 (28.2%) deaths in 177 patients aged 31 years or older, showed no 
significant difference in mortality ( p = 0.06). The demographic features of these 
young patients were similar but APACHE II was 11.47 +- 4.95 in survivors and 16.56 
+- 5.48 in non-survivors (p=0.007) and the organ failure scores were 0.78 +- 0.64 -
and 1.89 +- 1.05 respectively (p= 0.01). The causes of death were brain damage 
following cardiac arrest 1, respiratory failure 1, shock 1, and multiple organ failure in 
6. There was severe underlying disease in 3 patients who died, including a presumed 
collagen vascular syndrome, a subarachnoid haemorrhage and a patient with end-stage 
Prader-Willi syndrome and in 2 further deaths there was over a week's delay in 
seeking medical attention. The organisms that caused death included S. Pneumoniae 
in 2, S. Aureus (3), K. Pneumoniae (1), and there were dual infections in 3. 
The initial biochemical indices for survivors and non-survivors are shown in table 2 
... 
( data on 7 patients incomplete) and those that were significantly different in survivors 
and non-survivors are illustrated in figure 2. 
There were no significant differences for outcome for the different causative 
organisms although the odds of death was increased with S. aureus, K. pneumoniae 
and other Gram -ve infections (figure 3). Infections caused by a single organism only 
were included in each category and 26 patients had pneumonia caused by multiple 
microorganisms (25 were caused by 2 microorganisms and 1 by three) and are 
classified as a mixed group. The most common microorganisms in this mixed group 
were S. pneumoniae (18 isolates), H. influenzae (14), S. aureus (5), anaerobes (5), 
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Gram negative organisms (8), other Gram positive microorganisms (1), and 2 had 
what was considered clinically to be Mycobacterium tuberculosis in addition to a 
blood culture positive bacterial pathogen. Patients in whom no microorganisms were 
identified were designated "unknown". 
Severity of Illness Scoring 
The AP ACHE II score determined from the worst physiological abnormality in the 
first 24 hours of ICU admission showed a significant difference between survivors 
(15.3 ± 6.69), and non-survivors (22.36 ± 9.27 p = <0.001). The APACHE II scores 
and mortality are related in figure 4. Seven of 76 patients with APACHE II scores of 
12 or less died. The microorganisms causing pneumonia in the patients with low 
AP ACHE II scores were similar to the overall spectrum of pathogens, and deaths were 
due to S. pneumoniae in 2, S. aureus (1), Candida spp (1), unknown (3), and one had 
dual infection with S. pneumoniae and H. influenzae. In those with a low AP ACHE II 
score, 2 deaths were in patients with extensive malignancy and 1 with a collagen 
vascular syndrome; death was due to unremitting sepsis and multiple organ failure in 
all cases other than one who died of shock. 
The number of organs in failure on day one in survivors was 1.08 ± 0.8, and non-
survivors 2.17 ± 1.28 (P= <0.0001 ). The number of organs in failure related to 
mortality showed a significant increase in mortality if more than 2 organ failure was 
present on day 1 of ICU admission ( see figure 5). Organ failure was assessed daily 
for the first five days of ICU admission in patients admitted from 1988. The overall 
relationship of organ failure to mortality from day 1 to 5 is shown in figure 6. 
(available in 168 patients only). 
There was a significant difference in lung injury score between 126 survivors, mean 
score of 1.6 ± 0.64 and in 32 non-survivors 2.04 ± 0.69 (p = 0.0007).(Figure 7) The 
lung injury score showed minimal change over the first 3 days of admission being 1.6, 
1.64 and 1.56 in survivors and 2.04, 2.12 and 2.03 in non-survivors respectively. 
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The chest radiographs were available for review in 165 patients: 93 (56.4%) had lobar 
or segmental opacification, 23 (13.9%) bronchopneumonia, 24 (14.5%) interstitial, 
and 25 (15.2%) lobular changes. There was no statistical differences in mortality but 
the odds ratio for death in bronchopneumonia and lobular pneumonia were 2.17 and 
1.88 respectively. 47 patients had changes compatible with ARDS with a significantly 
higher mortality (p=0.0001 and odds ratio 4.58) 
Rules for predicting outcome 
It was possible to test 2 modified predictive BTS rules (Rule 1; any 2 of hypotension 
(SBP <80 mm Hg), renal failure (urea > 7 mmol/1) or respiratory rate of >29 
breaths/min; Rule 2: BTS rule 1 +- confusion instead of urea to make it immediately 
applicable) in 230 patients .(table 3) 14 
The predictors of outcome defined by Fine et al including a vital sign abnormality, age 
>65 years, confusion, high risk organism and neoplasia with the exclusion of pleuritic 
pain scored as 2 points for each positive function are shown in table 3 and 4.15 
Discussion 
While the conventional general ICU severity of illness scoring systems are able to 
predict mortality in cohorts of patients with severe pneumonia, we have been unable 
to show that either they or any other specific system for predicting outcome in 
pneumonia are accurate predictors for the individual patient. We found that the organ 
failure score was the most reliable and yielded the most reproducible results, but even 
this was only able to predict certain death in three patients with five organ failure on 
day 1, and in all patients with 4 organ failure on subsequent days. When applied as a 
prognostic rule, taking more than 2 organ failure as the index on day 1, it had a 
positive predictive value of only 69%, sensitivity of 37% and an overall accuracy of 
80%. The high specificity (94%), would make it of some use in individualising 
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decisions; but its low sensitivity would limit its use for decisions regarding resource 
allocation. 
The AP ACHE II system showed significantly higher scores for non-survivors, but 
considerable overlap occurred. When a score of more than 21 was applied as a cut-
off, the predictive value was generally worse than using >2 organ failure, although the 
sensitivity was slightly better. Other more recently developed scoring systems for 
pneumonia were also of lesser predictive value overall, than the organ failure score 
(Table 3). 
Age as previously reported, predicted an adverse outcome in those over the age of 65 
years. The average age of our patients was much lower than in most other series and 
only 28 patients were over the age of 65 years which may partially explain the lower 
mortality in this series.14,15 In the 9 deaths that occurred in patients under 31 years 
of age, a terminal illness was present in 3, and in 2 others there was considerable delay 
in obtaining medical treatment. 
Because the general ICU scoring systems perform relatively poorly in lung disease, a 
lung injury score has been proposed for scoring ARDS more accurately.10 We 
applied a modified lung injury score (excluding compliance) and tested a score of >2 
for predicting death. This performed worse than either the AP ACHE II or organ 
failure scores, and selecting a higher score would have proved no better.(Table 3) 
The modified rules 1 and 2 of the British Thoracic Society also performed poorly and 
both were less accurate than shock alone.14 The rules were modified by using a 
systolic blood pressure of<= 80 mmHg rather than a diastolic pressure of <60 mmHg, 
as we considered the systolic pressure to be more easily detected, particularly in septic 
patients, and therefore a more reliable measurement. However in a previous 
multicenter study of 60 patients requiring ICU admission, the unmodified rule 1 
identified only 75% of patients requiring ICU admission, and the positive predictive 
value was only 19%. Furthermore, no individual clinical or laboratory parameters 
were found to be significantly associated with death. 5 
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While Fine's scoring system using a score of >4 points achieved a specificity of 95% 
in our population, the sensitivity was only 20%. In a study validating this system 
using the MedisGroups comparative hospital database with a mortality of 11.1 %, the 
benefits of this system for classifying low risk patients were confirmed20; however 
the classification of "high risk aetiology" in the absence of definitive microbiology 
may have contributed to their successful validation. In our study, we found a relative 
risk of death of 2.4 in patients with more than 4 points and a similar positive 
predictive value to that achieved with the other scoring systems, suggesting that this 
score may not contribute additional information. 
In the cohort of patients with low APACHE scores (<13) who died, end stage, co-
existing disease may have contributed to death in a number of cases, and this is a 
factor which needs more weight in pneumonia than it is currently accorded by the 
chronic health component of the AP ACHE II score. There were no other striking 
differences between the patients with low APACHE II scores who survived and those 
who died, although three of the five patients who died were admitted from a general 
ward or referred from another hospital, with treatment already having been started. 
This suggests that there may have been failure to respond, and that the prior admission 
may have stabilised these patients resulting in a falsely low AP ACHE II score. 
However, only 67 patients (35%) were admitted directly from the emergency unit, 
making it unlikely that the low scores in those who died could be attributed only to 
prior stabilisation. 
More careful evaluation of patients with both low AP ACHE II scores and younger age 
who died against prediction suggests that severe co-morbid disease and delay in 
antibiotic therapy may both increase the risk of dying. It is well accepted that 
outcome in severe infection is related to timely and appropriate antibiotic therapy .7 ,23 
If a measure of delay in treatment, as well as the appropriateness of therapy and the 
initial response, could be included, prognostication might be improved as these factors 
are not identified by the standard scoring systems. 
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The microbiological aetiology of severe community-acquired pneumonia reported 
here is similar to recent reports from France 2,4 A high incidence of Gram negative 
and S. aureus infections which are asscociated with a high mortality, suggest that 
these pathogens may produce a more severe form of disease. The mortality rates for 
K. pneumoniae (36.8%, odds ratio 1.86 ), and S. aureus (40%, odds ratio 2.17) are 
considerably higher than for S. pneumoniae (15.4%, odds ratio 0.6), H. influenzae 
(14.3%, odds ratio 0.49) or Legionella and Varicella infections, where no deaths 
occurred. Leroy has included H Influenzae and Moraxella catarrhalis with Gram 
negative infections and while this is theoretically correct, it is conventional in 
community-acquired pneumonia to classify high risk organisms such as K. 
pneumoniae, E coli, Pseudomonas spp, Acinetobacter spp and Proteus spp as Gram 
negative infections, while H. influenzae and M. catarrhalis are grouped separately 
because of the difference in mortality and their association with chronic lung 
d. 4 1sease .. 
We have previously reported a significant increase in mortality associated with 
Klebsiella pneumonia requiring ICU admission, and other community based studies 
have documented the high mortality associated with S. aureus infections. 24,25 
Previous studies of community-acquired pneumonia both from the general hospital 
and the intensive care units have failed to take into consideration the important 
influence and prognostic value of the aetiological agent on the severity of disease, 
possibly because of the relatively small numbers of patients with infections caused by 
high risk organisms.2,4,14,18,26,27 
The importance of L. pneumophila as a cause of community-acquired pneumonia 
requiring hospitalisation, and also ICU care, has recently been described.3,5,19,28 
Infection with these agents with a high mortality should alert the clinician to the need 
for early ICU admission with appropriate antibiotic therapy. Of interest, the majority 
of patients with L pneumophila pneumonia treated in our hospital during this period 
required ICU admission; howevever, there were no fatalities suggesting that, with 
appropriate therapy, these patients do well. Mycoplasma pneumoniae, as in other 
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series of community-acquired pneumonia seldom requires ICU admission or causes 
death. 2-4 
A number of biochemical tests in this study were associated with death on univariate 
analysis including serum urea, inorganic phosphate , conjugated bilirubin and 
albumin. Only gross derangement of these parameters was a significant predictor of 
mortality. None of these parameters was highly discriminating and no combinations 
proved of value as a discriminant rule to predict outcome. The high serum phosphate 
was not invariably associated with renal failure and the mechanism of this 
derangement is unclear, although another study has identified it as a poor prognostic 
indicator in lobar pneumonia. 6 
The outcome of individuals with severe pneumoma continues to defy accurate 
prediction; however both AP ACHE II and organ failure are useful to predict mortality 
of a cohort. We have demonstrated that individual outcome can only be predicted 
with certainty if more than 4 organ failure is present on day 1 of admission or more 
than 3 organ failure on day 2, but the sensitivity of this prediction is less than 10%. A 
more sensitive · clinical decision could be made by considering both AP ACHE II, 
organ failure score and other individual discriminant factors, such as the type of 
microorganism, shock, the presence of ARDS, a low white cell and platelet count 
serum urea > 30m mol/1, serum albumin <20 m mol/1, conjugated bilirubin >30 m 
mol/1, associated disease and age >65 years, mechanical ventilation, pre-existing 
disease and the failure to respond, all factors which were found to be relevant in this 
cohort of patients. 
Similar factors, differing only in the significance of bacteraemia and lack of inclusion 
of high risk organisms, high conjugated bilirubin, and inorganic phosphate, which 
were found in this study, have been identified and validated by Leroy, who developed 
a scoring system with a score for individual parameters proportional to the the 
magnitude of its coefficient in a multivariate mortality model. Of the 16 parameters, 
the most heavily weighted were a high simplified acute physiologic score (> 11), 
multiple organ failure score (>2), low neutrophil count (3500 cells/ml), delayed need 
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for mechanical ventilation(>12hr), immunosuppression and ineffective initial 
antibiotic therapy and, when validated in 125 patients with 36 deaths, a sensitivity of 
61 % and specificity of 97% was found.29,30 With the maximum weight in this 
scoring system being applied to measures of failed antibiotic therapy, this system 
would be of greatest use only after the response to therapy could already have been 
assessed by other means. 
While scoring systems have become an integral part of the assessment of the severity 
of disease and are valuable in the planning of therapy, this does not necessarily mean 
that they are accurate predictors of outcome for the individual patient, particularly in 
the intensive care unit. It seems unlikely that the development of further scoring 
systems for pneumonia will be able to contribute more than we are already able to 
achieve with good clinical judgement. The large variety of schemes currently available 
does, however, serve to emphasise the urgent need for a general consensus on 
accepted standard management strategies, in order that new and different methods of 
therapy can be accurately compared and evaluated. 
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Table 1. Differences in demographics and other potential clinical prognostic features 
between survivors and non-survivors 
Survivors Non-survivors IE Odd RR 
s 
n= 178 59 
Age 43.93 ±16.9 49.15±17.03 0.041 
Race: Black 61 21 0.978 1.06 1.04 
Caucasian 15 5 0.587 1.01 1.01 
Other* 102 33 0.973 0.95 0.98 
Male/Female 102/76 39/20 0.298 1.45 1.15 
Co-morbid disease 89 19 0.026 0.47 0.64 
COPD 41 11 0.599 0.77 0.81 
Diabetes 24 8 0.837 1.01 1.01 
Bacteraemia 51 18 0.914 1.09 1.06 
APACHE II 15.3 +- 6.69 22.36 +- 9.27 <0.0001 
Organ failure 1.08 +- 0.8 2.17 +- 1.28 <0.0001 
Lung injury (n=126)1.6 ± 0.64 (n=32 )2.04 ± 0.69 0.0007 
X-ray >2 lobes 66 24 0.035 2.73 1.43 
(n=158) 
Xray >3 lobes 42 13 0.571 1.37 1.22 
ARDS (n=162) 27 20 0.0001 4.58 2.59 
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Table 2. Clinical features, haematology, and serum biochemistry related to mortality 
n Survivors n Non-survivors p= 
Clinical Features 
Temp.°C 173 37.6± 1.311 55 37.36 ± 1.68 0.34 
Respiratory Rate 169 30.882 ± 12.769 51 32.26 ± 11.28 0.488 
Confused 146 26 41 16 0.007 
Shock (SBP<80 mmHg) 151 28 47 27 <0.001 
wee cells/ml 172 19867.6 ± 3618 50 17730 ± 40392 0.777 
wee <4,000 cells/ml 172 19 50 12 0.036 
wee >30,000 cells/ml 172 16 50 7 0.45 
Platelets cells/ml 172 231459.9±120973 50 201268±170077 0.25 
Platelets <80,000 cells/ml 172 11 50 11 0.002 
Biochemistrv 
Na+ mmol/1 174 136.8± 6.7 54 136.5 ± 6.8 0.77 
K+ mmol/1 173 3.9 ± .7 51 4.13±1.1 0.18 
po4- mmol/1 144 0.972 ±0.6 40 1.597 ± 1.3 0.004 
Mg+ 34 0.959±1.1 7 0.843±0.2 0.57 
Urea mmol/1 174 10.97± 12.5 54 16.62 ± 13.8 0.004 
Cr- u mol/1 173 178.89 ± 493.3 54 251.8 ± 219.5 0.16 
ALT units/I 137 58.445 ± 104.4 39 39.41 ±40.1 0.086 
AST units/I 139 91.87 ± 123.7 38 88.66 ± 137 .8 0.89 
LDH units/I 128 620.016 ± 973.6 36 655.36 ±517.3 0.77 
Alk. Phos. IU/1 140 114.886 ± 82.5 38 112.132 ± 86.6 0.84 
Bilirubin Conj. u mol/1 141 8.9 ± 13.1 41 14.88 ± 16.9 0.041 
Bilirubin Total u mol/1 155 16.85 ± 15.1 44 22.36 ± 21 0.11 
S albumin g/1 156 28.88 ± 6.5 46 26.44 ± 6.7 0.027 
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Table 3: . The predictive value of the modified rules of British Thoracic Society and 
Fine et al, AP ACHE II, organ failure, and lung injury scoring systems and shock in 
determining individual outcome in severe community-acquired pneumonia. 
Positive Overall Sensitivity Specificity Youden's Relative 
predictive accuracy % % Index 
value% % 
*Rule 1 37 64 64 64 .29 
*Rule 2 42 73 39 83 .22 
**Fine 52 80 20 95 .15 
Shock 49 76 57 81 .39 
APACHE II 52 76 48 85 .33 
>21 
Organ failure 69 80 37 94 .31 
>2 
Lung Inj. >2 30 70 38 78 .16 
Positive predictive value = no. with positive function who died I no. with positive 
function. Overall accuracy = no. outcomes correctly identified I no tested with 
function. Sensitivity = no. with positive function who died I no. tested who died. 
Specificity = no with negative function who survived I no. tested who survived. 
Youden 's index = specificity + sensitivity - 1. Relative risk = proportion who died 
with positive function I proportion who died with negative function. 
* British Thoracic Society14; **>4 points as described by Fine et al 15. 
Risk 
2.4 
2.2 
2.4 
3.5 
3.1 
3.8 
1.78 
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Table 4. The prognostic index for patients hospitalised with community-acquired 
pneumonia described by Fine et al. 15 
Points* no of patients Survivors Non- X Odds ratio (95 % Cl) 
survivors 
2 146 123 23 0.0001 0.29 (0.15<or>0.56) 
4 63 42 21 0.07 1.89 (0.94<or>3.76) 
6 19 8 11 0.001 5.07 (1.76<or>14.8) 
8 2 1 1 0.42 3 .15 (OO<or> 117) 
* 2 points given for the presence of each prognostic factor including a vital sign 
abnormality, age >65 years, confusion or mental abnormality, a high risk micro-
organism, and neoplasia. 
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